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My thesis consisted of two studies. The first study was a part of a wider study; 
within this, we investigated the modulation of amygdala structure by the val66met 
BDNF (Brain Derived Neurotrophic Factor) polymorphism. Structural Magnetic 
Resonance Imaging (MRI) scans were obtained at 1.5 T in 87 Major Depressive 
Disorder (MDD) patients and 74 age, gender, and verbal IQ matched healthy 
controls. We used Freesurfer version 5.1.0 to examine the grey matter amygdala 
volume. 
In the second study, we investigated neuroendocrine abnormalities˗˗ 
Hypothalamus-Pituitary-Adrenal Axis (HPA) axis changes˗˗ in MDD and their 
relation to early life stress (ELS). In total 112 subjects took part, consisting of 
MDD patients with (n=28) and without (n=15) a history of ELS and healthy 
controls with (n=26) and without (n=43) a history of ELS. The cortisol awakening 
response (CAR) was used as an index of HPA axis activity.  
In both studies, the data were analyzed using Statistical Package for Social 
Science (SPSS version 22).  
In the first study, we did not find any modulatory effect of the val66met 
polymorphism on the grey matter of right and left amygdala volumes. In the 
second study, we showed that the CAR was most elevated in those who were 
both depressed and had a history of ELS, which supports the argument that the 
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 Introduction  
1.1 Major Depressive Disorder 
1.1.1 Overview 
Depression is the most common of the affective disorders. It is a debilitating 
worldwide mental illness, which is included in the Diagnostic and Statistical 
Manual of Mental Disorders, 5th Edition DSM-5 (American Psychiatric 
Association, 2013) and in the International Classification of Diseases Manual 
10th Edition (ICD-10). 
1.1.2 Epidemiology of major depressive disorder  
It has been estimated that depression will be the second major cause of disability 
after ischemic heart disease by 2020 (Murray et al., 1997). The point prevalence 
of depression among those 16-74 years of age was 2.6% in the UK, in the year 
2000 (Singleton et al., 2001). Kessler et al. (2005) argued that the lifetime 
prevalence of depression is 16.6%, which significantly changes when considering 
age group. While among the 30-44 years old, the rate is at its highest at 19.8%, 
it reaches its lowest at 10.8% in adults over 60 years old (Kessler et al., 2005). 
Women are 50% more likely to be recognized with an affective disorder during 
their life compared with men; thus, depression affects about 1 in 6 women and 1 
in 10 men (Kessler et al., 2005; Craighead et al., 2014). Reports suggest that the 
prevalence of depression is not equal in all countries. This may show the impact 
of a number of issues on the prevalence of depression, such as clinical diagnostic 
problems and the influence of countries cultures. While 12 month prevalence of 
major depressive disorder (MDD) has been measured at 5-8% in Europe (Andlin-
Soboki et al., 2004), Kessler et al. (2003) estimated it to be 6.6% in the USA. The 
highest rate was seen in Morocco at 26.5% (Kadri et al., 2010) and the lowest 
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rate was observed in China at 3.6% (Lee et al., 2009) and Japan at 3-7% 
(Kawakami et al., 2007).  
1.1.3 Risk factors for major depressive disorder 
The main risk factors for the development of depression are female gender, early 
life stress (Nemeroff et al., 2003), family history of mood disorders, former anxiety 
disorders, substance abuse and life events (Neigh et al., 2013).  
1.1.4 Clinical assessment of major depressive disorder 
Patients who are suspected of depression are normally recognized with clinical 
interviews. In regards to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV, 1994) depression is defined as a mental illness in which a 
person experiences a core feature of persistent low mood and/or anhedonia. 
People who have five or more of these following symptoms over a two-week 
period are recognized as having MDD: depressed mood for most of the day, 
anhedonia, significant weight loss, insomnia or hypersomnia, psychomotor 
agitation or retardation, loss of energy or fatigue, feeling guilt, poor concentration 
or having no ability to make a decision, and recurrent thoughts of death or suicide. 
At least one of these symptoms must be depressed mood or loss of pleasure in 
activities (DSM-IV, 1994). Social or occupational aspects of a person’s life must 
be impaired, and there must not be any relation to the physiological effects of 
substances or a medical condition (DSM-IV, 1994). Similarly, in the International 
Classification of Disease, Tenth Revision (ICD-10, WHO, 1992), depressed 
mood, anhedonia and reduced energy are the three core symptoms, two of which 
should be seen to diagnose depression. ICD-10 (1992) criteria include additional 
symptoms such as sleep interruption, poor concentration or indecisiveness, low 
self-confidence, changed appetite, thoughts or acts of suicide, agitation, or 
slowing of movements, and guilt or self-blame.  
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1.1.5 Longitudinal course of major depressive disorder  
A large number of studies have shown that the average age of the onset of 
depression is late adolescence or emerging adulthood, although this varies 
between studies (Hankin et al., 1999; Kessler et al., 2005).  
MDD is a recurrent disorder (Craighead et al., 2014). Fergusson et al. (2002) 
have demonstrated that around 45% of adolescents who experience an episode 
of depression suffer a second episode before age 24. Moreover, Rohde et al. 
(2013) conducted a study in MDD patients about incidence, recurrence, gender, 
comorbidity, duration, and suicide attempts during childhood (age 5-12.9 years), 
using the data from 816 participants (56% female). They found that around 50% 
of adolescents had a second episode by the age of 30, reinforcing the recurrent 
nature of depression. Furthermore, a follow-up study with 406 patients, consisting 
of 186 patients with depressive disorder and 220 patients with bipolar disorder, 
found that there is an association between the number of previous episodes of 
depression and a higher risk of recurrence (Kessing et al., 2004). 
In terms of treatment, a substantial minority of MDD patients do not respond to 
initial treatment, and are defined as having treatment resistant depression (TRD). 
In the short term, TRD patients have greater tendencies to be recurrent (Fekadu 
et al., 2007). Specifically, Rush et al. (2006) showed that more than 80% of those 
followed up after a response to treatment, relapse within a year. The rate of short-
term remission in TRD is very low. One study found a rate of under 20% (Dunner 
et al., 2006).  
Several studies have found that the duration of depressive episodes varies 
substantially between subjects (Craighead et al., 2014), and the average time of 




1.1.6 Treatment of major depressive disorder 
Several forms of treatment are used for MDD (Craighead et al., 2014). While 
antidepressants and psychotherapies are the main treatments, stimulation 
treatments including transcranial magnetic stimulation, deep brain stimulation, 
vagus nerve stimulation and electroconvulsive therapy represent other more 
rarely used treatment options. In association with this, recently, Ketamine has 
been used for treatment of depression. 
It is of note that combinations of treatments may be more efficacious than 
monotherapies; for example, Nemeroff et al. (2003) demonstrated that 
antidepressants and psychotherapies have broadly equivalent effectiveness, but 
remission rates are higher when using both treatments in combination.  
There is little evidence suggesting preferential efficacy of individual 
antidepressants for the treatment of depression among all subjects (Anderson et 
al., 2012). There is no consistent evidence to show clinically relevant superiority 
of one class of antidepressant over another, while there are more than 7 classes 
of antidepressant (Lin et al., 2014). 
Interestingly, one meta-analysis by Cipriani et al. (2009) assessed the effects of 
12 new-generation antidepressants (Bupropion, Citalopram, Duloxetine, 
Escitalopram, Fluoxetine, Fluvoxamine, Milnacipran, Mirtazapine, Paroxetine, 
Reboxetine, Sertraline, and Venlafaxine) on MDD. The results suggested that, 
for the initial treatment of moderate to severe MDD in adults, Sertraline could be 
the best choice, balancing efficacy against adverse effects. In this study, 
Mirtazapine, Escitalopram, Venlafaxine, and Sertraline were considerably more 
efficacious than Duloxetine.  
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1.1.7 The global concern about major depressive disorder 
Depression is a global mental health concern. The World Health Organization 
suggested that depression will be ranked as the second major cause of disease 
burden by 2020 (Menken et al., 2000).  
1.1.7.1 The impact of major depressive disorder on personal lives  
The personal and social influence of MDD is serious, in terms of personal 
suffering, disability and financial costs (Fekadu et al., 2009). Depression is 
associated with a high rate of suicide – 3.4% in the USA (Barlow, 2005), with a 
global rate of 1.3 to 4.4% (Walsh, 2009) – and disability. An increased risk of 
morbidity and mortality, including premature death from cardiovascular disease, 
stroke and diabetes, has been reported in some studies in association with 
depression (Barth et al., 2005; Egede et al., 2006; Loeb et al., 2012). Moreover, 
depression impairs the quality of relationships between people and within families 
(Arató et al., 1988; Rich et al., 1988). In line with this, MDD has a negative effect 
on general measures of patients’ quality of life (Wells et al., 1989).  
1.1.7.2 The economic burden and cost of major depressive disorder 
In regards to the calculations of the costs of depression to societies, the economic 
burden of MDD is a large issue. Medical and psychological treatments of MDD 
exert a tremendous cost. Greenberg et al. (2003) has reported total costs of $83.1 
billion per year in 2000 in the USA, and Sobocki et al. (2006) estimated the cost 
for Europe at around €118 billion per year. In particular, patients with TRD 
accumulate higher medical and mental health care costs, due to the association 
of MDD with physical comorbidity and higher illness burdens, such as disability 
and suicide (Fekadu et al., 2008).  
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1.2 Early Life Stress  
1.2.1 Overview  
Child abuse is a serious social problem. It is a complex global phenomenon, 
which does not respect boundaries of class, nationality, race, religion, age, or 
educational level and can happen both publicly and privately (Carr et al., 2013; 
Juruena et al., 2013). 
The consequences of child abuse may include biological, physiological, 
behavioural and cognitive dysfunction. It has been argued that child abuse could 
be a specific risk factor for psychiatric disorders such as unipolar depression. 
Rates of depression in adulthood are higher in those who have experienced child 
abuse. In a health maintenance organization (HMO) population, a dose–
response association between the number of childhood abuse experiences and 
the presence of a recent-in the past year- depressive episode or lifetime chronic 
depression has been observed (Chapman et al., 2004). One previous study in 
this population found 4-fold increase in the risk of depression in individuals with 
multiple childhood adverse experiences (Felitti et al., 1998). In association with 
the increasing risk of depression in individuals experienced childhood abuse, 
Heim et al. (2010), argued that the underlying mechanism of the higher risk of 
depression in the subjects experienced early life stress could be due to persistent 
changes in Corticotropin-Releasing Hormone-mediated (CRH-mediated) stress 
responses. MDD is related to increase cerebrospinal fluid (CSF) concentrations 
of CRH, increased CRH immunoreactivity, increased CRH mRNA expression in 
the hypothalamic paraventricular nucleus of hypothalamus (PVN), and 
downregulation of CRH-1, but not CRH-2, receptors in the cerebral cortex 
(Nemeroff et al., 1999; Heim et al., 2010). A number of clinical studies suggested 
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that childhood abuse may contribute to CRH and Hypothalamus-Pituitary-Adrenal 
(HPA) axis changes observed in depressed patients (Heim et.al 2000; 2002).  
The exact prevalence of child abuse is unclear for a variety of reasons, but 
estimates vary from 25% to 45% (Costello 1998; Heim et al., 2010).  
Considering the definition of early childhood experience which is a broad concept, 
the four main types of early life stress include: emotional abuse, physical abuse, 
sexual abuse, and neglect (physical and emotional) (Juruena et al., 2013). These 
are defined as follows: 
1.2.2 Emotional 
Verbal aggression that affects the welfare or the morale of a child or any conduct 
that humiliates, embarrasses, or threatens a child.  
1.2.3 Physical 
Physical aggression by someone older, with the risk of, or resulting in, injury. 
1.2.4 Sexual  
Any type of sexual contact or conduct between a child and someone older. 
1.2.5 Neglect (physical, emotional) 
Emotional neglect: failure of caretakers to provide for basic emotional and 
psychological needs such as love, motivation, and support.  
Physical neglect: failure of caretakers to provide for basic physical needs such 
as feeding, a home, security, supervision, and health (Bernstein et al., 2003). 
1.3 HPA axis 
The HPA axis is one of the most crucial endocrine systems of the body and one 
of the main biological systems involved in the stress response.  
1.3.1 Physiology of HPA axis 
The endocrine system plays an important role in the integration and regulation of 
several functions of the body and is functionally integrated with the nervous and 
27 
 
circulatory system. In response to stress, CRH is released from the 
Paraventricular Nucleus of hypothalamus (PVN) into the portal venous 
circulation. CRH has the major role in stimulating the synthesis of 
Proopiomelanocortin (POMC) by the corticotroph cells, which is the precursor of 
Adrenocorticotropic hormone (ACTH) subsequently released from the anterior 
pituitary cells. Therefore, three main roles of CRH involve the stimulating of 
POMC transcription, ACTH biogenesis and stimulating the release of ACTH. 
Increasing ACTH release activates glucocorticoid secretion from the adrenal 
cortex, which is the final part of the HPA axis. The adrenal cortex has the main 
role in the production of cortisol.  
1.3.2 Cortisol 
Cortisol has been hypothesised to have a crucial role in the onset and course of 
MDD, but there is no agreement as to what the exact role may be. Many 
unanswered questions have been raised during these years, and it remains 
unclear whether for example the evaluation of cortisol is necessary for MDD 
patients in routine clinical management or therapeutic processes. The optimal 
level of cortisol is not clear, which raises more doubts around reaching a 
conclusion about the exact role of cortisol (Herbert et al., 2013).  
It has been assumed that the optimal range of cortisol is not the same for all 
individuals. Cortisol can be characterized in terms of absolute levels, or as the 
shape or amplitude of the cortisol rhythm over 24 hours; normal range values for 
each of these may vary depending on subjects’ circumstances (Herbert et al., 
2012). 
Furthermore, it remains unclear to what extent the observed changes in cortisol 
levels – which will be explained later in my thesis – represent causes or effects 
of depression (Herbert et al., 2012).  
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In recent years, the cortisol awakening response (CAR) has been increasingly 
researched, and found to be reliable and useful measurement of HPA axis 
activity. Assessing the CAR is not an invasive test, and has been used for 
capturing information about stress reactivity in numerous studies (Pariante et al., 
2008; Adam et al., 2010).  
1.3.2.1 Cortisol synthesis  
The adrenal cortex is made up of three zones: zona glomerulosa, zona 
fasciculata, and zona reticularis, comprising the outer, the middle and the inner 
zones. Their major endocrine products are not similar as each of them expresses 
specific complements of steroidogenic enzymes. The most actively steroidogenic 
zone is the zona fasiculata, which makes the glucocorticoid hormone, cortisol.  
Captured low-density lipoproteins (LDL) particles, and cholesterol de novo made 
from acetate, are used to synthesize cortisol via a process consisting of several 
stages, within the large cells of zona fasiculata.  
Within the foamy cytoplasm of the large cells, Acyl CoA cholesterol transferase 
(ACAT) esterifies free cholesterol. Cholesterol is stored in the lipid droplets, which 
can be turned back to free cholesterol by hormone sensitive lipase (HSL). ACTH 
can increase this process of turning back to free cholesterol. 
A number of reactions within a steroidogenic pathway form cortisol. The first 
stage involves converting cholesterol to pregnenolone by the enzyme 
cytochrome P-450. After that, the enzyme 3b-hydroxysteroid-dehydrogenase 
converts pregnenolone to progesterone. Following this stage, cortisol is formed 
by 11-hydroxylase after the production of 11-deoxycortisol. 
1.3.2.2 Secretion, Effects and Receptors  
Cortisol production is regulated by the activation of the HPA axis. Cortisol 
negatively feeds back on the hypothalamus and pituitary to control its set point.  
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Cortisol levels begin to rise during the early predawn and morning hours (between 
01:00 a.m. and 04:00 a.m.) and reach a peak in the morning, then decrease 
during the daytime and evening hours to reach their lowest point at midnight. The 
free-hormone hypothesis (Mendel et al., 1989) proposes that only unbound 
cortisol, which is around 5% of total cortisol in non-stressed situation (Lewis et 
al., 2005), can enter the tissues and the capillary boundaries. In non-stress 
situations unbound cortisol constitute only 5% of total cortisol, but in regards to 
the free-hormone hypothesis only this free fraction can infiltrate tissues and 
circulate through cell membranes into the cytosol to bind the intracellular 
glucocorticoid receptor with high affinity (Perogamvros et al., 2012).  
Circulated cortisol binds to plasma proteins, consisting of albumin (10-15%) and 
Corticosteroid Binding Globulin (CBG – transcortin - a glycoprotein synthesized 
in the liver) (80%). Cortisol binds to CBG with high affinity and low capacity 
whereas to albumin it binds with low affinity and high capacity. The role of cortisol 
depends on induction of intracellular pathways. In consequence, clarifying which 
fraction is responsible for cortisol's entry into cells is important in order to identify 
and study its biological functions, and to relate these functions to circulating and 
tissue-available concentrations (Perogamvros et al., 2012). CBG is the most 
important transporter for cortisol and it regulates cortisol bioavailability, 
accompanied by other mechanisms that modulate systemic and tissue levels of 
glucocorticoids, such as corticosteroid 11β-dehydrogenase (Perogamvros et al., 
2012; Moisan et al., 2013). CBG plays important roles such as buffer, carrier and 
delivery molecule. The delivery role of CBG is a biological role that extends 
beyond that expected of a simple carrier molecule. In particular, CBG is a 
member of the serine proteinase inhibitors. It goes through conformational 
change on interaction with target proteinases, which affects its function as a 
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steroid-binding protein. Cleavage of human CBG by neutrophil elastase produces 
a conformational rearrangement and substantial loss of cortisol-binding activity. 
Cortisol has an important role in homeostasis and regulation of energy, which has 
been investigated in past studies (Chrousos, 1998). Several metabolic processes 
are mediated by cortisol, including increasing cardiovascular output and 
respiration, glucose metabolism and cerebral perfusion rate (Lupien et al., 1999). 
In terms of cortisol receptors, there are two distinct intracellular corticosteroid 
receptors through which cortisol exerts its effects: glucocorticoid (GR) and 
mineralocorticoid (MR) receptors (Juruena et al., 2009). The MR has a high 
affinity for endogenous glucocorticoids while the GR has a low affinity. Under a 
stressful situation when the cortisol concentration is high, negative feedback is 
mediated mainly by GRs in the hippocampus, hypothalamus and pituitary 
whereas under basal cortisol level MRs in the hippocampus come into play as 
the main receptors regulating cortisol levels (Juruena et al., 2009).There is some 
evidence that blocking GRs may be useful in the treatment of depression 
(Belanoff et al., 2001; Flores et al., 2006). 
1.3.3 Brain 
Several parts of the brain have been shown to be involved in MDD (Herbert et 
al., 2013) consisting of the regions of the frontal lobe such as prefrontal cortex, 
Brodman’s area 25 and anterior cingulate, the amygdala and the hippocampus 
(Almeida et al., 2003; Pezawas et al., 2005; Sartorius et al., 2007; Kennedy et 
al., 2011).  
Several studies have questioned whether or not cortisol can be considered a 
crucial factor in part of this brain network (Herbert et al, 2013). Moreover, high 
concentrations of GRs and MRs are found in the hippocampus which makes it 
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crucial to investigate the relation between altered cortisol levels and 
hippocampus structure and volume in MDD (Herbert et al., 2012). 
O’Brien et al. (2004) have reported that there is no relation between the 
hippocampus volume reduction and increased salivary cortisol in MDD patients. 
In contrast, a study by Dedovic et al. (2010) has shown an association between 
abnormal regulation of basal cortisol levels and the reduction of hippocampus 
volume. Specifically, three groups, consisting of control, subclinical and high risk 
subclinical groups on the basis of Beck Depression Inventory (BDI) scores, 
underwent a magnetic resonance imaging (MRI) scan (1.5-T) and gave saliva for 
the evaluation of cortisol (at the time of awakening, 30 minutes after awakening, 
60 minutes after awakening, 16:00 p.m., and 21:00 p.m.) during three non-
consecutive 24 hour periods when the subjects were working. Results showed 
that the high-risk subclinical group had a higher CAR and a decreased 
hippocampus volume compared with control subjects.  
1.3.4 Salivary Cortisol  
Numerous studies have focused on the evaluation of salivary cortisol in patients 
with mental illness (Obayashi et al., 2013). Saliva is produced by the parotid 
gland, the submandibularis gland, and the sublingualis gland and represents an 
early and reliably collected specimen for the assessment of cortisol (Herr et al., 
2007; Obayashi et al., 2013).  
Two biological systems play major role in response to a psychological stress: the 
sympathetic adreno-medullary system and the HPA axis. The secretion of cortisol 
in saliva is controlled by both systems, though mainly by the HPA axis (Obayashi 
et al., 2013). Cortisol is detectable in saliva, plasma and other fluids. Although 
previous studies pointed out that cortisol levels in saliva can be affected by many 
factors such as gender, age, circadian rhythm, meals, drugs, autonomic function 
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and salivary gland function (Schwartz et al., 1993; Toda et al., 2004; Nater et al., 
2006), with appropriate methodological care cortisol can be evaluated reliably in 
saliva (Obayashi et al., 2013). Thus, salivary cortisol has become a useful 
quantitative biomarker for patients with mental illnesses (Toda et al., 2013).  
The use of saliva cortisol as a biomarker has a number of advantages. First, no 
effect of salivary flow rate has been reported on salivary cortisol levels. Second, 
acute short-term psychological stress does not have an effect on salivary flow 
rate (Obayashi et al., 2013). Third, physical stress does not produce an important 
effect on the salivary cortisol level (Vanaelst et al., 2012). 
One of the other advantages is that cortisol can be stored for a long term, even 
at room temperature, and thus can be easily collected at home by subjects and it 
can represent a more naturalistic measure less affected by experimental 
procedures in comparison to other potential markers (Naumova et al., 2012). 
Salivary cortisol collection has been found to be a non-invasive, stress free and 
less anxiety-provoking method as opposed to blood testing (Desai et al., 2014; 
Wormwood et al., 2015).  
However, there are still methodological issues around measuring cortisol in saliva 
as there are no clear norms for the level of free cortisol in saliva either at 
awakening time (range of 4.7–18.5 nmol/l) or 30 minutes after awakening (range 
of 8.6–21.9 nmol/l) (Clow et al., 2004). 
1.3.5 Cortisol Awakening Response (CAR) 
1.3.5.1 Overview   
The CAR is a rapid increase in the cortisol level within the first hour after 
awakening (Pruessner et al., 1977; Clow et al., 2004). The CAR is a genuine 
response to awakening and is distinct from the 24 hours diurnal cortisol profile 
(Schmidt –Reinwald et al., 1999; Wilhelm et al., 2007; Fries et al., 2009). During 
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the CAR phase, cortisol concentration increases to a variable extent compared 
to the cortisol level at the awakening time, reaching its highest point between 30-
45 minutes after awakening (Clow et al., 2004; Fries et al., 2009).  
The standard clock times such as 9:00 a.m., which were previously used for 
calculating morning cortisol levels, have been to a large extent replaced by 
assessment of the CAR, due to the measurement bias in MDD patients whose 
awakening time often differs markedly from controls.  
Previous research conducted in adolescents aged 16 to 18 by Adam et al. (2010) 
found that the CAR is an important prospective predictor of MDD. In detail, 
salivary cortisol was collected six times during a 24 hour period over three 
consecutive weekdays. The time of saliva collections was at awakening, 40 
minutes after awakening and around 3, 8 and 12 hours after awakening. The 
outcome of the study showed that the increased CAR might be a predictive factor 
for both onset and recurrence of MDD.  
However, further research is required to know more about the CAR and its 
function. 
1.3.5.2 The reliability of the CAR  
The CAR is recognized as a reliable index of HPA axis activity (Schmidt-Reinwald 
et al., 1999). In particular, assessing the CAR is a non-invasive test increasingly 
noted to be a useful way of capturing information about stress reactivity in 
numerous studies (Pariante et al., 2008; Adam et al., 2010).  
It has been argued that the reliability of calculating the CAR is increased when 
CAR assessments are done consecutively over 48 hours (Wust et al., 2000; 
Kunz-Ebrecht et al., 2004). 
34 
 
In previous studies, the CAR has been widely investigated either in healthy 
subjects, or in association with cardiovascular, autoimmune, atopic, allergic, and 
psychiatric diseases (Wust et al., 2000; Clow et al., 2004).  
1.3.5.3 Function of the CAR 
The function of the CAR has not yet been fully clarified. It seems that it is 
associated with anticipation of the demand of the day ahead, supported by 
evidence showing that the CAR is higher on weekdays compared to weekends. 
Thus, numerous studies have observed a higher CAR during weekdays (Kunz-
Ebrecht et al., 2004; Schlotz et al., 2004; Thorn et al., 2006). The CAR may show 
changes in association with stress levels and with feeling of happiness (Kunz-
Ebrecht et al., 2004). It may also play a role as an adaptive response (Adam et 
al., 2006).  
1.3.5.4 Neural regulation of the CAR 
Both the limbic system and the prefrontal cortex are involved in the regulation of 
the CAR. The other part of the brain that can influence the CAR is the 
suprachiasmatic nucleus (SCN) (Edwards et al., 2001; Clow et al., 2004; 
Hucklebridge et al., 2005; Fries et al., 2009; Thorn et al., 2011). 
1.3.5.5 Factors affecting the CAR  
Previous studies have shown that several factors may influence the CAR, 
although there have been inconsistent outcomes in relation to these factors. Of 
note, a significant genetic impact contributing to each subjects’ CAR has been 
shown in previous studies (Wust et al., 2000; Hellhammer et al., 2007). 
1.3.5.5.1 Age and Gender 
Age and gender are important factors that should be considered. Some studies 
have found an impact of age on the CAR such as an association between older 
age and lower CAR (Kudielka et al., 2003), although this may be a statistical error 
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related to the sample size given that in those studies having a large sample size, 
no effect of age has been reported (Pruessner et al., 2007).  
In regards to gender, a number of studies have found that women have a larger 
CAR compared to men (Wust et al., 2000; Pruessner et al., 2007). Of note, 
Kudielka et al. (2003) found that there is a tendency for a delayed cortisol peaking 
in females as well. 
1.3.5.5.2 BMI  
An association between Body Mass Index (BMI) and elevated cortisol level has 
been reported (Bjorntorp et al., 2000). Furthermore, Therrien et al. (2007) 
assessed the CAR in obese and reduced obese-the obese people who lost 
weight- men and women; Fifty-one men (16 lean, 19 abdominally obese, and 16 
reduced obese) and 31 women (12 lean, 10 subcutaneously obese, and 9 
reduced obese) were participated – the groups were defined by strict ranges 
of BMI and waist circumference; lean (BMI <27 kg/m2, waist circumference <100 
cm for men and <90 cm for women); obese (BMI 30 to 35 kg/m2, waist 
circumference >100 cm for men and <100 cm for women; and reduced obese 
(BMI >30 kg/m2, waist circumference >100 cm for men and <100 cm for women) 
, before weight loss, minimal weight loss of 5 kg, still losing weight or just 
stabilized. Weight loss resulted from changes in eating and physical activity. The 
results showed that men with visceral obesity showed an increased cortisol 
response. In particular men with visceral obesity showed an increased cortisol, 
whereas this response tends to return to normal in a reduced obese state. 
Reduced obese women presented a significantly increased CAR compared with 
lean subjects, but there was no difference in this variable between lean and obese 




1.3.5.5.3 Stress   
Stress is one of the most important factors that can affect the CAR. For example, 
there is an association between chronic overload and increased CAR (Schlotz et 
al., 2004). In particular, the observed weekend-weekday changes in the CAR 
show that the day of the cortisol assessment is important. Of note, a higher level 
of perceived stress and worrying is associated with an increased CAR (Wust et 
al., 2000).  
1.3.5.5.4 Smoking 
Mixed results have been found about the effects of smoking on the CAR. One 
study has shown that smoking status is related to the elevated CAR, but found 
no differences between ex-smokers and never-smokers, suggesting that smoking 
has a short-term effect on the neuroendocrine system (Badrick et al., 2007).  
1.3.5.5.5 Alcohol 
Junghanns et al. (2007) pointed out that there is an association between alcohol 
consumption and CAR. In particular, heavy drinkers (above 28 units of alcohol 
consumption per week in men and 21 units per week in women) had a higher 
CAR compared to moderate drinkers (Junghanns et al., 2007).  
1.3.5.5.6 Pain 
Sudhaus et al. (2007) found an association between the CAR and behavioural 
pain coping-strategies. In detail, 31 low back patients (chronic and acute) and 14 
healthy controls participated in the study. Although there were significant 
interrelations between awakening responses and the behavioural pain coping-
strategies, the groups did not differ in their CAR.  
In a subsequent study, Generaal et al. (2014) found a lower CAR in subjects who 
suffered from multi-site musculoskeletal pain compared to controls. Another 
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study found that an increased CAR was associated with higher pain intensity and 
unpleasantness (Goodin et al., 2012). 
1.3.5.5.7 Sleep related factors 
1.3.5.5.7.1 Time of awakening 
Conflicting results have been found about the association of the CAR and time of 
awakening. Elevated CAR has been reported in subjects who wake up early 
compared to those waking later (Edwards et al., 2001; Kudielka et al., 2003), 
although the mode of awakening or waking up at unexpected times did not have 
an impact on the CAR (Wust et al., 2000).  
1.3.5.5.7.2 Sleep duration and insomnia  
Wust et al. (2000) presented evidence that in subjects who have shorter sleep 
duration there is a comparable CAR to those subjects having longer sleep 
duration.  
The findings of research investigating the influence of insomnia on the CAR are 
inconclusive. Both a lower awakening response in subjects suffering from 
insomnia (Backhaus et al., 2004), and no effects on the CAR, have been found 
(Dettenborn et al., 2007). 
1.3.5.5.8 Specific time of collection 
Okun et al. (2010) has shown that a delay of more than 15 minutes between the 
wakening time and collecting the first specimen can significantly affect the CAR. 
As a result, some studies have classified subjects with a delay of 10 or more 
minutes after awakening as non-compliant (Kunz-Ebrecht et al., 2004). 
1.3.5.5.9 Oral contraceptives and menstrual cycle 
Pruessner et al. (1997) observed a small effect of oral contraceptive use on the 
CAR; the study showed that in women who took oral contraceptives, there was a 
tendency for lower early morning free cortisol levels. However, overall studies 
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investigating the effect of menstrual cycle on the CAR are inconclusive. Thus, 
while some studies have found no difference between menstrual phases 
(Kudielka et al., 2003), Kirschbaum et al. (1999) found that salivary cortisol 
responses were considerably different between women in the luteal or follicular 
phase, and that the CAR increases during the luteal phase.  
1.3.5.5.10 Burnout and medical comorbidity 
An increased CAR has been reported in patients with burnout compared to 
healthy controls (De Vente et al., 2003), whereas evidence for a lower CAR in 
both clinical and non-clinical burnout has been found in a study by Oosterholt et 
al. (2015). 
Several other factors can have an impact on the CAR. Upper respiratory illness 
can reduce the level of the CAR (Edwards et al., 2003), whereas hypertension 
(Wirtz et al., 2007), atherosclerosis (Hurwitz et al., 2001) and functional 
gastrointestinal disorders (Bohmelt et al., 2005) can all increase the CAR.  
1.3.5.6 Calculation of the CAR  
For reporting changes in endocrinological variables, the use of repeated 
measurements over the time has been introduced into the study protocols in 
endocrinological research. For detecting a possible association between 
repeated measures and other variables, the area under the curve (AUC) is 
regularly used to integrate multiple time points.  
The formulas for computation of the AUC have varied between laboratories 
(Pruessner et al., 2002). Studies have calculated the AUC in two ways, both of 
which are based on the trapezoid formula, as follows:  
1) AUCg (Area under the curve with respect to the ground): The total cortisol 
released in the period after awaking. If the initial awaking cortisol concentrations 
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are high, then the AUCg will be large even if the increase following awaking is 
minimal (Edwards et al., 2001). 
2) AUCi (Area under the curve with respect to the increase): This is the CAR 
measured as the increase from baseline and it is not related to the actual cortisol 
levels at awakening. This measure of the CAR is said to be related to the 
sensitivity of the system (Chida et al., 2009).  
1.4 Biomarkers in Depression 
1.4.1 Overview  
Depression is known as a debilitating disorder, which currently lacks well-known 
biomarkers of aetiology and treatment response. To understand the complexity 
of depression and to develop new therapeutic targets, it is important to examine 
several aspects of the potential biological components of depression. Chief 
among the potential biomarkers are (1) genetic factors; (2) brain changes found 
with neuroimaging; and (3) endocrinological dysfunction, in particular alterations 
to the HPA axis.  
Numerous previous studies have been carried out to explore these factors in 
MDD patients. Many of these studies were undertaken in order to find novel 
biomarkers for MDD, and several studies have also attempted to look at the 
interaction of these factors.  
1.4.2 Genetics 
1.4.2.1 BDNF (Brain-Derived Neurotrophic Factor) and BDNF Val66Met 
polymorphism 
BDNF, a protein that is a member of the neurotrophic family of growth factors, is 
the most abundant neurotrophin in the brain (Hong et al., 2011). It is an important 
factor controlling the growth of new neurons and synapses, and the proliferation 
and survival of neuronal cells (Acheson et al., 1996). Thus, the regulation of 
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synaptic plasticity and connectivity is associated with BDNF (Verhagen et al., 
2010). It is active in the brain in the areas relating to memory, learning, and higher 
thinking. Therefore, there is a high concentration of BDNF in the hippocampus 
and cerebral cortex (Yamada et al., 2003).  
Previous studies have investigated the val66met polymorphism, a single 
nucleotide polymorphism in the BDNF gene that is due to variation between 
valine and methionine (Montag et al., 2009). This polymorphism has an effect on 
cellular processing, trafficking and activity dependent-secretion of BDNF (Hong 
et al., 2011). It seems a suitable factor for investigation to find a link between the 
BDNF gene and MDD (Hong et al., 2011).  
BDNF is associated with memory function in the brain. Poor memory 
performance, which is a symptom of depression (Veiel et al., 1997), is related to 
the met allele (Egan et al., 2003). Associated with this, the crucial role of BDNF 
in learning and memory has been shown in some studies (Bekinschtein et al., 
2008; Lu et al., 2008). Due to its important effects on synaptic plasticity, it seems 
that BDNF is necessary for short term and long-term memory storage (Alonso et 
al., 2002; Bekinschtein et al., 2008). 
A decrease in BDNF expression may play a major role in the pathophysiology of 
MDD (Karege et al., 2002; Duman et al., 2004; Schumacher et al., 2005; 
Angelucci et al., 2005; Lang et al., 2005). Peripheral BDNF levels are reduced in 
MDD patients (Sen et al., 2008). Karege et al. (2002) found that the level of BDNF 
in the serum of MDD patients is considerably lower than healthy controls. Animal 
and clinical studies have demonstrated the important role of BDNF in MDD and 
antidepressant drug action (Hong et al., 2011). An antidepressant-like influence 
in an animal model of depression has been observed by infusion of BDNF into 
the midbrain (Siuciak et al., 1997). Associated with this, it has been suggested 
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that BDNF up regulation in the hippocampus of MDD patients may be a result of 
using antidepressants (Shimizu et al., 2003; Duman et al., 2004; Angelucci et al., 
2005; Lang et al., 2005;) and that increasing BDNF levels may play an important 
role in antidepressant efficacy (Santarelli et al., 2003). Antidepressants such as 
fluoxetine have been observed to increase BDNF levels in the hippocampus 
(Herbert et al., 2012). 
Associated with these results, the BDNF val66met polymorphism seems to have 
a significant effect on the function of neural plasticity in the medial temporal lobe 
(Montag et al., 2009).  
The BDNF val66met polymorphism has a major role in the generation of 
spontaneous strategies during navigation behaviour in healthy controls. Several 
memory systems are involved in parallel processing of spatial information during 
navigation. A number of studies have determined between hippocampus-
dependent 'spatial' navigation, which relies on knowledge of the relationship 
between landmarks in one's environment to build a cognitive map, and habit-
based 'response' learning, which needs the memorization of a number of actions 
and is regulated by the caudate nucleus. Studies have demonstrated that people 
spontaneously use one of these two alternative navigational strategies with 
approximately equal frequency to solve a given navigation task, and that strategy 
correlates with functional magnetic resonance imaging (fMRI) activity and grey 
matter density (Banner et al., 2011). In association with this, increased 
hippocampal activation in the val group compared with the met group during a 
virtual navigation task has been found in a study. They showed that met carriers 
in compared to val homozygote used response strategy rather than spatial 
navigation (Banner et al., 2011). This has led to a suggested relationship between 
the BDNF val66met polymorphism and depressed patients, who consistently 
42 
 
show impaired spatial navigation (Cornwell et al., 2010). The evidence that the 
BDNF val66met polymorphism cannot fully explain differences in spontaneous 
learning strategies by itself supports the idea that some other actors, such as 
stress or polymorphisms in other genes, may have additional roles mediating 
between genotype and behaviour (Banner et al., 2011). The influence of BDNF 
on learning and memory strategies may be affected by exposure to stress as well 
(Song et al., 2006; Heldt et al., 2007).  
Bus et al. (2012) investigated the effect of gender on serum BDNF levels in 
healthy controls. In males, higher serum levels of BDNF were found in met 
carriers than val/val homozygotes whereas in females no effect of val66met 
genotype was found. In line with this, Verhagen et al. (2010) suggested that in 
MDD, the BDNF val66met polymorphism may play a more important role in men 
than women. These results (Verhagen et al., 2010; Bus et al., 2012) may suggest 
that the inconsistent findings of earlier results may have been influenced by male-
female ratios in previous studies. 
In sum, it has been argued that a lack of statistical power, small sample sizes and 
failure to account adequately for the influence of gender have contributed to the 
present controversies about the role of BDNF and the val66met polymorphism in 
MDD (Verhagen et al., 2010).  
1.4.3 Structural changes of the brain 
Volumetric changes have been found in a number of brain areas in MDD patients 
compared to healthy controls in previous studies, with suggestions that structural 
brain alterations may play an important role in MDD (Arnone et al., 2012; Samann 
et al., 2013). 
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Structural MRI is a key methodology that has been widely utilised to identify key 
regions of the brain having an important role in the pathophysiology of MDD 
(Drevets et al., 2001; Fitzgerald et al., 2008; Rigucci et al., 2010).  
Reduction of the grey matter volume in MDD has been observed in numerous 
studies, and specifically in regions within the limbic-cortisol circuits (Sacher et al., 
2011). Significant structural brain changes may be especially apparent in patients 
with severe or chronic depressive disorders. For example, Serra-Blasco et al. 
(2013) studied 66 MDD patients and 32 healthy controls. All patients were taking 
several medications at the beginning of the study. The patients consisted of 3 
groups: a chronic depressive/ treatment resistant group; a euthymic group with 
HAM-D 17 scores < 8 for the past 6 months but with three or more previous 
episodes of MDD; and patients with a first episode of depression. The study 
suggested that there is a negative effect of long-lasting depression on the grey 
matter, and in particular that there is an association between smaller 
frontotemporolimbic volumes and the duration of MDD.  
1.4.3.1 Amygdala  
Although, it has been shown that the amygdala has an important role in the 
pathophysiology of MDD because of its significant action in the process of 
memory and emotion in the brain (Hajek et al., 2009), the role of amygdala 
volumetric changes in MDD is still unclear. 
Results from studies investigated the structure of the amygdala in MDD have 
been inconsistent (Sheline et al., 2000; Hamilton et al., 2008; Lorenzetti et al., 
2009). Cohort studies with MDD patients have suggested either increased (Frodl 
et al., 2002; Frodl et al., 2003; Lange et al., 2004; Weniger et al., 2006; van 
Eijndhoven et al., 2009), reduced (Hastings et al., 2004; Tang et al., 2007; Frodl 
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et al., 2008); or unchanged amygdala volumes (Morys et al., 2003; Caetano et 
al., 2006; Monkul et al., 2007).  
Associated with this, conflicting results have been observed in studies that have 
investigated a variety of potential moderators of the association between 
amygdala volume and MDD, including laterality, gender, medication and clinical 
factors such as severity and duration, number of episodes, age of onset and the 
presence of psychiatric illness in the family (Sheline, 2000; Bass et al., 2004; 
Hamilton et al., 2008; Lorenzetti et al., 2009). In detail, considering the influence 
of medication on amygdala volume in MDD patients, Hamilton et al. (2008) 
argued that studies which used medicated subjects indicated that amygdala 
volume was significantly increased in depressed compared to healthy controls, 
whereas studies using unmedicated depressed subjects showed a reliable 
decrease in amygdala volume in depression. Regarding clinical factors, 
amygdala grey matter volume reduction has been found in first episode of 
depressed patients, who were mostly drug free, in compared with chronic patients 
and controls (Bora et al., 2011). Further, it has been argued that amygdala size 
may vary in association with illness duration, while age at onset does not seem 
to have a major role. In detail, while unipolar patients earlier in the course of 
illness tend to have increased amygdala volume, depressed patients with a 
longer illness duration and with higher number of MDD episodes tend to show 
volumetric reductions (Lorenzeti et al., 2009). In regards to laterality, it is not clear 
whether MDD affects the left and right amygdala in the same way (Lorenzeti et 
al., 2009); In details, Baas et al. (2004) by combining results among 54 fMRI and 
Positron Emission Tomography (PET) studies in a meta-analysis showed that the 
left and right amygdala may have important but not similar roles in the 
pathophysiology of MDD. The left amygdala is more often activated than the right 
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amygdala; which means they observed a strong preponderance of left amygdala 
activations over right amygdala activations in functional neuroimaging studies of 
emotion processing. In terms of the laterality of amygdala volume changes, 
Lorenzeti et al. (2009) observed a decreased left amygdala volume in remitted 
patients compared to healthy controls. In contrast, Bremner et al. (2000) found a 
decreased right, but not left, amygdala in remitted depressed patient compared 
to controls. Associated with this, Caetano et al. (2004) found a trend towards 
smaller left amygdala volumes in MDD patients compared to healthy controls. 
Importantly, it is not clear whether volumetric alterations of the amygdala are a 
state or trait related to MDD (Lorenzetti et al., 2009). Thus, Eijndhoven et al. 
(2009) have shown that larger amygdala volumes could be a state marker of 
MDD, specifically in the early onset of MDD. Supporting this, another study 
conducted by Lorenzetti et al. (2010) showed that the alteration of amygdala 
volume is state related as remitted patients had a larger amygdala volume 
compared to currently depressed patients. In particular, they observed larger 
amygdala volume in remitted patients who were antidepressant free for six 
months. This study did not show a significant difference between current 
depressed patients and healthy controls. It has been argued that increased left 
amygdala volume in remitted MDD patients may be a neurobiological marker of 
vulnerability to relapse, or may represent recovery from MDD. In this study, in 
terms of using antidepressants, they found that patients who were not taking 
medication during the past 6 months either they were the current MDD or the 
remitted MDD subjects, showed larger left amygdala volumes when compared to 
healthy controls. Although they did not observe an interaction between diagnosis 
and medication, significantly less remitted MDD participants were taking 
medication when compared to the current MDD subjects. Therefore, medication 
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may cause to an increased left amygdala size in the remitted MDD group 
compared to the healthy controls and to a non-significant trend for a larger 
amygdala compared to the current MDD patients. 
In contrast with this, another study found both amygdala to be considerably 
enlarged in currently depressed patients, but no difference between remitted 
patients and control subjects (Eijndhoven et al., 2009). Associated with this, in 
another study of patients with melancholic depression, patients with psychotic 
depression and normal controls, although they did not find any change in 
hippocampus volume, or anterior and posterior subgenual cortex, between 3 
groups; larger amygdala volumes of both patient groups were observed 
compared to controls (Vasilopoulou et al., 2011) 
1.4.3.2 Hippocampus  
Hippocampus volume reduction is one of the most frequently observed structural 
brain changes in MDD patients (Campbell et al., 2004; Mak et al., 2009; 
Koolschijin et al., 2009). Cole et al. (2010) reported deformations in the subiculum 
and the CA1 subfield extending into the CA2-3 subfields in the tail regions of both 
hippocampi in MDD patients compared to healthy controls. More recently, meta-
analyses have shown reduced hippocampal volume in first episode depression 
(Cole et al., 2011) and increased hippocampal volume in remitted depressed 
patients compared to currently depressed patients (Kempton et al., 2011).  
Hippocampal changes may be of clinical relevance. Thus, Frodl et al. (2008) has 
shown that lower hippocampus volume forecast a worse clinical outcome three 




1.4.3.3 Prefrontal cortex and other brain areas 
The reduction of grey matter volume in the fronto-limbic and other brain areas is 
one of the most important findings in MDD (Sacher et al., 2011, Serra-Blasco., 
2013). Numerous studies have reported grey matter reduction in orbitofrontal 
cortex (Scheuerecker et al., 2010), anterior cingulate gyrus (Tang et al., 2007) 
and temporal gyrus (Mak et al., 2009; Scheuerecker et al., 2010). In particular, 
they reported alterations in the superior temporal regions such as decreased 
volume in the superior temporal gyri bilaterally and in the left planum temporal in 
both current MDD patients and remitted MDD patients when compared with 
healthy controls (Takahashi et al., 2010b) and a decreased volume in the left 
insula of both current MDD and remitted MDD when compared with healthy 
controls (Takahashi et al., 2010a). Previous studies found alterations in the 
thalamus (Kim et al., 2008; Vasic et al., 2008), in particular shorter interthalamic 
adhesion, in current MDD when compared with healthy controls (Takahashi et 
al., 2009).  
Subsequent meta-analyses have also found grey matter volume changes in a 
number of brain regions such as frontal limbic and thalamus (Du et al., 2012; Bora 
et al., 2012). In association with these changes, Koolschijin et al. (2009) found a 
volume reduction in frontal lobes, orbitofrontal cortex, prefrontal cortex, and 
putamen in MDD patients compared with healthy controls. In line with this, volume 
reduction of caudate globus pallidus, thalamus and gyrus rectus were found by 
Kempton et al. (2011). Sacher et al. (2011) showed a lower grey matter volume 
in dorsolateral frontal cortex and the right paracingulate cortex. 
In contrast with these findings, previous studies have shown increases during 
time in the volume of grey matter within the caudate nucleus and hippocampus, 
and these increases were related to increased positive mood and increased 
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learning (Starkman et al., 2003; 2007). In line with this, Starkman et al. (2007) 
argued that decrease of cortisol concentration in Cushing's syndrome patients is 
significantly related with decrease in the degree of depression and the depressive 
syndrome, although there was no significant relationship between change in the 
depression subscale and change in urinary free cortisol concentration in the study 
(Starkman et al., 2007). This suggests that the effects of cortisol are less a direct 
linear effect on mood and more the result of the interaction of cortisol with caudate 
structure and function (Starkman et al., 2003; 2007).  
Taken together, previous studies found morphometric changes that could be 
argued to be either state- related brain changes, such as shorter interthalamic 
adhesion, or vulnerability trait markers, such as decreased insular volume in the 
medial prefrontal network. 
Interestingly, focusing on a specific region, one of the regions which its volume 
alteration has been most frequently observed in MDD patients (Klauser et al., 
2015) is the anterior cingulate cortex (ACC). The ACC is a part of the medial 
prefrontal network that has been shown to have crucial role in emotional 
processing. This medial prefrontal network surrounds the medial part of the 
orbito-frontal cortex – also known as ventromedial prefrontal cortex (vmPFC) – 
and can be broadened to limbic regions as well as to basal ganglia and thalamus 
to form an extended medial prefrontal network. In regards to ACC volume 
changes, previous studies have found reduced ACC volume in MDD patients 
compared to healthy controls (Tang et al., 2007; Frodl et al., 2008; Koolschijin et 
al., 2009; Abe et al., 2010). Furthermore, considering the effect of clinical factors, 
an association between a longer duration of illness and grey matter volume 
reduction in the rostral ACC has been found (Fornito et al., 2009; Ellison-Wright 
et al., 2010; Bora et al., 2011). In a recent study of grey and white matter in 
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patients with a life time history of MDD, ventromedial prefrontal cortex (vmPFC) 
grey matter bilateral reduction in remitted MDD patients when compared with 
currently depressed and healthy controls was found. These findings, therefore, 
support the argument that cortico-limbic disturbances may contribute to the 
underlying pathophysiology of MDD (Klauser et al., 2015).  
Interestingly, in regards to impacts of antidepressants, grey matter changes have 
been investigated as predictor of antidepressant treatment response in MDD 
patients in a number of previous studies (Samann et al., 2013). In regards to 
importance of early treatment response, biomarkers are essential to help to find 
patients that are less likely to respond to standard antidepressant treatment and 
other therapies at an early stage of the treatment. Samann et al (2013) found that 
the cortex volume of certain brain areas such as left hippocampus, right lateral 
temporal cortex, and subcallosal/orbitofrontal cortex is significantly associated 
with different responses to treatment through gender-by-region interactions. A 
hippocampal /temporolateral composite marker showed robust changes in both 
first episode and recurrent unipolar patients. 
Smith et al. (2012) showed that there is an association between volume increases 
of the left dorso lateral prefrontal cortex (DLPFC) with SSRI-treated depressed 
subjects over a 12 week period. However, In terms of the impact of 
antidepressant use, it is presently unclear, whether antidepressant treatments 
might have significant effects on regional grey matter volumes and whether these 
potential structural influences could be associated with their efficacy in treating 
clinical symptoms. 
In regards to BDNF , previous studies have shown, stress reduces the expression 
of BDNF, and other trophic factors, in brain areas associated with emotion and 
mood; and this could play a role in the cortical atrophy and vulnerability to relapse 
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seen in mood disorders. It has been shown that antidepressant therapy alters or 
blocks these influences (Duman et al., 2006). Increases in BDNF due to 
antidepressant therapy can cause dendritic arborization and increased numbers 
of synaptic contacts and spines, and rises in the development and plasticity of 
neural networks (Castren et al., 2010). It is possible that such synaptogenesis 
and increased dendritic arborization could cause increases in local grey matter 
volume. 
1.4.4 Genetics and Neuroimaging 
Heritability estimates for MDD are of the order of 48-75% (McGuffin et al., 1996). 
The combined use of neuroimaging tools and genetic methods to study mood 
disorders has increased over recent years. It is hoped that combining these two 
areas will advance our insight into the brain and refine our understanding of MDD, 
subsequently causing improved treatments. In association with this direction, 
investigating the effects of the val66met BDNF polymorphism, a valine (val) to 
methionine (met) substitution in the 5' pro-region of the human BDNF protein – 
as a genetic factor – on structural amygdala changes – as a neuroimaging factor 
–in MDD patients could give a new insight in understanding of MDD. 
1.4.4.1 BDNF val66met polymorphism and structural changes in the brain 
It has been found that the val66met polymorphism may have a significant 
influence on the volume of several parts of the brain, such as amygdala, 
hippocampus and parahippocampal gyrus (Pezawas et al., 2004; Bueller et al., 
2006; Montag et al., 2009). 
Interestingly, Montag et al. (2009) has shown an association between the 
val66met allele, parahippocampus, and right amygdala, in which met allele 
carriers had a smaller amygdala and parahippocampus.  
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Numerous studies have focused on hippocampal volumetric changes (Eagan et 
al., 2003; Harrier et al., 2003; Pezawas et al., 2004; Kanellopoulos et al., 2011). 
Although, many studies have shown no association between hippocampus 
volume alteration and the val66met gene polymorphism (Jessen et al., 2009; 
Karnik et al., 2010; Benjamin et al., 2010; Cole et al., 2011), for example, 
Harrisberger et al. (2015) in a meta-analysis suggested that there is no 
association between this BDNF polymorphism and hippocampal volumes. For 
each BDNF genotype, the hippocampal volumes were significantly lower in 
neuropsychiatric patients than in healthy controls. 
Hajeck et al. (2012) in a meta-analysis observed an increased hippocampal 
volume in val homozygotes compared to the met-allele carriers in healthy controls 
(Hajeck et al., 2012). This finding supports an effect of the BDNF val66met 
polymorphism on hippocampal volume changes, presumably due to decreased 
BDNF secretion. Considering these studies in more details, Egan et al. (2003) 
examined the influence of val 66met polymorphism on hippocampus and memory 
function. The met allele was associated with poorer episodic memory, abnormal 
hippocampal activation assayed with fMRI, and lower hippocampal n-acetyl 
aspartate (NAA), assayed with MRI spectroscopy. Neurons transfected with 
green fluorescent protein (met-BDNF-GFP) showed lower depolarization-induced 
secretion, while constitutive secretion was unchanged. In line with this finding, 
met-BDNF-GFP did not localize to secretory granules or synapses. These results 
showed BDNF and its val/met polymorphism could affect memory and 
hippocampal function; furthermore, it has been argued val/met exerts these 
effects by influencing intracellular trafficking and activity-dependent secretion of 
BDNF (Egan et al., 2003; Pezawas et al. 2004; Hariri et al., 2003; Kanellopoulos 
et al., 2011).  
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Consistent with the results of studies confirming the effects of val66met 
polymorphism on hippocampus volume, healthy met carriers with high trait 
depression showed a decreased hippocampal grey matter volume compared to 
subjects that were homozygotes for the val allele (Joffe et al., 2009). One study 
in both healthy controls and MDD patients has shown that carriers of at least one 
met allele have significantly smaller hippocampus volume (Frodl et al., 2007).  
Few studies have been undertaken in relation to right compared to left 
hippocampus volume alteration in association with the val66met BDNF 
polymorphism. However, val/val MDD patients showed decreased left 
hippocampal volume compared to right in a study by Gonul et al. (2011).  
When considering other regions of the brain, a smaller volume of the thalamus, 
fusiform gyrus and several parts of the frontal gyrus were observed in met allele 
carriers (Montag et al., 2009).  
Interestingly, one study in young Chinese adults by combining cortical thickness 
analysis and voxel based morphometry (VBM) analysis found grey matter 
reduction in frontal, temporal, cingulate and insular cortex in the met/met group 
in comparison with a val/val group. In fact, by combining cortical thickness 
analysis and VBM, the specific role of the met/met genotype could be assessed 
in detail for the first time, because of a higher frequency of the met/met genotype 
(27.9%) (Yang et al., 2012).  
1.4.5 Early life stress and major depressive disorder 
The link between stressful life events and MDD has been well documented 
(Cleare et al., 1995). Nemeroff et al. (1999) has argued that the biological basis 
of the association between early life stress and MDD could be related to constant 
activation and hyper responsiveness of the hypothalamic and extra hypothalamic 
corticotropin-releasing circuits and alterations in other neurotransmitter systems 
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involved in the regulation of the stress responses (Nemeroff et.al, 1999; Heim et 
al., 2001). In line with this, it has been suggested that neuroanatomical changes 
of the brain such as hippocampal volume alterations could play a role in the 
association between early life stress and MDD (Heim et al., 2008).  
Epidemiological studies have demonstrated considerable evidence to show a link 
between early life stress and a significantly increased risk of developing 
depression (Heim et al., 2008). In line with this, a strong dose-response 
relationship between the number of childhood abuse experiences and general 
mental health in adulthood has been shown before (Edwards et al., 2003). 
Of note, not all forms of depression are related to early life stress. Some evidence 
suggests the existence of biologically identifiable subtypes of depression as a 
function of childhood trauma (Heim et al., 2008). Furthermore, early-life stress is 
certainly not the only factor causing HPA axis dysregulation in depression, but 
probably interacts with other risk factors, such as genotype variations and gender. 
For instance, the dominance of women in depression might be due to gender 
differences in the prevalence of childhood abuse. In the same way, Heim et al. 
(2010) has suggested that the effect of gender can be an important factor in the 
response to childhood abuse. It has been argued that women are more 
vulnerable to the impact of stressful life events. In line with this, overall rates of 
MDD in women who have suffered from early life stress are 4 times higher than 
in women without a history of childhood abuse (Heim et al., 2000). 
It has been suggested that the potency of acute life stress as a risk factor for 
depression depends on the presence or absence of early life stress. Also, 
symptom patterns and the clinical course of depression may differ as a function 
of childhood abuse. In particular, childhood trauma has been consistently related 
to early onset of depression as well as a larger number of episodes or more 
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chronic depression (Heim et al., 2001; 2008). In association with this, Brown et 
al. (1994) have shown that there is a relation between the chronicity of depression 
and both family violence and sexual abuse experienced in early childhood.  
In fact, biological and symptom patterns as a result of childhood abuse might 
extend over DSM diagnostic categories, giving insight into the nature of 
comorbidity in depression, for instance with anxiety disorders and substance 
abuse (Heim et al., 2008). 
Depressive disorders are recognized to show substantial variability in terms of 
clinical presentation, onset, course, neurobiological changes, and treatment 
response, suggesting a heterogeneous group of etiologically distinct disorders. 
In regards to the past, a binary model of depression prevailed for many years that 
distinguished between endogenous/psychotic and reactive/neurotic subtypes of 
depression. In contrast, it is likely that several manifestations of depression are 
located along a continuum of a single subtype with a psychobiological final 
common pathway. DSM-III introduced descriptive classification dependent on 
phenomenology seemingly representing a research-based medical model rather 
than a clinical-based biopsychosocial model. There is an argument that this 
current classification has hampered depression research and delayed the 
discovery of consistent neurobiological findings or predictors of treatment 
response, and that instead paradigms using all subtypes of depression should be 
experimentally examined using clinical, etiological, neurobiological and genetic 
variables. It has been argued that developmental factors should be noted when 
deriving new depression models. A new typology of depression, based on genetic 
factors, developmental pathways, and neurobiological patterns might lead to 
improved diagnosis and treatment, and the identification of reliable predictors of 
treatment response (Heim et al., 2008). 
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In line with this, the fact that the impact of childhood trauma may be associated 
with the subtype of depression, and the evidence that not all individuals who have 
experienced childhood abuse suffer from MDD, suggest that the association 
between early life stress and depression is complicated.  
Previous neurobiological studies of depression have often not measured or 
controlled for the effects of childhood abuse. Because of the high prevalence of 
early life stress among MDD patients, and to a lesser degree in healthy controls, 
a number of studies did not adequately differentiate the effect of childhood abuse 
and the effect of MDD. Therefore, the probable influence of early life stress have 
not been noticed; and an effect of early life stress may have been considered 
only as an influence of MDD. In line with this, previous results about the 
neurobiology of depression might be affected by the effect of early life stress, and 
this hidden influence may explain the conflicting results of the studies. For 
instance, in studies in which groups only based on presence or absence of MDD, 
there were no significant influence in regards to stress responsiveness whereas 
when defining groups based on childhood abuse and MDD, highly significant 
effects appeared, only in MDD patients with childhood trauma, showing changes 
in stress response systems (Heim et al., 2004; 2008). 
Interestingly, there is an association between childhood abuse and remission 
rates in MDD. Thus, prospective studies have shown that depressed subjects 
with a history of childhood abuse are less likely to have a full response to 
treatment than subjects without a history of childhood abuse (Zlotnick et al., 
1997). 
Regarding the consequences of MDD, there is a strong association between the 
risk of attempted suicide and any kind of childhood abuse in chronic and 
treatment resistant depression (Tunnard et al., 2014), while previous studies 
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have pointed out that the exposure to early life stress significantly increases the 
risk of suicide (Dube et al., 2001).  
1.4.5.1 Types of early life stress and major depression disorder (Emotional, 
Physical, Sexual, and Neglect)  
The high prevalence of childhood abuse, estimated at around 3 million cases in 
the U.S. each year, reinforces the importance of conducting research into early 
life stress. Numerous epidemiological studies have assessed rates of exposure 
to early life stress to be 25-45% (Costello et al., 1998; McCloskey et al., 2000). 
More recently, a retrospective self-report study of community adults found that 
the prevalence of childhood abuse was 30% in women and 41% in men (Scher 
et al., 2004). In particular, the breakdown of abuse into subtypes has been 
reported to be about 60% neglect, 20% physical abuse, and 10% sexual abuse 
(Children’s Bureau, Administration of Children, Youth, and Families, 2006). 
In line with this, Briere et al. (2003) investigated the prevalence of childhood 
abuse through a mailed questionnaire to the general population in the U.S. From 
1,442 randomly contacted subjects, 935 (64.8%) replied completely. 66 men and 
152 women (14.2% and 32.3%, respectively) reported childhood sexual abuse, 
and 22.2% males and 19.5% females fulfilled the criteria for physical abuse.  
Considering sexual abuse, several studies have suggested that around 20–25% 
of women and 8-9% of men have experienced sexual abuse before the age of 18 
(Gorey et al., 1997; McCauley et al., 1997; Holmes et al., 2005). Moreover, 28% 
of the girls suffered from sexual abuse between the age of 6-16 and 16% 
experienced physical abuse (Horowitz et al., 1997). 
Previous studies showed that the type of abuse and increasing severity, duration 
and frequency of abuse increases the risk of developing depression (Sedney et 
al., 1984; Briere et al., 1988; Murphey et al., 1988; Bifulco et al., 1991; Mullen et 
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al., 1993). In particular, physical abuse is related to post traumatic stress disorder 
(PTSD) and the severity of anxiety disorder, whereas sexual abuse is more 
related to panic disorder, agoraphobia, and obsessive-compulsive disorder. In 
line with this emotional abuse is associated with social phobia combined with 
substance abuse; and emotional neglect is generally related to the severity of 
psychopathology (Carr et al., 2013). 
Numerous studies have shown the important role of emotional abuse, sexual 
abuse, physical abuse and neglect in the pathophysiology of depression (Nestler 
et al., 2002; Heim et al., 2011; Davidson et al., 2012). For example, Heim et al. 
(2000), in a study of 49 healthy women aged 18 to 45, showed that hyperactivity 
of the HPA axis and autonomic nervous system is an important consequence of 
early life stress, and in particular, physical and sexual abuse. Specifically, this 
study recruited four groups of women with regular menses, and without a history 
of mania or psychosis. The four groups comprised: 13 subjects with a history of 
current MDD who also had a history of sexual and physical abuse, 10 subjects 
with current MDD but without a history of abuse, 14 subjects without MDD but 
with a history of sexual or physical abuse, and 12 subjects without a history of 
abuse or any psychiatric disorder. Further exclusion criteria were a history of 
substance abuse or eating disorders within 6 months, and the use of psychotropic 
or hormonal medication. Women with a history of childhood abuse and a current 
MDD showed a more than 6-fold higher ACTH response to stress than age-
matched controls. 
Another study in almost 2000 women suffering from depression and anxiety 
showed that levels of psychological problems and physical symptoms and the 
number of suicide attempts is higher in women with a history of physical and 
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sexual child abuse compared to women without a history of physical and sexual 
abuse (McCually et al., 1997).  
Returning to clinical factors, it has been reported by Carr et al. (2013) that there 
is an association between chronicity of depression and childhood physical and 
sexual abuse. It has been argued that there is a link between the severity of MDD 
and these two types of abuse as well (Carr et al., 2013). Sexual abuse may also 
be related to an earlier age of first onset of depression. Carr et al. (2013) argued 
that there is an association between emotional abuse and social abuse. 
Specifically, there is a link between emotional neglect and the early onset of 
depression, depressive symptoms and chronicity of depression.  
1.4.6 Early Life Stress, HPA axis and cortisol awakening response 
The existence of association between cortisol levels and early life stress has been 
found in a number of studies (King et al., 2001; Cicchetti et al., 2001; Lupien et 
al., 2009). 
For instance, Lemieux et al. (1995) found increased 24 hours urinary cortisol 
excretion in females with a history of childhood sexual maltreatment and PTSD. 
In contrast, Stein et al. (1997) in women with a history of childhood sexual abuse 
observed hyper suppression of salivary cortisol concentrations in response to a 
low dose of dexamethasone, although no effect on basal morning cortisol 
concentration in women was observed. However, decreased concentrations of 
basal plasma salivary cortisol in the morning have been found in abused women 
in other studies (Heim et al., 2001). 
Associated with this, King et al (2001) investigated the basal functioning of the 
HPA axis by measuring morning salivary cortisol in relation to early sexual 
abuse in girls aged 5 to 7 years. The study showed that abused subjects had 
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significantly lower cortisol in comparison to control subjects, suggesting that 
children may have an impaired HPA axis after childhood abuse.  
However, it is not well documented whether the effect on cortisol levels continues 
into adulthood, due to few longitudinal studies having been undertaken (Power et 
al., 2012). Nevertheless, a number of studies have suggested that severe 
childhood abuse can impact on cortisol secretion in adulthood, where it presents 
as hypocortisolemia in adulthood (Stein e al., 1997; Gunnar et al., 2001; Roy et 
al., 2002; Weissbecker et al., 2006; Power et al., 2012). Furthermore, Power et 
al. (2012) demonstrated that in a non-clinical population, flattened morning 
cortisol secretion is related to the degree of cumulative early life stress in 
childhood.  
It has been suggested that the specific type of early life stress may have an 
impact on the patterns of cortisol secretion (Lupien et al., 2009). Thus, low 
glucocorticoid concentrations seem to develop in early childhood in response to 
trauma, raising the possibility that these low cortisol levels in turn render an 
individual vulnerable to developing PTSD in response to trauma in adulthood. 
However, arguing against such a pathway, another study by Peng et al. (2014) 
argued that childhood neglect may cause hyperactivity of the HPA axis. This 
study consisted of 28 MDD patients with childhood neglect and 30 MDD patients 
without childhood neglect, who were compared with 29 age and gender matched 
healthy controls without childhood neglect and 22 control subjects with childhood 
neglect. The change in cortisol levels between the time of awakening and 30 
minutes after awakening was used as the measure of the HPA axis reactivity. 
They found childhood neglect may cause hyperactivity of the HPA axis 




In line with this, other studies of adults who have experienced childhood abuse 
show hyper-reactivity of the HPA axis in abused, depressed subjects and 
hypoactivity in subjects with PTSD. The changes in abused, depressed adults 
have been associated with CRH-induced escape of glucocorticoid secretion from 
suppression by treatment with dexamethasone, showing that the glucocorticoid 
feedback of the HPA axis is impaired with increased hypothalamic drive. 
Therefore, a decreased capacity of glucocorticoids to inhibit the HPA axis when 
it is stimulated could further accentuate CNS responses to stressors (Lupien et 
al., 2009). 
Considering the CAR as an index of the HPA axis, Engert et al. (2010) argued 
that there is an association between both increased CAR and increased 
afternoon cortisol and a history of low parental care. Specifically, 58 subjects 
consisting of 19 men and 39 women aged 18 to 30, were selected by 
psychological questionnaires. Saliva cortisol was collected at awakening, 30 min 
afterwards and at 3 p.m., 6 p.m., and 9 p.m. on three non-consecutive working 
days. The participants with low parental care showed an increased CAR and 
afternoon cortisol level compared to those who had received high parental care. 
1.4.7 HPA axis, cortisol and cortisol awakening response  
One of the most widely replicated and potentially important results of previous 
studies in MDD patients is the alteration of the HPA axis (Carroll et al., 1976, 
Young et al., 2001), which is one of the most crucial findings in 
psychoneuroendocrinology (Arborelius et al., 1999; Nestler et al., 2002). 
Although numerous studies have shown that there is a relation between 
hyperactivity of the HPA axis and MDD, and hypercortisolemia in MDD patients 
has been observed in several previous MDD studies (Gold et al., 1985; Holsboer 
et al., 1985), for example a study by Vreeburg et al. (2009) showed a higher CAR 
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among both subjects with current MDD and subjects with remitted MDD, and 
argued that this may be indicative of an increased biological vulnerability for 
depression (Vreeburg et al., 2009), One meta-analysis pointed out that there is 
no strong relation between cortisol and depression (Knorr et al., 2010). 
A number of cross-sectional studies have shown an increased cortisol in MDD 
patients (Young et al., 2006; Vinberg et al., 2008; Dougherty et al., 2009; 
Vreeburg et al., 2010; Carnegie et al., 2013). In association with this, an 
increased level of cortisol has been observed in some cross-sectional studies of 
subjects at high risk, such as having familial history of depression, in MDD (Young 
et al., 2006; Vinberg et al. 2008; Dougherty et al., 2009; Vreeburg et al., 2010). 
In particular, higher basal level of cortisol and higher cortisol after both 25 mg and 
5 mg dexamethasone intake (Young et al., 2006); higher evening cortisol level 
(Vinberg et al., 2008); elevated morning cortisol (Dougherty et al., 2009); and 
higher morning cortisol (Vreeburg et al., 2010). In sum, the cross sectional 
studies have shown an association between increased CAR and MDD but could 
not show cause or tease out the aetiology.  
The evidence that pathological and iatrogenic hypercortisolaemic states are 
associated with a high prevalence of depressive symptoms (Patten et al., 2000; 
Pereira et al., 2010) suggests the hypothesis that the abnormal HPA axis function 
may be a causative factor in the increased risk of subsequent MDD, although the 
findings from this large prospective cohort study could not confirm the hypothesis 
that the CAR, or other basal salivary cortisol measures consisted of cortisol at 
each time point, diurnal drop and area under the curve, increase the risk of 
developing a depressive illness (Carnegie et al., 2013).  
It has been pointed out that several factors might contribute to the observed HPA 
axis alterations in MDD patients. Considering age and gender, a number of 
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studies have suggested that gender may have an important role. In line with this, 
Deuschle et al. (1997) and Linkowski et al. (1985) have found the higher 24 hours 
mean cortisol levels in male unipolar and bipolar MDD patients compared to male 
healthy controls, although no significant difference in 24 hours mean ACTH level 
was observed. In line with this, Young et al. (2001) has suggested that elevated 
cortisol levels˗˗ten minute sampling for ACTH and cortisol was performed for 24 
hours˗˗are found only in 24% of premenopausal women in compared to healthy 
premenopausal control women. Recently, the role of age has been investigated. 
One study argued that older MDD patients show higher rates of abnormal HPA 
axis activity when compared with younger MDD patients (Murri et al., 2013). In 
line with this, in a study of older age MDD patients, Bremmer et al. (2007) has 
demonstrated that MDD in late life is associated with both hyper and 
hypocortisolemia. Specifically, the study consisted of 1185 subjects aged 65 and 
older. The morning cortisol plasma level was measured. The result of the study 
suggested that the association between cortisol and MDD is U-shaped rather 
than linear. The U-shaped relation of cortisol and MDD implies that there is an 
optimal range of cortisol values associated with the lowest depression rates that 
is located at the trough of their study’s curve. On the other hand, they found clear 
evidence of a U-shaped relation between plasma cortisol and late-life MDD, but 
not subthreshold depression. The findings may show that in the elderly, 
depression is related to an imbalance in stress homeostasis causing either 
hypoactivity or hyperactivity of the HPA axis. Hypocortisolemic depression was 
associated with female sex, joint disease, and smoking, and the relation between 
low cortisol levels and depression was most notable in recurrent depression. 
Hypercortisolemic depression was related to male sex, older age, cardiovascular 
disease, current use of NSAIDs, and cognitive impairment. Of note, the majority 
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of cortisol values they found were within the normal range of 150-700 nmol/L (4% 
<150 and 12.5% >700). They defined hypocortisolemic and hypercortisolemic 
depression relative to one another, that is, lowest, middle, and highest tertile. 
In agreement with this, Herbert et al. (2012), in a study of the relationship between 
the BDNF val66met polymorphism and morning cortisol level, also found 
evidence that the relation between cortisol and MDD may be U-shaped rather 
than linear. Their study consisted of 279 premenopausal women who were at 
high risk of MDD. Morning salivary cortisol was calculated for up to 10 days. 
Subjects were observed for about 12 months by telephone calls at 3-4 monthly 
intervals. There was a significant U-shaped association between adjusted 
morning cortisol levels at baseline and the probability of depression onset during 
observation. The BDNF val66met genotype was not directly associated with 
onset of depression or with cortisol levels, but there was significant interaction 
between val66met and cortisol; the association between baseline cortisol and 
depression was restricted to those with the val66val genotype. It should be 
considered that they found a quadratic association between depressive onset 
and cortisol: as well as higher cortisol anticipating increased risk for MDD in their 
subjects, there was some evidence that levels in the lower range also 
represented increased risk. 
In terms of remission, a number of studies have shown that the alteration of the 
HPA axis is an important finding in remitted MDD patients (Bhagwagar et al., 
2003; Vreeburg et al., 2009). For example, Bhagwagar et al. (2003) found 
recovered MDD patients had a significantly greater CAR than age and gender 
matched comparison subjects. The waking increase in free cortisol is caused by 
enhanced release of ACTH, which suggests that recovered MDD patients may 
have abnormalities in ACTH secretion or in the responsiveness of the adrenal 
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gland to ACTH stimulation. That recovered patients may show abnormalities in 
HPA axis function, supports the argument that this abnormality may represent a 
trait marker of vulnerability to depression, as do the observed changes in 
cortisol response to the combined CRH-dexamethasone test in participants at 
high genetic risk of depression (Bhagwagar et al. 2003). More studies are 
essential to determine whether the exaggerated increase in CAR concentrations 
in remitted MDD patients is related prospectively to the risk of depressive relapse, 
or indeed to the development of comorbid medical disorders, such as coronary 
heart disease. 
As discussed earlier, there have been inconsistencies in these findings to date. 
The conflicting results around the association between cortisol and MDD may 
have been caused by methodological variation, such as changes in salivary 
collection protocols, and different sample populations such as medicated or un-
medicated subjects, and whether subjects were remitted, chronic or acute MDD 
patients. Inconsistencies may also be due to the inherent problems in reliably 
assessing an endocrinological system with marked diurnal as well as pulsatile 
variations (Lopez-Duran et al., 2009, Carnegie et al., 2013). Using a systematic 
and comprehensive methodological approach, and having a larger sample sizes, 
may lead to a more reliable of HPA axis changes in MDD (Carnegie et al., 2013). 
Interestingly, it has been argued that the prevalence of abnormalities is related to 
the measure chosen and the subtypes of depression (Young et al., 2001). Thus, 
when ten-minute sampling for ACTH and cortisol was performed for 24 hours in 
premenopausal depressed women, increased cortisol was found in MDD patients 
meeting criteria for endogenous (12.17 ± 4 microg/dl). There was no difference in 
mean cortisol between the patient groups as a whole (8.36 ± 2.9 microg/dl) and 
those MDD patients with atypical depression (8.38 ± 1.9 microg/dl. The baseline 
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component area under the curve of cortisol secretion was increased at a trend 
level (P=0.64); and the baseline AUC for ACTH was significantly increased in 
MDD patients. 
The association between CAR as an index of HPA axis function and MDD, is still 
unclear. Of note, the focus on the CAR is essential, since it has been found that 
CAR is more reliable and useful in the studies of MDD than traditional measures 
of the HPA axis, such as the dexamethasone suppression test (Dedovic et al., 
2015).  
Beginning with subclinical depression, some studies have investigated the 
relationship between subclinical levels of depression and the CAR. For example, 
in a study of moderate and high subclinically depressed young males and 
females, Dedovic et al. (2010) found a flattening of cortisol level during the first 
hour of awakening associated with subclinical depression: lower CAR AUCi was 
observed in high subclinical depression compared to the healthy controls, with 
moderate subclinical depression group presenting AUCi level between these two 
groups (Dedovic et al., 2010). In association with this, Mangold et al. (2011) 
conducted a study on males and females (aged 18-38) with low, moderate, and 
high subclinical depression symptoms. They found that high compared to low–
moderate subclinical depression symptoms were related to a flattening of the 
CAR. Similarly, a study investigating young males, whose scores on the Hamilton 
Depression Inventory were within the low, non-clinical range, showed a positive 
relation between low, non-clinical depression levels and the CAR AUCi 
(Pruessner et al., 2003). 
Focusing on clinical MDD, depression has been associated with both increased 
and lowered CAR in previous studies (Dedovic et al., 2015). For example, a 
higher CAR was observed in a large study of middle-aged MDD patients in 
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comparison to control subjects. Thus, Vreeburg et al. (2009) in a large cohort 
study showed that there is a strong link between MDD and CAR. This study 
consisted of three groups including control subjects without psychiatric disorders, 
subjects with remitted MDD, and patients with a current MDD. They observed a 
higher CAR among both subjects with current MDD and subjects with remitted 
MDD. This finding may be suggestive of an increased biological vulnerability for 
depression. Although both remitted and acute MDD groups had a significantly 
increased CAR, compared to healthy controls, surprisingly, no association was 
found between MDD characteristics such as severity, chronicity, symptom profile 
and early life stress. Similar to their findings, Ulrike et al. (2013) found a higher 
CAR in female MDD patients compared to controls. The CAR was calculated at 
0, 30, 45, and 60 min after awakening. In line with this, in a study, consisted of 
women ranging in age from 17 to 23, the similar result was observed. Each 
participant provided salivary cortisol samples after awakening and 30 minutes 
after awakening on five consecutive weekdays. The main finding was that, 
individuals at risk for depression had higher CAR than control participants 
(Dienes et al., 2013). In agreement with this, Bhagwagar et al. (2005) in a study 
consisting of 20 acutely un-medicated MDD patients and 40 healthy controls 
found that although after 60 minutes of awakening the CAR was similar in healthy 
controls and MDD patients, there was an approximate 25% increase in the CAR 
in MDD patients at 30 min after awakening. The overall CAR was higher than in 
MDD patients than healthy controls.  
Consistent with these results, studies which have focused on remitted MDD 
patients have generally found a higher CAR in remitted subjects. For example, 
higher CAR levels were found in a remitted middle-aged depressed subjects who 
were using medication (Vreeburg et al., 2009). In line with this finding, Bhagwagar 
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et al. (2003) found a similar result in remitted patients who were not using 
medication. 
In contrast, a number of studies found a blunted or lower CAR in MDD patients 
compared to controls. For example, a study of young adult women with current 
mild to moderate clinical depression found a blunted CAR in depressed women 
compared to non-depressed subjects (Stetler et al., 2005). In agreement with 
this, older subjects without a lifetime depression and/or anxiety disorder were 
compared with older subjects with a duration of 6 month MDD in a study by 
Rhebergen et al. (2015). The MDD patients showed a decreased ability to 
respond to the stress of awakening among depressed older persons compared 
to the other group. In line with this, in a sample of outpatient MDD subjects, 
salivary cortisol was collected at awakening, 45min after awakening, and at 12:00 
p.m., 17:00 p.m., and 21:00 p.m. Flattened diurnal patterns were associated with 
more severe levels of depressive episode (Hsiao et al., 2010). In agreement with 
these results, Miller et al. (2005) has suggested that there may be an association 
between a blunted CAR and moderate or mild depression in outpatients.  
Some previous studies found no association between CAR and depression. For 
instance, Vammen et al. (2014) in a repeated cross-sectional and short-term 
design found that the CAR is not associated with self-reported symptoms of 
depression or with clinical depression. Explaining the detail of this study, a 
questionnaire along with salivary cortisol test tubes for home administration were 
sent to around 10,000 public sector employees. Morning (30min after awakening) 
and evening (20:00 p.m.) salivary samples were provided. They gathered around 
3500 questionnaires and valid saliva samples. Approximately 4 months later, a 
subsample of the subjects provided three morning saliva samples (at awakening, 
20min and 40min after awakening) plus an evening sample (20:00 p.m.); In line 
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with this, subjects with high baseline scores of self-reported depressive 
symptoms, burnout and perceived stress were invited to a standardized interview 
to diagnose clinical depression and the symptom questionnaire was repeated for 
subsample subjects. The study was repeated in 2 years later with questionnaires 
and salivary test tubes with around 2500 participants. In four cross-sectional and 
two short-term follow-up analyses, sex, age, income, education, family history 
of depression, physical activity and alcohol consumption were adjusted for 
subjects. In sum, they examined the impacts of several saliva cortisol measures 
consisted of morning, evening, mean of morning and evening but they could not 
find any association between cortisol levels or CAR with depressive symptoms 
or clinical depression.  
A number of studies have focused on familial or parental history of MDD as a 
factor which may affect the CAR either in healthy controls with no history of 
depression or depressed subjects with acute MDD. It has been argued that 
familial risk is associated with a higher CAR even in the asymptomatic 
participants. Specifically, an increased CAR over the first 30 minutes after 
awakening in young people with high familial risk of depression compared to 
control participants was observed in one study (Mannie et al., 2007). They argued 
that this finding could not be explained by current mental state of subjects 
because both subjects with familial history of depression and control subjects 
scored the same on ratings of mood symptoms and perceived stress. They also 
argued that it is not clear that increased waking salivary cortisol levels can 
anticipate individual risk of illness and whether the increased cortisol secretion 
has implications for general health and cognitive function.  
In another study, three groups were investigated, consisting of people without a 
familial history of MDD, with a self-reported familial history of MDD and with a 
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diagnosed familial history of MDD. These groups were compared either with each 
other or with a comparison group of subjects with a remitted or current major 
depressive disorder and/or current panic disorder with agoraphobia. They 
showed that, in comparison with healthy controls without a familial history of 
MDD, healthy subjects with familial history of depression or anxiety showed a 
higher CAR at 30 minutes, 45 minutes, and 60 minutes after awakening, which 
was similar to that observed in MDD patients with depression or anxiety disorders 
themselves. Unaffected people with self-reported parental history did not differ in 
awakening cortisol levels from unaffected people without parental history. The 
higher cortisol levels were only found in offspring of patients with a diagnosis 
treated in specialised mental healthcare and not in offspring with affected parents 
based on self-report. In sum, this study argued that a higher CAR reflects a trait 
marker, which can demonstrate an underlying biological vulnerability for the 
development of depressive and anxiety disorders and they demonstrated that 
their findings may show that self-report of parental psychopathology is of 
insufficient reliability (Vreeburg et al., 2010).  
Findings from previous studies suggest that increased CAR could be related to 
MDD onset and recurrence. The work to date shows that CAR is highly heritable 
which represent that to a certain degree, it is a trait-like feature; however it is 
affected by environmental and situational items, and it may serve as an index of 
an individual’s overall vulnerability to depression as it associates to stressful 
experiences. In conclusion the association between CAR and depression is 
complicated and future studies are essential to clarify this association (Dedovic 
et al., 2015). 
Considering morning salivary cortisol instead of the CAR, one study conducted 
by Herbert et al. (2012) has suggested that there is an association between low 
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level of morning salivary cortisol and increased risk of MDD. Moreover, several 
studies have shown that cortisol level during the morning may predict the onset 
of major depressive episodes or symptoms (Harris et al., 2000; Halligan et al., 
2007; Goodyer et al., 2010; Vrshek-Schallhorn et al., 2012). For example, in one 
of these studies which also focused on CAR, Vrshek-Schallhorn et al. (2012) 
showed that at 6 months after cortisol sampling, any one-unit rise in the baseline 
standardized CAR was related with a higher than 3-fold increase in risk per month 
for MDD onset. This risk then decays, remaining a statistically significant predictor 
in other sample for around 2.5 years (out of 4 years), but not significantly so after 
such time. 
In line with this, Harris et al. (2000) has shown that morning cortisol may play a 
role as a risk factor for subsequent MDD in adult women. In detail, women not 
currently depressed, but known to be vulnerable to the onset of MDD for 
psychosocial reasons, were selected for baseline interview and followed up after 
12 months. Their mental state was examined using the Schedule for the Clinical 
Assessment in Neuropsychiatry (SCAN). MDD patients were defined using DSM-
IV or the Bedford College measurement. Saliva was collected over four 
consecutive days consisting of two times over 24 hours: at 8: 00 a.m. and at 20:00 
p.m. The study found an association between the subsequent onset of MDD and 
morning cortisol level. In particular, this was related with severe adverse life 
events and difficulties during the follow-up period; mean morning cortisol levels 
at entry; and the presence of any of three vulnerability factors. 
Considering antidepressant therapy, interestingly, a number of previous studies 
have assessed the association between antidepressants and changes in cortisol 
levels (Rota et al., 2005; Nikisch et al., 2005, Aihara et al., 2007).  
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In particular, Rota et al. (2005) investigated the effect of Amitriptyline and 
Fluvoxamine on HPA axis activity in MDD patients. Plasma cortisol and ACTH 
levels were determined in three samples, drawn at 20min intervals between 8:00 
a.m. and 9:00 a.m.; cortisol levels were determined again at 20:00 p.m. They 
could not demonstrate any effect of antidepressant therapy on the cortisol 
circadian rhythm abnormality. In another study investigating the effect of 
antidepressants on HPA axis function in MDD patients, a combined 
dexamethasone suppression and corticotropin-releasing hormone stimulation 
test, following a placebo week after 2, 4, and 16 weeks of 40 mg/day Citalopram 
treatment was performed. The study found that decreased AUC cortisol was 
highly associated with S-citalopram concentration in plasma. They showed that 
long-term, 4-6 weeks, Citalopram administration decreases the responsiveness 
of the HPA axis in patients with major depression.  
In line with this , there are studies investigating the effect of the selective 
serotonin reuptake inhibitors (SSRIs) therapy on cortisol level in saliva of MDD 
patients, which have shown decreasing cortisol secretion as an effect of SSRI 
therapy (Rota et al. 2005; Nikisch et al. 2005; Mondelli et al. 2006; Aihara et al. 
2007). Dziurkowska et al. (2013) observed that the level of morning salivary 
cortisol decreases in inpatients females after 30 days of admission and therapy.  
 In association with this, a randomised, blinded, placebo-controlled, parallel group 
design study looked at the effects of the SSRI citalopram in the first degree-
relatives of patients with MDD (Knorr et al., 2012). The results of this study 
suggested that 4 weeks administration of Escitalopram reduces HPA axis activity 
in healthy controls, as the level of awakening salivary cortisol and all 
day salivary cortisol were lower in the subjects taking SSRI compared with 
subjects taking placebo. 
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In sum, the association of cortisol level or CAR in MDD has still remained unclear, 
suggesting a complex relation between cortisol and MDD. 
1.4.8 The Association of the Biomarkers   
It seems likely that that there is an association between structural changes to the 
brain and other potential predictor biomarkers of MDD. For example, previous 
studies found a reduction of hippocampus volume in MDD patients with a history 
of child abuse (Heim et al., 2008). More specifically, it has been shown that the 
left hippocampus in MDD women with a history of early life stress is 18% smaller 
compared to non-abused MDD women and 15% smaller compared to healthy 
controls (Vythilingam et al., 2002). 
Previous studies in healthy controls also provided some evidence of possible 
links between genetic factors, structural brain changes and early life stress. In 
particular, smaller amygdala and hippocampal volumes were observed in healthy 
met carriers with a history of childhood abuse (Gatt et al., 2008).  
In agreement with a possible link between biomarkers, the association between 
life stress and val66met polymorphism in the BDNF gene has recently received 
much attention. In detail, Wichers et al. (2008), conducted a study on the study 
sample consisted of 621 participants aged 18-46 years who were taking part in 
an ongoing longitudinal, general population twin study. Childhood adversity was 
measured using the shortened version (Bernstein et al., 1997) of the 70-item CTQ 
questionnaire. Their result showed that childhood abuse had a larger impact on 
depression scores in BDNF met carriers than in BDNF non-met carriers. Another 
important finding of this study was a main effect of BDNF val/met genotype on 
reported childhood abuse, meaning that heterozygous val/met subjects reported 
significantly more childhood adversity than other subjects. Therefore, they argued 
that BDNF heterozygous subjects may have differences in personality that 
73 
 
increase the likelihood of exposure to adversities or make them more sensitive to 
experience stress and/or poor outcome following exposure to adversities.  
 In line with this, Aguilera et al. (2009) has demonstrated that childhood abuse 
predicted higher level of adult depressive symptoms. In detail, they found that 
childhood sexual abuse, childhood emotional abuse and childhood emotional 
neglect may play a role on symptoms of MDD. Of note, childhood sexual abuse 
had a stronger influence on depressive symptoms in met allele carriers of 
the BDNF gene in compared to the val/val group. 
However, recently, a systematic review, argued that the interaction between 
BDNF, brain volume and childhood adversity is more convoluted, meaning that 
the interaction between BDNF and life stress in MDD is stronger for stressful life 
events compared to childhood abuse (Hosang et al., 2014).  
Turning to investigations which tried to find a link between brain structural 
changes and endocrinological factors, Lu et al. (2013) found an association 
between an elevated CAR and the cingulate gyrus volume. The study comprised 
healthy controls with childhood abuse and age and gender matched individuals 
without childhood abuse. Each subject collected salivary samples in the morning 
at four time points: at awakening, 30, 45, and 60 min after awakening for the 
assessment of the CAR on the MRI scan day. All of the subjects were scanned 
using a 3 Tesla scanner; and VBM was conducted on structural images. The 
study showed an association between an increased CAR and grey matter volume 
reduction in the right cingulate gyrus volume in healthy controls with a history of 
early life stress. Of note, previous studies have found a link between early life 
stress and structural changes of other brain regions. In detail, increasing 
evidence has shown a strong link between decreased hippocampus volume and 
early life stress, as well as profound reductions of medial prefrontal cortex 
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volume. Also, it has been found that there is a correlation between deprivation 
and reduced orbital-fronto cortical volume in post institutionalized children (Lu et 
al., 2013). 
In sum, it is important to consider associations between several biomarkers in 
MDD to make clear insight for understanding of this complex disorder; these 
previous studies represent first steps towards findings such associations, but 
future work remains to be undertaken. 
1.5 Aims and Objectives  
My thesis focused on the aetiology, role and interaction of genetic, neuroimaging 
and endocrinology measures, aiming to find a potential biomarker in MDD; it 
consisted of two main parts: 
1. Genetics and Neuroimaging, specifically, the interaction of genetic factors and 
structural brain changes in MDD  
2. Endocrinology, specifically, characterizing the nature of HPA axis changes in 
MDD, using the CAR, and investigating the effect of childhood abuse in the 
aetiology of HPA axis changes in MDD 
1.5.1 Aims and Objectives of the first study  
The aim of the first study of my thesis was to investigate the modulation of 
amygdala structure by the val66met BDNF gene polymorphism 
In particular, the hypotheses were as follows: 
1. MDD patients have a decreased amygdala volume compared to healthy 
controls 
2. In healthy controls, met allele carriers have a decreased amygdala volume 
compared to the val/val genotype 
3. In MDD patients, met allele carriers have a decreased amygdala volume 
compared to the val/val genotype 
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4. The effect of the met allele on amygdala volume is larger in those with MDD 
than in controls  
1.5.2 Aims and Objectives of the second study 
The main aim of the second study of my thesis was to investigate neuroendocrine 
abnormalities in MDD, using the CAR as an index of HPA axis, and the 
association of these neuroendocrine abnormalities with early life stress  
The hypotheses of the second study were as follows: 
1. The CAR is elevated in MDD patients compared to healthy controls  
2. The CAR is elevated in those with a history of childhood abuse compared to 
those without such a history 
3. This effect is additive in that the CAR is most elevated in those who are both 
depressed and have a history of ELS  
4. The CAR in patients with MDD but without a history of ELS is not elevated  






  THE FIRST STUDY, METHODOLOGY AND RESULTS 
2.1 Methodology 
2.1.1 Subjects 
Our case control study consisted of 87 recurrent MDD patients and 74 healthy 
controls, matched for age, sex, verbal IQ and the tendency to use either the right 
or the left hand.  
2.1.2 Clinical Assessments 
Patients had experienced two or more depressive episodes of at least moderate 
severity and they met criteria for recurrent MDD, as characterised by the DSM-IV 
using the Schedules for Clinical Assessment in Neuropsychiatry interview (Wing 
et al., 1990). The Schedules for Clinical Assessment in Neuropsychiatry interview 
was used as the main clinical assessment tool (Wing et al., 1990). This was 
undertaken in patients in order to confirm the presence of MDD and exclude 
inappropriate diagnosis, and in healthy controls to exclude a history of psychiatric 
disorder.  
The Beck Depression Inventory was used to measure current depressive 
symptoms (Beck et al., 1961). The Wechsler Abbreviated Scale for Intelligence 
was performed to assess the IQ of participants (Wechsler, 1999). Data in regards 
to current use of antidepressant medications were collected from the MDD 
patients.  
All participants had taken part in genetic association studies (Cohen-Woods et 
al., 2009; Uher et al., 2010). 
2.1.3 Exclusion and Inclusion Criteria  
Contraindications to magnetic resonance imaging (MRI) were considered for all 
participants during screening. Subjects with any history of head injury causing a 
loss of consciousness, conditions known to affect brain structure or function such 
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as alcohol or substance abuse, or any diagnosis of neurological disorder, were 
not included. If a participant, or if one of their first-degree relatives, ever fulfilled 
criteria for mania, hypomania, schizophrenia, or mood incongruent psychosis, 
they were not included. 
2.1.4 Ethical Approval  
Local ethics committee approval was received for the study and the subjects 
signed informed consent forms. 
2.1.5 Neuroimaging and Genetic protocols 
2.1.5.1 Genotyping 
Val66met BDNF genotyping was undertaken using either polymerase chain 
reaction or a Taqman 5’ exonuclease assay (Cohen et al., 2009). In terms of 
BDNF genotype, patients comprised three groups: val/val, val/met and met/met. 
For the purpose of the present analysis, the groups were combined into two 
groups – val/val homozygotes and met carriers – due to the small number of 
met/met homozygote subjects. Genotype frequency was tested to ensure that 
Hardy Weinberg equilibrium was not violated.  
2.1.5.2 Neuroimaging 
Magnetisation-prepared rapid gradient echo (MP-RAGE) T1-weighted scans 
were acquired at 1.5 T (Signa HDx 1.5 T system, General Electric, Wisconsin, 
USA) with the following parameters: time to echo 3.8 ms, repetition time 8.59 ms, 
flip angle 8°, field of view 24 × 24 cm2, slice thickness 1.2 mm, number of slices 
180 and image matrix 256 × 256. The MP-RAGE volume was acquired using the 
Alzheimer’s disease Neuroimaging Initiative (ADNI) custom pulse sequence, with 
full brain and skull coverage.  
Grey matter volumes, surface area and average cortical thickness measurements 
were measured using Freesurfer version 5.1.0 (Westman et al., 2013). 
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Further to the priori hypothesis, analysis focussed on the amygdala as a region 
of interest.  
A multivariate ANOVA was used to assess MDD patients and healthy controls 
and val/val BDNF genotypes and met carriers (val/met and met/met genotypes).  
2.1.6 Statistical analysis  
Data were analyzed with SPSS (Statistical Package for Social Sciences, Version 
22).  
A Shapiro Wilk’s test, a Kolmogorov-Smirnov test and visual inspection of 
histograms, Q-Q plots and box plots showed that the data of our study were 
normally distributed, and thus parametric statistic were used. 
Chi square was used to analyze categorical variables (such as gender). An 
independent student t test was used for comparing mean scores on continuous 
variables. 
The prior region of interest (ROI) was the amygdala. This was analyzed for both 
left and right sides as a priori hypothesis. 
A multivariate ANOVA was used to assess differences in amygdala volumes 
between healthy controls and MDD patients and between val/val BDNF 
genotypes and met carriers (val/met and met/met) and the estimated marginal 
means were presented.  
If p < 0.05 the null hypothesis was rejected.  
The hypotheses of the first study were as follows: 
1. MDD patients have a decreased amygdala volume compared with controls. 
2. In healthy controls, met allele carriers have a decreased amygdala volume 
compared with the val/val genotype. 
3. In MDD patients, met allele carriers have a decreased amygdala volume 
compared with the val/val genotype. 
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4. The effect of the met allele on amygdala volume is larger in those with MDD 
than in controls. 
Post hoc tests were undertaken using a univariate ANOVA on both right and left 
amygdala to find differences between: val/val and met carriers in MDD; val/val 
and met carriers in healthy controls; val/val MDD and val/val in controls; and met 
carriers in MDD and met carriers in healthy controls and the estimated marginal 
means were presented.  
2.2 Results 
Our subjects consisted of 2 groups (161 subjects) and 4 subgroups (explained at 
page 82) 
1. Healthy Controls (74) 
2. MDD Patients (87)  
(Table 2.1)   







There was no difference in terms of gender between the groups (Table 2.2). 
Table 2.2 Gender 
 Controls MDD Statistics 
Male 34 (22%) 28 (17%) p= 0.7 
x²=2.6 Female 40 (24%) 59 (37%) 
 
There was no difference in terms of age between groups (Table 2.3) 
Table 2.3 Age 
 Controls MDD Statistics 








There was no difference in terms of Verbal IQ between groups (Table 2.4). 
Table 2.4 Verbal IQ 
 Controls MDD Statistics 
Verbal IQ 
 
119.0±8.7 116.8±11.4 p=0.1 
t=1.3 
 
There was no difference in terms of the tendency to use either the right or the left 
hand between groups (Table 2.5). 
Table 2.5 The tendency to use either the right or the left hand 
 Controls MDD Statistics 
Right Left Right and 
Left 




63(86%) 9 (12%) 1(2%) 74(84%) 11(12.5%) 3 (3.5%) p=0.6 
x²= 0.7 
 
There was no difference in terms of BDNF genotype between groups (Table 2.6). 
Table 2.6 Genotype 
 Controls MDD Statistics 
 
val/val met carriers val/val met carriers p=0.6 












2.2.1 Comparing the amygdala volume between MDD patients and healthy 
controls 
Although the mean amygdala volume was numerically lower in MDD patients, 
there was no significant volume reduction in MDD patients compared with 
controls (right amygdala-p=0.09; left amygdala-p=0.1) (Table 2.7) 
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Table 2.7 Comparing the amygdala volume between MDD patients and healthy controls 
 







Right Amygdala 1479.1  230.5 1552.5 271.3 0.09 
Left Amygdala 
 




















Figure 2-1 Right amygdala volume in MDD patients and healthy controls 
  
 
Figure 2-2 Left amygdala volume in MDD patients and healthy controls 
 
2.2.2 Comparing the amygdala volume between Val/Val Carriers and Met 
Carriers (Val/Met, Met/Met) 
Although the amygdala volume was smaller in met carriers compared with the 
val/val BDNF genotype, the reduction was not significant (right amygdala-p=0.3; 
left amygdala-p=0.1) (Table 2.8) 
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Table 2.8 Comparing the amygdala volume between val/val carriers and met carriers 
 
Brain Region met carriers 
mm³ 






1486.8  252.5 1529.1 251.5 0.3 
Left  
Amygdala 
1372.2 216.02 1422.5 251.2 0.1 
 
 
Figure 2-3 Comparing the right amygdala volume between val/val carriers and met carriers 
 
 





There was no significant interaction between BDNF genotype and groups˗˗or sub 
groups explained on page 82˗˗on amygdala volume either in right or left amygdala 
(right amygdala-p=0.06; left amygdala-p=0.2). The estimated marginal mean 
values represent the mean value for each factor, adjusted for any other variables 
in the model. - The estimated marginal means of right and left amygdala in MDD 


























In order to test our hypotheses, new sub groups were then formed, consisting of 
healthy controls and MDD patients as below (Table 2.9) 
1. val/val BDNF healthy controls (HC): 48 subjects 
2. met carriers healthy controls (HC): 26 subjects 
3. val/val BDNF MDD : 52 subjects 
4. met carriers MDD: 35 subjects  
 
Table 2.9 New groups in regards to genotype 
val/val HC met HC val/val MDD met MDD 
48(30%) 26(16%) 52(32%) 35(22%) 
 
 
2.2.3 Comparing the amygdala volume between Met Carriers and Val/Val 
Carriers in healthy controls 
The amygdala volume was numerically smaller in met carriers compared with 
val/val homozygotes in healthy controls, but the reduction was not statistically 
significant (right amygdala-p=0.7; left amygdala-p=0.5). Table 2.10 













1575.0 263.1 1510.8 286.2 0.7 
Left  
Amygdala 




2.2.4 Comparing the amygdala volume between Met Carriers and Val/Val 
Carriers in MDD patients 
The amygdala volume was numerically smaller in met carriers compared with 
val/val homozygotes in MDD patients, but the reduction was not statistically 
significant (right amygdala-p=0.9; left amygdala-p=0.9) (Table 2.11). 












1491.2  235.2 1461.2 225.5 0.9 
Left  
Amygdala 
1390.06 230.7 1357.8 205.6 0.9 
 
 
2.2.5 Comparing the amygdala volume between Met Carriers in healthy 
controls and Met Carriers in MDD patients 
There was no statistically significant difference in amygdala volume between met 
carriers in healthy controls and met carriers in patients. Patients had a 
numerically smaller amygdala volume which was not significant (right amygdala-
p=0.8; left amygdala-p=0.9) Table 2.12  

















1510.8  286.2 1461.2 225.5 0.8 
Left  
Amygdala 




2.2.6 Comparing the amygdala volume between Val/Val Carriers in healthy 
controls and Val/Val Carriers in MDD patients 
The amygdala volume was numerically smaller in MDD patients compared with 
healthy controls, but the reduction was not statistically significant (right amygdala-
p=0.3; left amygdala-p=0.4) Table 2.13 
Table 2.13 Comparing the amygdala volume between val/val carriers in healthy controls and 






Volume HC  
mm³ 






































   THE SECOND STUDY, METHODOLOGY AND 
RESULTS 
3.1 Methodology 
The study used a cross-sectional design with four subject groups, consisting of 
healthy controls with no diagnosis of any psychiatric disorder and no history of 
childhood trauma (CB), healthy controls with no diagnosis of psychiatric disorder 
but with a history of childhood trauma (CA), MDD patients without a history of 
childhood trauma (PB), and MDD patients with a history of childhood trauma (PA). 
3.1.1 Subjects 
Subjects aged 18 to 75 years who fulfilled the inclusion criteria for one of the four 
study groups were recruited into the study.  
MDD patients were recruited from inpatients and outpatients of the Affective 
Disorders Service. 
All patients had a history of unipolar MDD diagnosed according DSM-ІV. MDD 
patients who had an organic cause for their depression, had any illness or 
neurological problem that might affect the HPA axis, were current heavy smokers 
(more than 40 cigarettes in 24 hours); were regularly using corticosteroid, had 
alcohol or drug dependency or who were pregnant or nursing were not included 
in the study.  
Healthy controls were recruited from the general population, including a number 
of healthy controls who were part of the volunteer database and had previously 
taken part in other studies of the Affective Disorders Research Group.  
Healthy controls who had a problem that could affect the HPA axis, such as a 
personal history of psychiatric illness as defined by DSM-IV, psychiatric illness in 
any first-degree relative, use of medication which could affect the HPA axis, 
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pregnancy or lactation, endocrinological disorders and heavy smoking (more than 
40 cigarettes in 24 hours) were not included.  
Subjects were assessed either at the Inpatient Affective Disorders Unit – for those 
who were inpatients at the time of assessment – or at the subjects’ home. For 
those undertaking the study at home, we posted a package consisting of 
instructions on how to collect saliva in saliva tubes, questionnaires and an 
envelope in order to return the package to the laboratory. Further support and 
instructions were delivered to them by telephone. All procedures were approved 
by the hospital ethics committee. Both MDD patients and healthy controls gave 
written informed consent form prior to participating to the study. 
3.1.2 Clinical Assessments  
Demographic and clinical information was collected using the following forms and 
questionnaires.  
3.1.2.1 International Classification of Diseases - ICD-10 Criteria 
MDD patients underwent full clinical assessment by a psychiatrist and were 
required to meet both DSM-IV and ICD-10 criteria for major depressive disorder 
or major depressive episode.  
3.1.2.2 Hamilton depression rating scale 17 items and 21 items  
For assessing the clinical severity of MDD, all subjects were interviewed using 
the Hamilton Depression rating scale 17 items (HAM-D 17) and 21 items (HAM-
D 21) versions (Hamilton, 1960). We used Hamilton 21 items to provide more 
information such as whether diurnal variation or paranoid symptoms are present. 
3.1.2.3 Clinical History 
Psychiatric and clinical history was obtained from MDD patients, including 
duration of current depressive episode, age of onset of first depressive episode, 
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total duration of illness, the number of previous depressive episodes and the 
number of previous antidepressants used. 
3.1.2.4 Stage of Treatment Resistance 
The Maudsley Staging Method was applied to measure the degree of treatment 
resistance in MDD patients (Fekadu et al., 2009b). They were assessed by 
psychiatrists and the patients consisted of mild, moderate and severe stage. 
3.1.2.5 Self-Rated Questionnaires  
Questionnaires were sent to the subjects for measuring the severity of depressive 
symptoms, anxiety, current level of health and function, disability, life events over 
the last 12 months, symptoms of PTSD, sleep quality, current social stress and 
early life stress (childhood trauma).They were completed by the subjects and 
returned with the saliva packs. 
This process led to some questionnaires being incomplete or missing. Where 
possible missing data were then collected by telephone; where appropriate and 
available, data from previous studies they may have taken part in were used.  
Total scores were summed for each questionnaire and the correlation between 
the CAR and each questionnaire was calculated in all groups. If the data were 
normally distributed, one way ANOVA – or t test if there was data only for two 
groups – was used to compare between groups. If the data were not normally 
distributed, Mann-Whitney U test or Kruskal-Wallis test was conducted. 
3.1.2.5.1 IDS30 - Inventory of Depressive Symptomatology (IDS) (Rush et 
al., 1986) 
The Inventory of Depressive Symptomatology (IDS) is a questionnaire used for 
measuring signs and symptoms of MDD. There are many versions of this 
questionnaire; for this study we used the 30-item self-report version. It is a reliable 
questionnaire and shows good correlation with both the HAM-D and the BDI. The 
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factor structure for the IDS30 shows four factors: mood/cognition, anxiety, 
selected endogenous symptoms, and hyperphagia-hypersomnia. The IDS 
appears suitable for both inpatients and outpatients with endogenous, atypical, 
and non-endogenous MDD. 
3.1.2.5.2 Zung Self-rating Anxiety Scale (Zung, 1971)  
The Zung Self-rating Anxiety Scale quantifies symptoms of anxiety and is simple 
for subjects to fill in. It is available in two formats, for participant and observer. In 
this study the self-report version was used consisting of 20 questions. The 
subjects are asked to mark the correct column for each symptom as below (Table 
3.1). 
 
Table 3.1 ZSAS 
Little of the time Some of the time Good part of the time Most part of the time 
 
3.1.2.5.3 Medical Outcomes Survey Short Form 36 (SF-36)  
The SF-36 is a short-form and multi-purpose health survey with 36 questions. It 
consists of 8-subscales profiling functional health and well-being scores; 
psychometrically-based physical and mental health measures; and a preference-
based health utility index. It is a general measure of function and quality of life. 
Of note, the SF-36 has been widely used both in the general population and in 
specific subject groups to compare the burden of illness, and to clarify the health 
benefits produced by many types of treatments.  
The SF-36 was designed to satisfy minimum psychometric standards necessary 
for group comparisons. The eight health concepts were chosen from 40 included 
in the Medical Outcomes Study (MOS) (Ware et al., 1992). Those chosen indicate 
the most frequently measured concepts in broadly-used health surveys and those 
most affected by illness and of note treatment (Ware et al., 1993; 1995). The 
questionnaire items represent multiple operational indicators of health, including: 
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behavioral function and dysfunction; distress and well-being, objective reports 
and subjective ratings, and both favorable and unfavorable self-evaluations of 
general health status (Ware et al., 1993). 
3.1.2.5.4 Work and Social Adjustment Scale (WSAS)  
The Work and Social Adjustment Scale (WSAS) is a simple, widely-used 5-item 
measure of disability. 
The maximum score on the WSAS is 40, lower scores being better. A WSAS 
score above 20 appears to suggest moderately severe or worse 
psychopathology. Scores between 10 and 20 are associated with significant 
functional impairment but less severe clinical symptomatology. Scores below 10 
appear to be associated with subclinical populations. Whether such a pattern will 
generalize to other illness (apart from OCD and depression) remains to be tested. 
The WSAS is a valid and change-sensitive measure of work/social and other 
adjustment in phobia, in particular in agoraphobia and social phobia. 
3.1.2.5.5 OSLO Social Support Scale (OSS-3) 
The OSS-3 provides a brief measure of social functioning and is recognized to 
be one of the best predictors of future mental health problems. It assesses 
several aspects of social support by measuring the number of people the 
participant feels close to, the interest and concerns shown by others, and the 
ease of gaining practical help from the others. The OSS-3 scoring system is from 
3-14, with a score of 3-8 indicating poor support, 9-11moderate support and 12-
14 strong support. 
3.1.2.5.6 List of Threatening Events (LTE)  
The List of Threatening Events was developed from a larger scale devised by 
Brugha et al. (1985) that had 9 more items. The scale’s purpose is to quantify the 
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occurrence of recent life events, focusing on those happening in the last 12 
months and whether the subject thinks they are having a continuing effect. 
3.1.2.5.7 Impact of Events Scale (IES) 
This scale is used to measure the impact that a trauma has had on a person and 
can be used to quantify severity of PTSD symptoms. This instrument measures 
the ongoing degree of stress caused by traumatic events, centered on two 
subscales: Intrusion and Avoidance. 
The format of the scale is a 15-item self-report in which subjects identify a 
stressful event and then reply to subsequent questions referring to the effects of 
this event using a 4-point scale.  
3.1.2.5.8 Pittsburgh Sleep Quality Inventory (PSQI) 
This is a self-related questionnaire comprised of seven components each rated 
weighted from 0 to 3 resulting in a global score of 0-21. The higher the overall 
score, the worse the quality of sleep. There are 19 items in the main questionnaire 
and 5 questions for the bed partner that are just for clinical information and not 
for scoring. It is easy for subjects to fill in and it usually takes 5 minutes. The scale 
has high sensitivity and specificity for insomnia patients compared to the healthy 
controls. The components assessed by the scale include duration of sleep, 
latency of sleep, and quality of sleep, sleep interruption and use of medication. 
3.1.2.5.9 Perceived Stress Scale (PSS) 
This is the most extensively used psychological instrument for assessing 
individuals’ current perceptions of the level of subjective stress they are 
experiencing. It is a measure of the degree to which situations are assessed as 
stressful in one’s life, and includes elements to assess how uncontrollable, and 
overwhelmed, subjects find their lives. The subjects are asked how often they felt 
or thought in a certain way over the past month. The questions are 
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comprehensive in nature and free of content specific to any sub population group. 
All items begin with the phrase: “In the past month, how often have you felt…?”  
The 10-item of this self-report instrument with a five-point scale was used (Table 
3.2). 
Table 3.2 PSS 
0 = never, 1 = almost never, 2 =sometimes, 3 = fairly often, 4 = very often 
 
3.1.2.5.10 Childhood Trauma Questionnaire (CTQ) (Bernstein, 1998)  
The presence or absence of childhood trauma was determined using the 
Childhood Trauma Questionnaire (Bernstein et al., 1998).  
The CTQ is a 28-item, self-report instrument that includes five subscales 
(emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical 
neglect). Published guidelines for the classification of CTQ subscale total scores 
were applied to determine threshold severity or absence of maltreatment on each 
subscale. It is an effective, clinical tool, which can be administered in 5 minutes. 
Subjects generating scores for low/minimal levels of maltreatment were not 
chosen for the abused groups in the study (Bernstein et al., 2003; Carpenter et 
al., 2007). 
3.1.3 Cortisol Awakening Response (CAR) 
3.1.3.1 Saliva Sample Collection  
Subjects were asked to collect six saliva samples in plain polypropylene tubes by 
using the drooling method. Plastic straws were available to aid with the collection. 
The test was undertaken on any normal weekday except Monday, with 
appropriate precautions taken for those working irregular patterns to avoid testing 
on the morning after a rest day. Women were asked to collect the samples during 
the first ten days of their menstrual cycle, i.e. during the follicular stage. Subjects 
were guided by careful instructions to collect six samples of saliva over the course 
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of a morning. The first one should have been collected at awakening and the 
other samples at 15, 30, 45, 60 and 90 minutes after the first one.  
Although the actual time of collecting was not controlled, subjects were asked to 
take the first sample while they were relaxed and still in bed. Subjects received a 
full set of tubes and details of collection. They were informed about not brushing 
their teeth and not eating or drinking at least one hour before collection. This was 
in order to avoid falsely high cortisol values due to plasma exudates, or from 
meal-stimulated rises in cortisol. They were instructed to avoid stressful situations 
and try to remain relaxed during the collection. In order to control for the time that 
the subjects gave the samples and to ensure that other confounders for the CAR 
were not missed, subjects completed a form for the day they collected the salivary 
samples. Subjects were instructed to fill in the time of sample collection and to 
comment on their activities and mood state during the collection. Subjects were 
instructed to add in the forms whether they experienced any form of physical pain 
or any other information that they could think would be of relevance and that could 
be problematic for the study and the protocol. They were informed to write about 
any unavoidable stressful events during collection. 
Subjects were advised to use the parafilm which was in the pack they received, 
if they experienced a dry mouth. They were asked to keep the samples in a fridge 
and then send them back to the lab. After arriving at the laboratory, samples were 
kept at -20°C in the freezer until analysis.  
Subjects who collected the samples at home were provided with a prepaid 
envelope in order to post the samples back to the Affective Disorders Unit. 
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3.1.3.2 Salivary Cortisol Analysis 
Saliva cortisol concentrations were determined using the chemiluminescence 
assay on the ‘Immulite’-DPC’s automated Immunoassay analyser 
(www.diagnostic.siemens.com). 
The method correlated well with an in-house and previously published (Juruena 
et al., 2006) Time-Resolved Fluoruimmunoassay (TR-FIA) (r=0.94, y=0.004+1.08 
x, N=41). It had analytical sensitivity of 0.2 nm/l, mean recovery of cortisol of 
106.1% (range from 5 to 65 nm/l) and inter/intra-assay precision (% CV) of less 
than 10% (range 5 to 25 nm/l).  
The linearity upon dilution test (parallelism) resulted in a straight line (r=0.99, 
y=0.144+1.014 x). The calibration graph was highly reproducible (n=11 assays) 
with slope (mean±sem) of 0.197+0.004.  
3.1.3.3 Area Under the Curve (AUC) 
The methodology for calculating the CAR was described earlier in my thesis 
(Section 1.3.5.6). Further details are as below.  
AUCg and AUCi were measured and calculated between 0 and 90 min as 
described earlier using the methods of Pruessner et al. (2003). The precise 
formulas used for the calculation of AUC were as follows:  
 
With ti denoting the individual time distance between measurements, mi the 
individual measurement, and n the total number of measures.  
 
 
With mi denoting the single measurements, ti denoting the time distance between 




Applying these formulae to the data in this study gave the following calculations:  
AUCg = (cortisol1+ cortisol0)/2*15 + (cortisol2+ cortisol1)/2*15 + (cortisol3+ 
cortisol2)/2*15+ (cortisol4+ cortisol3)/2*15+ (cortisol5+ cortisol4)/2*30 
AUCi= ((cortisol1+cortisol0)/2*15+ (cortisol2+ cortisol1)/2*15+ (cortisol3+ 
cortisol2)/2*15+ (cortisol4+ cortisol3)/2*15 + (cortisol5+ cortisol4)/2*30) - 
(cortisol0*90)) 
Where cortisol 0 is the value at 0 minutes post awakening, cortisol1 is the value 
at 15 minutes post awakening, cortisol2 is the value at 30 minutes post 
awakening, cortisol3 is the value at 45 minutes post awakening, cortisol 4 is the 
value at 60 minutes post awakening and cortisol 5 is the value at 90 minutes post 
awakening.  
If the cortisol values at 0 minutes and/or 90 minutes were missing data, the AUC 
was not measured. For the cases having other missing values – i.e. not at 0 or 
90 minutes – the mean value of the two proximal measures was used and the 
value interpolated. 
3.1.4 Statistical Analysis 
The study was powered to detect an effect size of 0.4, with 20 patients in each 
group and setting α = 0.05 at a power of 0.9.  
Data were analyzed with SPSS (Statistical Package for Social Sciences) Version 
22. 
A value of p<0.05 was considered as statistically significant (if p<0.05 the null 
hypothesis was rejected). All p values reported were two tailed. 
A Shapiro Wilk’s test, a Kolmogorov-Smirnov and visual inspection of their 
histograms, Q-Q plots and box plots were used to determine if the data were 
normally distributed. Chi square was used to analyze categorical variables such 
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as gender. An independent student t test was presented for comparing the mean 
score on the continuous variables if the data were normally distributed. 
If the data were not normally distributed, data were transformed using a natural 
log transformation prior to analysis.  
In our analysis, the data were not normally distributed, and log transformation 
could not be used (e.g. there were negative values), or did not lead to a normal 
distribution. Therefore non-parametric tests were used. In this case, Mann-
Whitney U test for analysis of two independent groups on continuous measures 
and Kruskal-Wallis test to test the scores on continuous variables for four groups 
were undertaken. In the tables of our analysis, we reported all median, IQR, mean 
and standard deviations. 
We used boxplots to find the outliers in our analysis. An outlier is an observation 
that lies an abnormal distance from other values in a random sample from a 
population. The box plot is a standardized way of displaying the distribution of 
data based on the five sample statistics: minimum, first quartile, median, third 
quartile, and maximum. In box plot, the central rectangle spans the first quartile 
to the third quartile (the interquartile range or IQR). A segment inside the 
rectangle presents the median and "whiskers" above and below the box show the 
locations of the minimum and maximum. There are two types of outliers: 
1. Extreme outliers are either 3×IQR or more above the third quartile or 3×IQR or 
more below the first quartile. 
2. Suspected outliers are slightly more central versions of outliers: either 1.5×IQR 
or more above the third quartile or 1.5×IQR or more below the first quartile. 
In all cases of outliers, we looked back at the data collection sheets to find any 
probable error in collection that might account for the abnormal values. After that 
we checked all the forms to find the possible cause of having outliers in our data. 
101 
 
We did not include any outliers who had cortisol values of more than 25 nm/l at 
all time points. 
The AUC was defined as the main outcome variable. Both AUCg and AUCi were 
used.  
Correlation analysis between the AUC and cortisol values at all individual points 
on one hand, and psychometric measures on the other, was performed using 
Spearman correlation coefficients, giving values from 1 to -1 for positive 
correlations or negative correlations respectively.  
3.2 Results  
A total of 140 subjects were recruited from the Affective Disorders Unit and the 
healthy population as described previously. 
Of these, 10 subjects were subsequently excluded as they were in the remission 
phase of depression (HAM-D ≤7 if HAM-D-17; ≤8 if HAM-D-21) at the time of 
testing, 10 subjects were not included because their depression was of subclinical 
intensity (HAM-D 8-13 on the HAM-D-17; or 9-15 on the HAM-D-21). A further 5 
subjects were not included due to protocol violations in the cortisol collection, 
either because they did not collect cortisol 0 – the cortisol sample at the time of 
awakening – or cortisol 5 – the cortisol sample at 90 minutes; or because they 
had 2 missing values at other time points preventing interpolation of missing data. 
One subject was not included because of failure to do sample collection within 
the appropriate time (collecting over 4 hours instead of 90 minutes). One subject 
was not included because the level of cortisol was more than 25 nm/l at all the 
time points. Finally, one subject refused to sign the consent form. 
The final included sample was 112 subjects divided into 4 groups (Table 3.3) 




2. Group 2: Healthy controls with a history of childhood trauma (CA, controls 
abused) 
3. Group 3: MDD patients without a history of childhood trauma (PB, depressed 
non-abused) 
4. Group 4 :MDD patients with a history of childhood trauma (PA, depressed-
abused)  
 
Table 3.3 Number of subjects in all groups  
 
 CB  CA PB PA 
43 (38.4%) 26(23.2%) 15(13.4%) 28(25%) 
Healthy Controls (CB and CA)  
69 (61.6%) 
Patients (PB and PA) 
43 (38.4%) 
Non-Abused (CB and PB) 
56 (50%) 
 
 Abused (CA and PA) 
 56(50%)  
  
3.2.1 Hamilton depression rating scale scores 
There was no difference between CB and CA in terms of HAM-D 17 (p=0.9, z=-
0.2) and HAM-D 21 (p=0.7, z=-0.3). There was no difference between PB and PA 
in terms of HAM-D 17 (p=0.06, z=-1.8) and HAM-D 21 (p=0.06, z=-1.8). Table 3.4  
Table 3.4 Hamilton Depression Rating Scale scores 
 
 
CB CA Statistics PB PA Statistics 
HAM-D 
17 
Median,(IQR) 0,(2) 0.5,(3) P=0.9 
Z=-0.2 
18,(4) 23.5,(9) P=0.06 
Z=-1.8 Mean±SD 1±1.4 1.2±1.3 20.4±5.9 23.3±5.1 
HAM-D 
21 
Median,(IQR) 0,(2) 0.5,(3) P=0.7 
Z=-0.3 
19,(6) 24.5,(10) P=0.06 
Z=-1.8 Mean±SD 1±1.4 1.3±1.4 20.7± 5.9 23.7±5.3 
 
3.2.2 Comorbidity 
Among patients, there was one non-abused MDD patient with OCD (obsessive 
compulsive disorder) and GAD (Generalized Anxiety Disorder), one non-abused 
MDD patient with OCD and Tick Disorder, one non-abused MDD patient with 
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OCPD (Obsessive Compulsive Personality Disorder), one non-abused MDD 
patient with GAD and one abused MDD patient with GAD.  
3.2.3 Psychosis  
Two non-abused MDD patients and two abused MDD patients suffered with 
depression with psychotic symptoms.  
3.2.4 Duration of MDD 
The median duration of MDD since the age of onset was 16 (IQR=24) years in 
 PB group, and 17 (IQR=26) years in the PA group. There was no difference 
between the two groups (11 PB, 12PA) (p=0.8, z=-0.1). Table 3.5 
 
 
Table 3.5 Duration of MDD  
 
Group  Duration of Illness (year) Statistics 
Median,(IQR) Mean±SD 
PB 16,(24) 21.1±15.5 p=0.8 z=-0.1 
 PA  17,(26) 21±16.9 
 
3.2.5 Age of onset of the first episode 
The median age of onset of first episode was 25 (IQR=16) for non-abused MDD 
patients and 29 (IQR=16) for abused MDD patients. There was no difference 
between the two groups (12PB, 15PA), (p=0.2, z=-1.1). Table 3.6 
Table 3.6 Age of onset of first episode 
 
Group Age of onset of first episode Statistics 
Median,(IQR) Mean±SD 
PB 25,(16) 27±9.7 p=0.2 , z=-1.1 




3.2.6 Duration of the current episode 
The median duration of current episode was 3 (IQR=3) years in the non-abused 
MDD patients, and 3.5 (IQR=8.5) years in the abused MDD patients. There was 
no difference between the groups (PB=11, PA=12) (p=0.8, z=-0.1) Table 3.7 
Table 3.7 Duration of current episode 
 




PB 3,(3) 4.2±2.7 p=0.8, z=-0.1 
 PA  3.5,(8.5) 7 ± 8.2 
  
3.2.7 Number of previous episodes 
There was no difference in median numbers of previous episodes between 
patient groups. The median number of episodes was 1 (IQR=2) for non-abused 
patient and 4 (IQR=5) for abused patients (PB=11, PA=15) (p=0.1, z=-1.6) Table 
of 3.8 
 
Table 3.8 Number of previous episodes 
 




PB 1,(2) 1.3±1.7 p=0.1 z=-1.6 
PA  4,(5) 4±4.2 
 
3.2.8 Number of previous antidepressants 
MDD patients were taking several types of antidepressants. The median number 
of previous antidepressants in non-abused patients was 5.5 (IQR=5); although 
use of antidepressants was numerically higher in abused patient 8.5 (IQR=5) 
there was no significant difference between two groups (PB=12, PA=14) 
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(p=0.1, z=-1.6) Table 3.9 
Table 3.9 Number of previous antidepressants  
 
Group Number of previous antidepressants Statistics 
Mean,(IQR) Median±SD 
PB 5.5,(5) 6± 4.1 p=0.1 z=-1.6 
 PA  8.5,(5) 8.2±3.5 
 
There was no significant correlation between the cortisol at any individual time 
points or between AUC and duration of current episode, age of onset of first 
episode, duration of MDD, number of previous depressive episodes and number 
of previous antidepressants. The only significant positive correlation was found 
between cortisol15 and age of onset of first episode, such that when the first 
episode occurs later in life the cortisol is higher at 15 minutes after awakening 

















Table 3.10 Correlations between cortisol, AUC, and clinical characteristics  
 Cortisol0 Cortisol15 Cortisol30 Cortisol45 Cortisol60 Cortisol90 
current episode p=0.9       
r=-0.02 
 
p=0.7        
r=-0.06 
 
p=0.8         
r=-0.04 
 
 p=0.9          
r=-0.01 
 
p=0.8      
r=-0.05  
 
p=0.8          
r=-0.04  
 
 first episode p=0.08         
r=0.3 
 
p=0.04         
r=0.3 
 
p=0.08         
r=0.3 
 
p=0.5          
r= 0.1 
 
 p=0.3         
r= 0.1 
 
p=0.1             
r=0.2  
 
 duration p=0.4          
r= 0.1 
 
 p=0.6          
r=0.1 
 
 p=0.5          
 r=0.1 
 
 p=0.4            
r=0.1  
 
p=0.5           
r=0.1  
 
p=0.6            
r=0.1  
 
previous episode p=0.3           
r=0.1 
 
p=0.3            
r= 0.1 
 
 p=0.7          
r=0.06 
 
p=0.7          
r=-0.06  
 
p=0.3            
r=-0.2  
 
p=0.1         
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MDD patients and healthy controls were not similar in terms of gender, with a 
higher number of females compared to males in the patient group (p=0.009; 
Table 3.11). There was no difference between the abused and non-abused 
groups (p=0.5). There was also a significant difference among the 4 groups on 
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Chi square testing when considered separately (p=0.03), but this appeared to 
reflect the gender difference noted below Table 3.11  
Table 3.11 Gender 
 CB CA PB PA Statistics 
Male 19 14 5 5 p=0.03 
x²=8.3 Female 24 12 10 23 
 Patients Controls Statistics Abused Non-
Abused 
Statistics 
Male 10 33 p=0.009 
x²=6.7 
20 23 p=0.5 
x²=0.3 Female 33 36 36 33 
 
3.2.10 Age 
Age of subjects is shown in Table 3.13. There was no difference among the 4 
groups in terms of age (p=0.9, df=3, Mean ranks / CB =42.9, CA=45.2, PB= 54.0, 
PA=55.2). 
There was a significant difference between controls and MDD patients in terms 
of age, we had older patients compared to the controls (p=0.02, z=-1.6, Mean 
Rank / Controls=43.7, Patients=54.6). 
There was no difference between abused and non-abused group in terms of age 
(p=0.6, z=-0.4, Mean Rank/ Abused=47.9, Non-Abused=45.3). Table 3.13  
3.2.10.1 Correlation between age and CAR  
The correlation between age of the subjects and cortisol at individual time points 
was positive and significant at time of awakening. When looking at AUC, the 







Table 3.12 Correlation between cortisol at all individual time points, AUC, and age 
 
 cortisol0 cortisol 15 cortisol 30 cortisol 45 cortisol 60 cortisol 90 

























3.2.11 Body Mass Index (BMI) 
The BMI of subjects is shown in Table 3.13. There was no difference among the 
4 groups in terms of BMI (p=0.3, df= 3, Mean Ranks/ CB=44.08, CA=43.30, PB= 
50.7, PA=57.6). 
There was no difference between MDD patients and healthy controls in terms of 
BMI (p=0.09, z=-1.6, Mean Ranks/ Controls=43.7, Patient=54.6).  
There was no difference between abused and non-abused groups in terms of 
BMI (p=0.6, z=-0.46, Mean Ranks / Abused=47.9, Non-abused=45.3) Table 3.13 
Table 3.13 Age and BMI  
 
 CB CA PB PA Stat 
AGE Median,(IQR) 
 
48,(22) 47.5,(19) 55,(24) 50,(20) P=0.9 
Mean±SD 43.8± 13.7 46.3±11.4 52.3±13.3 50.1± 12.4 
BMI (Kg/m²) Median,(IQR) 25.1,(6) 24.3,(8) 30,(11) 27.7,(5) P=0.3 
Mean±SD 25.6 ± 4.4  26.2 ± 5.1 27.4±5.7  27.6± 4.1 
 Patients Controls Stat Abused Non-Abused Stat 
AGE Median,(IQR) 52,(21) 48,(20) P=0.02 49,(23) 50,(17) P=0.6 
Mean±SD 50.9±12.6 44.7± 2.8 48.0±12.2 46.1±13.9 
BMI 
(Kg/m²) 
Median,(IQR) 28.5,(6) 25,(5) P=0.09 26.1,(7) 26.2,(8) P=0.6 




3.2.11.1 Correlation between BMI and CAR 
The correlation between BMI and CAR was not significant at any time points 
Table 3.14 
Table 3.14 Correlation between cortisol at all individual time points, AUC, and BMI 
 
 cortisol0 cortisol15 cortisol30 cortisol45 cortisol60 cortisol90 






















3.2.12 CAR  
Cortisol30 was appeared as the highest cortisol among all of the time points 
(nml/L) .Table 3.15  
  
Table 3.15 Cortisol-All the time points 
 Median, (IQR) Mean±SD 
cortisol0  10.3, (8.2) 11.3±6.2 
cortisol15 13.9, (9.9) 13.5±6.9 
cortisol30 15.10, (11.9) 15.3±8.2 
cortisol45 12.30, (11.7) 13.9±7.5 
cortisol60 11.80, (9.5) 12.2±7.2 






3.2.12.1 Comparing cortisol at all individual time points between MDD 
patients and healthy controls  
Cortisol at all individual time points was higher in MDD patients compared with 
controls and the changes was statistically significant at 15, 30, 45 and 60 minutes 
after awakening (cortisol15-p=0.01, z=-2.3 , Mean Rank=65.6; cortisol30-p=0.03, 
z=-2.1, Mean Rank=64.6; cortisol45-p=0.009, z=-2.6, Mean Rank=66.70; cortisol 
60-p=0.02, z=-2.2, Mean Rank=65.3). 
There was no difference in cortisol at 0 and at 90 minutes between MDD patients 


































Cortisol Awakening Response / All Time Points
ALL SUBJECTS




Table 3.16 Comparing cortisol at all individual time points between MDD patients and healthy controls 
 
 Patients Controls p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 11.1,(8) 11.8±5.9 9.4,(8) 11.0±6.5 0.3 
cortisol15 15.6,(8) 15.0±6.0 11.7,(10) 12.6±7.2 0.01 
cortisol30 17.3,(10) 16.6±7 12.9,(11) 14.4±8.8 0.03 
cortisol45 16.5,(12) 16.1±7.1 10.4,(7) 12.5±7.4 0.009 
cortisol60 13.7,(10) 14.0±7.4 10.0,(9) 11.0±6.8 0.02 
cortisol90 11.0,(9) 11.9±7.1 8.7,(8) 9.9±6.2 0.1 
 
 
Figure 3-2 Cortisol-MDD patients and healthy controls 
  
 
3.2.12.2 Comparing cortisol at all individual time points between abused 
and non-abused subjects 
There was no difference between abused and non-abused groups (cortisol0-
p=0.8, z=-0.1, Mean Rank=56.9; cortisol15-p=0.2, z=-1.0, Mean Rank=59.8, 

























Rank=62.2; cortisol60-p=0.1, z=-1,3, Mean Rank=60.6; cortisol90-p=0.4, z=- 0.8, 
Mean Rank=59.0) Table 3.17 
Table 3.17 Comparing cortisol at all individual time points between abused and non-abused subjects 
 Abused Non-Abused p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 10.35,(9) 11.7±6.9 10.4,(7) 11.0±5.6 0.8 
cortisol15 14.6,(13) 14.2±7.1 11.9,(9) 12.9±6.6 0.2 
cortisol30 16.8,(12) 16.4±8.2 12.9,(9) 14.1±8.1 0.09 
cortisol45 15.2,(11) 14.9±7.1 10.8,(8) 12.8±7.8 0.6 
cortisol60 13.3,(10) 13.0±7.5 10.8,(8) 11.3±6.8 0.1 




Figure 3-3 Cortisol-Abused and non-Abused 
 
3.2.12.3 Comparing cortisol at all individual time points between healthy 
controls with a history of childhood trauma and healthy controls without a 
history of childhood trauma (CA compared with CB)  


























(cortisol0-p=0.8, z=-0.2, Mean Rank CB=34.2, cortisol15-p=0.6, z=-0.2, Mean 
Rank=33.5; cortisol-p=0.8, z=-0.2, Mean Rank=35.6; cortisol45-p=0.6, z=-0.6, 
Mean Rank=36.2; cortisol60-p=0.7, z=-0.4, Mean Rank=35.8; cortisol90-p=0.8, 
z=-0.2, Mean Rank=35.7).Table 3.18 
Table 3.18 Comparing cortisol at all individual time points between healthy controls with a history of 
childhood trauma and healthy controls without a history of childhood trauma (CA compared with CB) 
 CB CA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 9.7,(7) 11.0± 5.9 
 
9.3,(9) 11.1±7.5 0.8 
cortisol15 11.4,(9) 
 
12.7±7.0 12.9,(9) 12.5±7.8 0.6 
cortisol30 12.9,(8) 
 
14.1±8.5 12.6,(13) 14.9±9.4 0.8 
cortisol45 10.3,(6) 
 
12.4±7.9 10.4,(10) 12.6±6.5 0.6 
cortisol60 9.8,(6) 
 
11.0±6.09 11.1,(11) 11.1± 6.8 0.7 
cortisol90 8.2,(7) 
 





Figure 3-4 Cortisol-Healthy controls with a history of childhood trauma and healthy controls without a history 
of childhood trauma (CA compared with CB) 
 
3.2.12.4 Comparing cortisol at all individual time points between MDD 
patients with a history of childhood trauma and MDD patients without a 
history of childhood trauma (PA compared with PB)  
There were significant changes in cortisol at the time points of 15 minutes 
(cortisol15-p=0.04, z=-2, Mean Rank=24.8), and 45 minutes (cortisol45-p=0.03, 
z=-2.1, Mean Rank=24.9). Table 3.19 
Although cortisol appears to be higher in the PA group, there was no significant 
difference at awakening time (cortisol0-p=0.2, z=-1.0, Mean Rank=23.4 ), 30 
minutes (cortisol-p=0.05, z=-1.9, Mean Rank=24.7), 60 minutes (cortisol60-
p=0.1, z=-1.4, Mean Rank=24.0) and 90 minutes after awakening (cortisol 90-



























Table 3.19 Comparing cortisol at all individual time points between MDD patients with a history of childhood 
trauma and MDD patients without a history of childhood trauma (PA compared with PB) 
 PB PA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 11,(6) 10.2±4.1 11,(10) 12.7 ± 6.6 P=0.2 
cortisol15 14.2,(8) 12.7±6.0 16.9,(6)  16.3±5.8 P=0.04 
cortisol30 13,(8) 13.9±6.4 19,(8)  18.1±7.07 P=0.05 
cortisol45 12.5,(10) 13.3±5.9 19.05,(12)  17.6±7.4 P=0.03 
cortisol60 12.5,(11) 11.8±5.9 14.7,(10)  15.2±8.02 P=0.1 
cortisol90 9.9,(11) 10.2±6.1 11.3,(10)  12.8±7.6 P=0.3 
 
 
Figure 3-5 Cortisol-MDD patients with a history of childhood trauma and MDD patients without a history of 
childhood trauma (PA compared with PB) 
 
3.2.12.5 Comparing cortisol at all individual time points between healthy 
controls with a history of childhood trauma and MDD patients with a history 
of childhood trauma (CA compared with PA)  
Cortisol was higher in the PA group compared with the CA group and the changes 
were significant at cortiaol15 (cortisol15-p=0.01, z=-2.4, Mean Rank=32.6) and 


























At time of awakening (cortisol0-p=0.2, z=-1.0, Mean Rank=29.6), at 30 
(cortisol30-p=0.06, z=-1.8, Mean Rank=31.2), at 60 (cortisol60-p=0.07, z=-1.7, 
Mean Rank=31.1) and at 90 minutes after awakening (cortisol 90-p=0.1, z=-1.3, 
Mean Rank=30.3) there was no difference Table 3.20 
Table 3.20 Comparing cortisol at all individual time points between healthy controls with a history of 
childhood trauma and MDD patients with a history of childhood trauma (CA compared with PA)  
 CA PA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 9.3,(9) 11.1±7.5 11,(10) 12.7 ± 6.6 0.2 
cortisol15 12.9,(9) 12.5±7.8 16.9,(6)  16.3±5.8 0.01 
cortisol30 12.6,(13) 14.9±9.4 19,(8)  18.1±7.07 0.06 
cortisol45 10.4,(10) 12.6±6.5 19.05,(12)  17.6±7.4 0.02 
cortisol60 11.1,(11) 11.1± 6.8 14.7,(10)  15.2±8.02 0.07 
cortisol90 9.1,(9) 10.2±6.5 11.3,(10)  12.8±7.6 0.1 
 
 
Figure 3-6 Cortisol-Healthy controls with a history of childhood trauma and MDD patients with a history of 



























3.2.12.6 Comparing cortisol at all individual time points between healthy 
controls without a history of childhood trauma and MDD patients without a 
history of childhood trauma (CB compared with PB)  
There were no statistically significant differences at any time point in the PB group 
when compared with the CB group. 
(cortisol0-p=0.9, z=-0.07, Mean Rank=29.7; cortisol15-p=0.7, z=-0.3, Mean 
Rank=30.7; cortisol30-p=0.7, z=-0.3, Mean Rank=30.8; cortisol45-p=0.4, z=-0.9, 
Mean Rank=32.3; cortisol60-p=0.3, z=-0.3, Mean Rank=33; cortisol90-p=0.7, z=-
0.6, Mean Rank=30.8).Table 3.21 
Table 3.21 Comparing cortisol at all individual time points between healthy controls without a history of 
childhood trauma and MDD patients without a history of childhood trauma (CB compared with PB)  
 CB PB p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 9.7,(7) 11.0± 5.9 
 
11,(6) 10.2±4.1 0.9 
cortisol15 11.4,(9) 
 
12.7±7.0 14.2,(8) 12.7±6.0 0.7 
cortisol30 12.9,(8) 
 
14.1±8.5 13,(8) 13.9±6.4 0.7 
cortisol45 10.3,(6) 
 
12.4±7.9 12.5,(10) 13.3±5.9 0.4 
cortisol60 9.8,(6) 
 
11.0±6.09 12.5,(11) 11.8±5.9 0.3 
cortisol90 8.2,(7) 
 





Figure 3-7 Cortisol-Healthy controls without a history of childhood trauma and MDD patients without a history 
of childhood trauma (CB compared with PB) 
 
3.2.12.7 Comparing cortisol at all individual time points between MDD 
patients with a history of childhood trauma and healthy controls without a 
history of childhood trauma (PA compared with CB) 
Cortisol appears higher in the PA group when compared with the CB group, and 
the changes were significant at all-time points except at time of awakening and 
at 90 min after awakening. 
(cortisol0-p=0.2, z=-1.0, Mean Rank=39.2; cortisol15-p=0.01, z=-2.4, Mean Rank 
=43.4; cortisol30-p=0.008, z=-2.6, Mean Rank=44.0; cortisol45-p=0.003 , z=-2.9, 
Mean Rank=44.9; cortisol60-p=0.01, and z=-2.5, Mean Rank=43.5; cortisol90-






























Table 3.22 Comparing cortisol at all individual time points between MDD patients with a history of childhood 
trauma and healthy controls without a history of childhood trauma (PA compared with CB) 
 CB PA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
cortisol0 9.7,(7) 11.0±5.9 
 
11,(10) 12.7 ± 6.6 0.2 
cortisol15 11.4,(9) 
 
12.7±7.0 16.9,(6)  16.3±5.8 0.01 
cortisol30 12.9,(8) 
 
14.1±8.5 19,(8)  18.1±7.07 0.008 
cortisol45 10.3,(6) 
 
12.4±7.9 19.05,(12)  17.6±7.4 0.003 
cortisol60 9.8,(6) 
 
11.0±6.09 14.7,(10)  15.2±8.02 0.01 
cortisol90 8.2,(7) 
 
9.7±6.0 11.3,(10)  12.8±7.6 0.06 
 
 
Figure 3-8 Cortisol-MDD patients with a history of childhood trauma and healthy controls without a history 






























3.2.12.8 Comparing cortisol among all the groups (CB, CA, PA, and PB)  
There were significant changes in cortisol among the four groups(Kruskal-Wallis 
test) at 15 and 45 minutes post awakening but not at awakening time, 30 , 60 and 
90 minutes after awakening (cortisol-p=0.6; cortisol15-p=0.03; cortisol30-p= 
0.05; cortisol45-p=0.01; cortisol60-p=0.07, cortisol90-p=0.3, df= 3). 
The PA group had the highest cortisol at each time point compared with the other 
groups. PA (Mean Rank)/ cortisol0 (63.3), cortisol15 (71.8), cortisol 30(71.0), 
cortisol45 (73.2), cortisol60 (69.7), cortisol90 (66.3).Table 3.23 
Table 3.23 Comparing cortisol among all the groups 
 CB CA PB PA P 
cortisol 0 9.7 11.0± 5.9 
 
9.3 11.1±7.5 11 10.2±4.1 11 12.7 ± 6.6 0.6 
cortisol15 11.4 
 
12.7±7.0 12.9 12.5±7.8 14.2 12.7±6.0 16.9  16.3±5.8 0.03 
cortisol30 12.9 
 
14.1±8.5 12.6 14.9±9.4 13 13.9±6.4 19  18.1±7.07 0.05 
cortisol45 10.3 
 
12.4±7.9 10.4 12.6±6.5 12.5 13.3±5.9 19.05  17.6±7.4 0.01 
cortisol60 9.8 
 
11.0±6.09 11.1 11.1± 6.8 12.5 11.8±5.9 14.7  5.2±8.02 0.07 
cortisol90 8.2 
 





Figure 3-9 Cortisol-All the groups 
 
3.2.13 Area Under the Curve (AUC) CAR 
 
 AUCg and AUCi-CAR- for all subjects are presented below Table 3.24 
Table 3.24 AUCg and AUCi 
 Mean Median,(IQR) 
AUCg 60 819.3±392.3 836.2,(607) 
AUCi 60 135.3±312.4 100.1,(338) 
AUCg 90 1161.7±568.3 1145.6,(842) 
AUCi 90  351.8±547.7 258.0,(680) 
  
3.2.13.1 Comparing AUCi and AUCg between MDD patients and healthy 
controls  
We looked at both of the AUC measures in two ways. First, AUC values were 
calculated using all time points up to 60 minutes after awakening (AUC60), in 
order to obtain results compatible with the method used in most previous studies, 
which have generally measured only the first 60 minutes after awakening. 























CB CA PB PA
122 
 
minutes after awakening (AUC90), to give the fullest account of the overall 
dynamic of the cortisol. 
There was a statistically significant difference between MDD patients and 
controls when taken together, (AUCg60-p=0.01; AUCg-90-p=0.02; AUCg60-z=-
2.4; and AUCg90-z=-2; AUCi60-p=0.03; AUCi60-z=-2.1). Patients had higher 
AUCg60, 90 (Mean Rank= 66.1, 65.2) and AUCi60 (Mean Rank=64.8).Table 3.25  
Table 3.25 Comparing AUCg and AUCi between MDD patients and healthy controls 
 Patients Controls p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
AUCg60 982.5,(483) 913±358.5 677.2,(511) 760.9±403.6 0.01 
AUCi60 205.5,(426) 199.2±315.7 68.2,(304)  95.5±305.9 0.03 
AUCg90 1374,(789) 1298.8±554.3 888,(727) 1076.2±564.0 0.02 
AUCi90 481.5,(704)  464.3±561.8 217.5,(623) 281.7 ± 530.9 0.05  
 
 


























3.2.13.2 Comparing AUCi and AUCg between abused and non-abused 
subjects  
The AUCg and AUCi were not significantly higher in abused individuals compared 
with non-abused individuals when patient and control groups were combined 
(AUCg60-p=0.1; AUCg90-p=0.1; AUCg-60-z=-1.5 ; AUCg90-z=1.5; Mean Rank= 
AUCg60=61.4; and Mean Rank AUCg90=61.3; AUCi60-p=0.2; AUCi90-p=0.3; 
AUCi60-z=-1.2; AUCi90-z=1.0; Mean Rank AUCi60= 60.2; Mean Rank AUCi90= 
61.3) (Table 3.26).  
Table 3.26 Comparing AUCg and AUCi between abused and non-abused subjects 
 Abused Non-Abused p 
Median,(IQR) Mean±SD Median(IQR) Mean±SD 
AUCg60 962.2,(656) 870.9±389.1 702.3,(510) 767.6±392.2 0.1 
AUCi60 178.5,(360) 168.3±324.3 70.8,(295) 102.4±299.3 0.2 
AUCg90 1314.7,(893) 1234.3±573.6 10.6,(721) 1089.1±558.6 0.1 
AUCi90  404.2,(731) 410.7±565.4 212.6,(615) 292.9±527.9 0.3 
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3.2.13.3 Comparing AUCi and AUCg between healthy controls without a 
history of childhood trauma and healthy controls with a history of 
childhood trauma (CB compared with CA) 
There was no difference˗˗AUCg60-p=0.9; AUCg90-p=0.8; AUCg60-z=-0.006; 
AUCg90-z=-0.2; and AUCi60-p=0.7; AUCi90-p=0.7; AUCi60-z=-0.2; AUCg60-
z=0.2) ˗˗between abused controls group and non-abused controls group. The 
mean of AUC was marginally higher in the CA group compared with the CB group 
but the changes were not significant (Mean Rank AUCg60= 35.0; Mean Rank 
AUCg90=35.7; Mean Rank AUCi60=34.0; Mean Rank AUCi90=34.1) Table 3.27 
Table 3.27 Comparing AUCg and AUCi between healthy controls without a history of childhood trauma and 
healthy controls with a history of childhood trauma (CB compared with CA) 
 CB CA p 





721.8,(556) 768.9±402.7 0.9 
AUCi60 81.0,(216) 93.5±307 
 
34.1,(397) 98.8±310.1 0.7 
AUCg90 888.0,(697) 1068.1±569.7 
 
993.,7(840) 1089.6±565.4 0.8 
AUCi90 217.5,(421) 276.4±537.8 
 




Figure 3-12 Salivary cortisol response to awakening-Increase over the base line in healthy controls without 
a history of childhood trauma and healthy controls with a history of childhood trauma (CB compared with 
CA) 
  
3.2.13.4 Comparing AUCg and AUCi between MDD patients without a 
history of childhood trauma and MDD patients with a history of childhood 
trauma (PB compared with PA)  
The AUCg60 was significantly higher in the PA group compared with the PB 
group (p=0.04, z=-2.0), (Mean Rank: AUCg60=24.8) (Table 3.28) 
Table 3.28 Comparing MDD patients without a history of childhood trauma and MDD patients with a history 
of childhood trauma (PB compared with PA) 
 PB PA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
AUCg60 819.7,(625) 766.6±314.2 1072,(398) 991.4±361.2 0.04 
AUCi60 74.2,(432) 151.4±228.7 220.1,(411) 224.9±354.9 0.2 
AUCg90 1112.2,(962) 1086.5±469.5 1431,(743) 1412.6±570.3 0.06 
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Figure 3-13 Salivary cortisol response to awakening-Increase over the baseline in MDD patients without a 
history of childhood trauma and MDD patients with a history of childhood trauma (PB compared with PA) 
  
3.2.13.5 Comparing AUCg and AUCi between healthy controls with a history 
of childhood trauma and MDD patients with a history of childhood trauma 
(CA compared with PA)  
There was a significant difference between healthy controls with history of 
childhood trauma and MDD patients with a history of childhood trauma (AUCg60-
p=0.02; and AUCg90-p=0.03; AUCg60-z=-2.3; AUCg90-z=2.0; AUCi60-p=0.05, 
AUCi90-p=0.07; AUCi60-z=-1.9; AUCi90-z=-1.7), with the MDD patient groups 
showing higher AUCg60 and AUCg90 (Mean Rank AUCg60=32.2; Mean Rank 
AUCg90= 31.7) Table 3.29 
Table 3.29 Comparing AUCg and AUCi between healthy controls with a history of childhood trauma and 
MDD patients with a history of childhood trauma (CA compared with PA) 
 CA PA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
AUCg60 721.8,(556) 768.9±402.7 1072,(398) 991.4±361.2 0.02 
AUCi60 34.1,(397) 98.8±310.1 220.1,(411) 224.9±354.9 0.05 
AUCg90 993.7,(840) 1089.6±565.4 1431,(743) 1412.6±570.3 0.03 
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Figure 3-14 Salivary cortisol response to awakening-Increase over the baseline in healthy controls with a 
history of childhood trauma and MDD patients with a history of childhood trauma (CA compared with PA) 
 
3.2.13.6 Comparing AUCg and AUCi between healthy controls without a 
history of childhood trauma and MDD patients without a history of 
childhood trauma (CB compared with PB) 
There was no significant difference between these two groups although both 
AUCg and AUCi appeared numerically higher in the patient group (AUCg60-
p=0.6; and AUCg90-p=0.6; AUCg60-z=-0.4; and AUCg90-z=-0.4; Mean Rank 
AUCg60=31.3; and Mean Rank AUCg90=31.0; AUCi60-p=0.6; AUCi90-p=0.7; 
AUCi60-z=-0.4; AUCi90-z=-0.2; Mean Rank AUCi60=31.2; Mean Rank AUCi90= 





























Table 3.30 Comparing AUCg and AUCi between healthy controls without a history of childhood trauma and 
MDD patients without a history of childhood trauma (CB compared with PB) 
 CB PB p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
AUCg60 606.7,(511) 750±408.85 
 
819.7,(625) 766.6±314.2 0.6 
AUCi60 81.0,(216) 93.5±307 
 
74.2,(432) 151.4±228.7 0.6 
AUCg90 888.0,(697) 1068.1±569.7 
 
1112.2,(962) 1086.5±469.5 0.6 
AUCi90 217.5,(421) 276.4±537.8 
 





Figure 3-15 Salivary cortisol response to awakening-Increase over the base line in healthy controls without 
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3.2.13.7 Comparing AUCg and AUCi between healthy controls without a 
history of childhood trauma and MDD patients with a history of childhood 
trauma (CB compared with PA) 
There were significant differences between healthy controls without a history of 
childhood trauma and MDD patients with a history of childhood trauma. Both 
AUCg and AUCi were higher in the PA group. 
(AUCg60-p=0.004; AUCg90-p=0.007, AUCg60-z=-2.8; AUCg90-z=-2.7, Mean 
Rank AUCg60=44.7; Mean Rank AUCg90=44.2; AUCi60-p=0.02; AUCi90-p= 
0.007; AUCi60-z=-2.2; AUCi60-z=-2.0; Mean Rank AUCi60=42.6; Mean Rank 
AUCi90=42.2) Table 3.31 
Table 3.31 Comparing AUCg and AUCi between healthy controls without a history of childhood trauma and 
MDD patients with a history of childhood trauma (CB compared with PA) 
 CB PA p 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD 
AUCg60 606.7,(511) 750±408.85 
 
1072,(398) 991.4±361.2 0.004 
AUCi60 81.0,(216) 93.5±307 
 
220.1,(411) 224.9±354.9 0.02 
AUCg90 888.0,(697) 1068.1±569.7 
 
1431,(743) 1412.6±570.3 0.007 
AUCi90 217.5,(421) 276.4±537.8 
 







Figure 3-16 Salivary cortisol response to awakening-Increase over the baseline in healthy controls without 
a history of childhood trauma and MDD patients with a history of childhood trauma (CB compared with PA)  
 
3.2.13.8 Comparing AUCg and AUCi among all the groups  
AUCg and AUCi were not similar among the four groups. The PA group showed 
the highest post awakening increase in cortisol over baseline. Using a Kruskall 
Wallis test across all four groups showed that there was a significant difference 
for both AUCg 60-p=0.02 and AUCg 90-p=0.04 among the 4 group (Table 3.32).
  
Table 3.32 Comparing AUCg and AUCi among all the groups 
 CB CA PB PA P 
AUCg60 606.7 750±408.85 
 
721.8 768.9±402.7 819.7 766.6±314.2 1072 991.4±361.2 0.02 
AUCi60 81.0 93.5±307 
 
34.1 98.8±310.1 74.2 151.4±228.7 220.1 224.9±354.9 0.1 
AUCg90 888.0 1068.1±569.7 
 
993.7 1089.6±565.4 1112.2 1086.5±469.5 1431 1412.6±570.3 0.04 
AUCi90 217.5 276.4±537.8 
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Figure 3-17 Salivary cortisol response to awakening-Increase over the base line among all the groups 
 
 
3.2.14 Self-Rated Questionnaires 
The questionnaires were sent to the subjects and were filled by them. A number 
of subjects did not fill in the forms appropriately, and therefore those 
questionnaires could not be used in the analysis; where possible the data for 
these patients were gathered from previous studies. 
The scores were compared between groups, and the correlation between cortisol 
values˗˗or CAR˗˗and the scores were calculated for the different groups. If the 
data were normally distributed, a one way ANOVA was performed to compare 
the groups. If the data were not normally distributed Mann Whitney U and Kruskal 
Wallis tests were conducted. 
Due to missing or incomplete data the numbers analyzed for these comparisons 
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3.2.14.1 Work and Social Adjustment Scale (WSAS) 
The WSAS was higher in the PA group compared with the other groups 
(Table3.33). The change was significant across the 4 groups using ANOVA (p< 
0.001). 
In detail, 37 CB, 24 CA, 11 PB, 23 PA were compared to each other using one-
way ANOVA and post hoc test. There was a significant difference between PA 
compared with CB (p< 0.001, mean dif =26.3), PA compared with CA (p<0.001, 
mean dif= 26.1), PB compared with CB (p<0.001, mean dif=22.6); and PB 
compared with CA (p<0.001, mean dif=22.5). The difference between the two 
healthy controls groups (CB compared with CA) was not significant (p=1.0, mean 
dif =1.25). The two patient groups did not show a significant difference (PA 
compared with PB, p=0.3, mean dif=0.1).  
In all subjects, there were significant positive correlations at 45 and 60 minutes 
after awakening between WSAS scores and the cortisol (cortisol0-p=0.8, r=0.01; 
and cortisol15-p=0.1, r=0.1; and cortisol30-p=0.1, and r=0.1; cortisol45-p=0.003, 
r=0.3; cortisol-60-p=0.01, r=0.2; cortisol90-p=0.07, r=0.1). In line with this, the 
correlation between AUC and WSAS was also positive and significant (AUCg60-
p=0.01; and AUCg90-p=0.01; AUCg60-r=0.2; AUCg90-r=0.2; AUCi60-p=0.01; 
AUCi90-p=0.02; AUCi60-r=0.2; AUCi90-r=0.2).Table 3.34 
Table 3.33 WSAS 
WSAS CB CA PB  PA 
Median,(IQR) 0.0,(0.0) 0.0, (0.0) 19,(13) 28, (16) 







Table 3.34 Correlation between WSAS and AUC 
WSAA/AUC AUCg60 AUCi60 AUCi90 AUCg90 










3.2.14.2 Zung self-rating anxiety scale (Zung)  
Considering the data that we gathered from anxiety questionnaires (37 CB, 24 
CA, 3 PB, 15 PA), we did not perform a comparison among the 4 groups. We 
compared (Mann-Whitney U test) patients and controls, and abused and non-
abused subjects, as there was too much missing data for a 4 group analysis. 
There was a significant difference between patients and controls, with higher 
scores for the patients (p<0.001, z=-5.4, Mean Rank patients =65.6 and Mean 
Rank controls=32.4). Between abused and non-abused subjects the score was 
significantly different, with higher scores with abused ones (p=0.004, z=-2.9, 
Mean Rank abused =47.4, Mean Rank non-abused=32.4).Table 3.35 
In all subjects, there was a significant positive correlation between Zung self-
rating anxiety scale and cortisol at 45, 60 and 90 minutes post-awakening 
(cortisol0-p=0.1, r=0.1; and cortisol15-p=0.08, r= 0.1; and cortisol30-p=0.07, 
r=0.2, cortisol45-p=0.003, r=0.3; cortisol60-p=0.007, r=0.1; cortisol90-p=0.02 
r=0.2).  
In line with this, the correlation between AUCg and ZSAS was positive and 
significant (AUCg60-p=0.006, r=0.3; AUCg90-p=0.008, r=0.2). 
Table 3.35 ZUNG  
ZUNG Controls Patients Abused Non-abused 
Stat p <0.001 
z= -5.4 
mean rank patients/controls= 65.6/32.4 
p= 0.004 
z= -2.9 




Table 3.36 ZUNG correlation with cortisol and AUC 
 AUCg60 AUCi60 AUCi90 AUCg90 








 cortisol0 cortisol15 cortisol30 cortisol45 cortisol60 cortisol90 
Stat p=0.1 r=0.1 p=0.08 r= 0.1 p=0.07 r=0.2 p=0.003 r=0.3 p=0.007 r=0.1 p=0.02 r=0.2 
 
 
3.2.14.3 Medical Outcomes Survey Short Forms 36 (SF-36)  
Due to the data that we gathered from SF-36 questionnaires (37 CB, 24 CA, 16 
PB, 3 PA), we did not make a comparison among the 4 groups. We compared 
(Mann-Whitney U test) patients and controls, and abused and non-abused 
subjects, as there were too many data missing for a 4 group analysis. The 
questionnaire consists of several subscales: General health (GH), Physical 
functioning (PF), Role limitation due to physical Health (RL-PH), Role limitation 
due to emotional problem (RL-E), Fatigue/Energy (FE), Emotional well-being 
(EW), social functioning (SF) and pain. There was a significant difference 
between patients and controls, and abused and non-abused subjects, with higher 
scores for controls and non-abused which suggests better quality of life for these 











Table 3.37 SF36 
 Patients Controls Statistics 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD p , z 
GH 40,(45) 46.2± 24.3 80,(20) 78.4±14.7 p<0.001, z=-4.7 
PF 70,(55) 62.0±23.5 100,(10) 88.5 ± 23.5 p<0.001, z=-4.1 
RL-PH 25,(75) 82.0±225.1 100,(0) 91.0±22.7 p<0.001, z=-4.7 
RL-E 0,(0) 10.8±27.6 100,(0) 92.5±22.9 p<0.001, z=-7.2 
FE 15,(25) 22.8±18.2 70,(30) 70±17.4 p<0.001, z=-6.1 
EW 84,(18) 33.4±22.3 84,(18) 82.1±14.4 p<0.001, z=-6.1 
SF 37.5,(37.5) 41.7±26.8 100,(12.5) 90.1±19.7 p<0.001, z=-6.0 
Pain 62.0,(57.5) 56.0±29.3 90,(20) 89.3±13.8 p<0.001, z=-5.9 
 Abused Non abused Statistics 
Median,(IQR) Mean±SD Median,(IQR) Mean±SD p , z  
GH 70,(35) 65.6±25.3 80,(20) 76.2±16.7 p=0.1, z= -1.6 
PF 90,(37.5) 77.2±28.7 100,(10) 87.4±25.2 p=0.03, z=-2.0 
RL-PH 100,(75) 88.1±151.3 100,(0) 89.7±27.3 p=0.007, z=-2.7 
RL-E 100,(100) 58.2±47.1 100,(0) 88.8±29.9 p=0.001, z=-3.4  
FE 55,(47.5) 52.4±29.9 70,(30) 65.6±21.2 p=0.04, z=-2.0 
EW 76,(44) 62.3±30.8 84,(24) 79.2±17.2 p=0.01, z=-2.3 
SF 75,(62.5) 68.7±32.8 100,(12.5) 89.1±22.2 p= 0.003, z=-2.9 
Pain 84,(32.5) 76.5±26.4 90,(20) 86.5±18.5 p= 0.08, z=-1.7 
 
In all subjects, there was a negative correlation between the SF-36 scores and 
cortisol values at several time points (Table 3.38). The correlation between GH 
at cotisol30 (p=0.02), cortisol45 (p=0.01), and cortisol60 (p=0.01) and cortisol90 
(p=0.007) was significant. The correlation between PF and cortisol was negative 
and insignificant; the same as RL-PH (Table 3.38).  
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The correlation between RL-E was significant at all-time points except time of 
awakening (cortisol0-p=0.3, cortisol15-p=0.001, cortisol30-p=0.005, cortisol45-
p=0.001, cortisol60-p<0.001, cortisol90-p=0.004). The correlation between FE 
and cortisol was significant and negative at 45 (p=0.008), 60(p=0.004) and 90 
(p=0.02) minutes post awakening. The correlation between EW and cortisol was 
significant at all-time points except at awakening (cortisol0-p=0.1, cortisol15-
p=0.02, cortisol30-p=0.01, cortisol45-p=0.004, cortisol60-p=0.003, cortisol90-
p=0.02). The correlation between SF and cortisol was not significant at any time 
points (Table 3.38) .The correlation between pain and cortisol was significant at 
all time points except at time of awakening (cortisol0-p=0.1, cortisol15-p=0.001 
,cortisol30-p=0.001, cortisol45-p<0.001, cortisol60-p<0.001, cortisol90-p=0.001) 
(Table 3.38). 
In line with these results, there was a negative correlation between AUCg60 and 
SF-36. This correlation was significant for GH, RL-E, EW and pain (Table 3.38). 
AUCi60 revealed a significant correlation with SF-36 which was significant at RL-
E, FE and pain (Table 3.38). In agreement with these results, there was a 
negative correlation between AUCg90 and SF-36 which was significant at GH, 
RL-E, FE, EW and pain (Table 3.38) AUCi90 showed a significant correlation at 











Table 3.38 SF-36 Correlation with cortisol and AUC 





 r=-0.2  
 
 p=0.02           
 r=-0.2  
 
 p=0.01            
 r=-0.2  
 
 p=0.01 
  r=-0.2  
 
p=0.007            
r=-0.3  
 
PF p=0.8     
r=-0.01 
 
 p=0.3              
r=-0.09  
 
 p=0.2             
 r=-0.1  
  
 p=0.08            
 r=-0.1  
 
 p=0.2              
r=-0.1  
 
p=0.2                 
r=-0.1  
 
RL-PH  p=0.8    
r=0.01  
 
 p=0.3      
 r=-0.1  
 
 p=0.2             
 r=-0.1  
 
 p=0.1            
 r=-0.1  
 
 p=0.1              
r=-0.1  
 
 p=0.1           
 r=-0.1  
RL-E  p=0.3     
 r=-0.1  
 
p<0.001                         
r=-0.2  
 
p=0.005               
r=-0.3  
 
 P<0.001             
 r=-0.3  
  
 p<0.001             
 r=-0.3  
 
p=0.004            
r=-0.3  
  
FE p=0.7           
r=-0.03  
 
p=0.2              
r=-0.1  
 
p=0.05             
r=-0. 2  
 
p=0.008              
r=-0.2  
 
 p=0.004           
 r= -0.3  
 
p=0.02              
r=-0.2  
 
EW p=0.1           
r=-0.03  
 
p=0.02              
r=-0.1  
 
 p=0.01             
 r=-0.2  
 
 p=0.004            
 r= -0.2  
 
p=0.003               
r=-0.3  
 
p=0.02              
r=-0.2  
 
SF p=0.6      
r=-0.05  
 
p=0.08              
r=-0.1  
 
p=0.1             
 r=-0.1  
  
p=0.08               
r=-0.1  
 
p=0.06              
r=-0.2  
 
p=0.08              
r=-0.1  
  
Pain p=0.1       
r=-0.1  
 
P<0.001            
r=-0.3  
 
P<0.001             
 r=-0.3  
 
 p<0.001            
 r= -0.3  
  
p<0.001             
r=-.04  
 
p=0.001            
r=-0.3  
 
 AUCg60 AUCi60 AUCg90 AUCi90 
GH p=0.02 r=-0.2  p=0.2 r=-0.1  p=0.01 r=-0.2  p=0.05 r=-0.2  
PF p=0.2 r=-0.1  p=0.2 r=-0.1  p=0.2 r=-0.1  p=0.2 r=-0.1  
RL-PH p=0.2 r=-0.1  p=0.1 r=-0.1  p=0.2 r=-0.1  p=0.1 r=-0.1  
RL-E p=0.003 r=-0.3  p=0.008 r=-0.2  p=0.001 r=-0.3  p=0.005 r=-0.3  
FE p=0.4 r=-0.2  p=0.009 r=-0.2  p=0.02 r=-0.2  p=0.006 r=-0.3  
EW p=0.006 r=-0.3  p=0.05 r=-0.2  p=0.006 r=-0.3  p=0.04 r=-0.2  
SF p=0.1 r=-0.1  p=0.1 r=-0.1  p=0.09 r=-0.1  p=0.1 r=-0.1  
Pain p<0.001 r=-0.3  P<0.001 r=-0.3  p<0.001 r=-0.3  p<0.001 r=-0.3  
 
  
3.2.14.4 Inventory of Depressive Symptomatology (IDS) 
Due to the data that we gathered from IDS questionnaires (37 CB, 24 CA, 3 PB, 
12 PA), we did not make a comparison among the 4 groups. Instead, we 
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compared (Mann-Whitney U test) patients and controls, and abused and non-
abused subjects, as there were too many missing data for a 4 group analysis. 
There was a significant difference between MDD patients and controls, with 
higher scores in the patient group (p<0.001, z=-5.7, Mean Rank =67.9). 
There was a significant difference between abused and non-abused subjects, 
with high scores in abused subjects (p=0.02, z=-2.3, Mean Rank=44.5). 
In all subjects, the correlation between IDS and cortisol values was significant at 
all time points except at time of awakening and 90 minutes post awakening 
(cortisol0-p=0.06, and r=0.2; cortisol15-p=0.01, r=0.2; cortisol30-p=0.006, r=0.3; 
cortisol45-p=0.01, r=0.2; cortisol60-p=0.01, r=0.2; cortisol90-p=0.1, r=0.1). 
In line with this, there was a significant positive correlation between AUCg60, 90 
and IDS (AUCg60-p=0.005; AUCg90-p=0.01; AUCg60-r=0.3; AUCg90-r=0.2). 
Table 3.39 IDS 
 Controls Patients Abused Non-abused 
Stat p<0.001  
z=-5.7  
mean rank patients/controls =67.9/31.2 
p=0.02  
z=-2.3  
mean rank Ab/Nab=44.5/32.7 
 
 
Table 3.40 IDS correlation with cortisol and AUC 
 AUCg60 AUCi60 AUCi90 AUCg90 








 cortisol0 cortisol15 cortisol30 cortisol45 cortisol60 cortisol90 













3.2.14.5 Oslo Social Support scale (OSS-3) 
Thirty-seven CB, 24 CA, 11PB and 24PA were analyzed. There was no difference 
among the 4 groups in terms of total score (p=0.07, df=3). Table 3.41 
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In all subjects, there was not a significant correlation at any time point (cortisol0-
p=0.1, and r=-0.1; cortisol15-p=0.3, and r=-0.9; cortisol30-p=0.3, and r=-0.9; 
cortisol45-p=0.1, r=-0.1; cortisol60-p=0.2, r=-0.1; cortisol90-p=0.2, r=-0.1) 
In line with this, AUC did not reveal a significant correlation with OSS-3 (AUCg 
60-p= 0.2; and AUCg90-p=0.3; AUCg60-r=-0.1; AUCg90-r=-.09; AUCi60-p=0.6; 
AUCi90-p=0.7, AUCi60-r=0.04; AUCi90-r= 0.03). Table 3.42 
Table 3.41 OSS-3 
 CB CA PB PA 
Stat p= 0.07 , df=3 
 
Table 3.42 OSS-3 correlation with cortisol and AUC 
























3.2.14.6 List of Threatening Events (LTE) 
Thirty seven CB, 24 CA, 12 PB and 25 PA were analyzed. There was a significant 
difference among the 4 groups in the overall score of the LTE questionnaire 
(p<0.001, df=3). The PB group showed the highest scores (mean=1±0.8, 
median=1(IQR=0.7), Mean Rank=71.9).  
In all subjects, there was no significant correlation between LTE and cortisol at 
any time point (cortisol0-p=0.7, and r=-0.03; cortisol15-p=0.7, r=0.02; cortisol30-
p=0.8, r=0.01; cortisol45-p=0.5, and r=0.06; cortisol60-p=0.6, r=0.04; cortisol90-
p=0.8, r=-0.02).Table 3.44 
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In line with this, there were no significant correlations between AUC and LTE 
(AUCg 60-p=0.7; AUCg90-p=0.8; AUCg60-r=0.03; AUCg90-r=0.02; AUCi60-p= 
0.2; AUCi90-p=0.3, AUCi60-r=0.1; AUCi90-r=0.09) Table 3.44 
Table 3.43 LTE 
 CB CA PB PA 
Stat P<0.001 , df= 3 
 
Table 3.44 LTE correlation with cortisol and AUC 
























3.2.14.7 Impact of Event Scale (IES) 
Due to missing data (16 CB, 15 CA, 1PB and 1PA) we only analyzed the controls 
and not patients. There was no significant difference between abused controls 
and non-abused controls (p=0.7, z=-.0.2, Mean Rank=16.4). 
The correlation between cortisol at all-time points in all subjects, and the IES 
scores was not significant (cortisol0-p=0.8, r=-0.04; cortisol15-p=0.4, r=-0.1; 
cortisol30-p=0.6, r=-0.07; cortisol-45-p=0.5, r=-0.09; cortisol60-p=0.7, r=-0.06; 
cortisol90-p=0.8, r=-0.02). 
In line with this, the correlation between AUC and IES was not significant (AUCg 
60-p=0.7; AUCg90-p=0.6; AUCg60-r=-0.06; AUCg90-r=0.08; and AUCi60-p= 0.8 





Table 3.45 IES correlation with cortisol and AUC 
























3.2.14.8 Perceived Stress Scale (PSS) 
16 CB and 13 CA were analyzed. There was no difference between CA and CB 
(p=0.6, t=-0.4, F=1.6, df=27) (mean =23.2± 5.8, median=22(IQR=7.5)). There 
was no data in PB group, and only 3 subjects in the PA had scores available for 
this variable. 
In all subjects, the correlation between cortisol and PSS scores was not 
significant at any time points (cortisol0-p=0.9, r=-0.1; cortisol15-p=0.5, r=-0.1; 
cortisol30-p=0.3, r=-0.1; cortisol45-p=0.3, r=-0.1; and cortisol60-p=0.4, r=-0.1; 
cortisol90-p=0.5, r=-0.1). 
In agreement with this, the correlation between AUC and PSS was not significant 
(AUCg60-p=0.5; AUCg90-p=0.5; AUCg60-r=-0.1; AUCg90-r=-0.1; AUCi60-p= 
03; AUCi90-p=0.2, AUCi60-r=-0.1; AUCi90-r=-0.1). 
Table 3.46 PSS correlation with cortisol and AUC 

























3.2.14.9 Pittsburgh Sleep Quality Index (PSQI)  
15 CB and 13 CA were analyzed. There was no data in PB group. One subject in 
the PA group returned the questionnaire. There was no difference between CA 
and CB (Table 3.47). 
Table 3.47 PSQI 
















CB 0.6±0.6 1.2±0.8 0.8±0.8 0.3±0.4  0.2 ± 0.4  1.1±0.6 0.4±1.0 
CA 0.6±0.9 0.5±0.5 1.0±1.0 0.3±0.6  0.4 ± 0.9  1.1±0.6  0.3±0.6 
 Median,(QIR) 
CB 1,(1) 1,(1) 1,(1) 0.0,(1) 0,(1) 1,(0) 0,(0) 
CA 0,(1) 1,(1) 1,(2) 0.0,(1) 0,(1) 1,(1) 0,(1) 
 
The correlation between PSQI and cortisol at all-time points was not significant 
(Table 3.48). In line with this, the correlation between PSQI and AUC was not 














Table 3.48 PSQI correlation with cortisol and AUC 
 cortisol0 cortisol15 cortisol30 cortisol45 cortisol60 cortisol90 
Quality p=0.4 r=0.1 
             
 
p=0.2 r=0.2 p=0.6 r=0.08 p=0.5 r=0.1 p=0.8 r=0.04 p=0.8 r=0.02 




























































Medication  p=0.3   r=-0.1  
 










p=0.3 r=-0.1  
 
 
 AUCg60 AUCi90 AUCg90 AUCi90 


























































3.2.14.10 Correlation between specific type of abuse and all individual time 
points of cortisol 
There was a positive correlation between the severity of certain type of abuse 
and cortisol at all-time points in all subjects (Table 3.49). 
There was a significant correlation between emotional abuse severity and cortisol 
at 15 (p=0.01), 30 (p=0.003), 45 (p=0.003) and 60 (p=0.02) minutes post-
awakening (Table 3.49). There was a significant correlation between physical 
abuse severity and cortisol at time of awakening (p=0.04). 
There was a significant correlation between severity of sexual abuse and cortisol 
at 30(p=0.02), 45(p=0.006), 60(p=0.007) and 90(p=0.02) minutes post-
awakening. There was no significant correlation between emotional and physical 
neglect and cortisol at any time point, except at 15 minutes after awakening in 















Table 3.49 Correlation between child abuse and cortisol at all individual time points  
 cortisol0 cortisol15 cortisol30 cortisol45 cortisol60 cortisol90 
Emotional p=0.3        
r=0.8 
 
p=0.01       
r=0.2 
 
p=0.003           
r=0.2 
 
p=0.003          
r=0.2 
 
p=0.02          
r=0.2 
 











p=0.2        
r=0.1 































































3.2.14.10.1 Correlation between specific type of abuse and the score of 
HAM-D 17, 21 
There was a positive and significant correlation between the score of HAM-D 17, 
21 and the severity of all types of abuse except physical abuse and physical 
neglect .Table 3.50 
Table 3.50 Correlation between child abuse and HAM-D 17, 21 
 Emotional Physical Sexual  Emotional n Physical n 
HAM-D 17 p<0.001            
r=0.3 
 
p=0.2         
r=-0.1 
 
p=0.02              
 r=0.2 
 
p=0.001                
r=0.2 
 
p=0.1           
r=0.1 
 
HAM-D 21 p<0.001            
r=0.3 
 
p=0.3       
r=-0.09 
 
p=0.02               
r=0.2 
 
p=0.001              
r=0.3 
 







4.1 Overview  
With the fast increasing population of people who become depressed, and 
considering the adverse consequences of MDD, which could affect several 
aspects of the lives of people and their societies, it is time to consider this serious 
and debilitating disorder as a global concern.  
The amount of extensive research that has been conducted to understand the 
complexity of MDD has shown that gaining insight into MDD is not easy and 
simple. Identifying underlying biomarkers of depression may play a significant 
role in solving the puzzle of MDD; thus, research into biomarkers could be a big 
step towards decreasing the damaging consequences of depression. 
In order to identify biomarkers of MDD, numerous studies have been conducted 
on several types of biomarkers. In my thesis I focused on a number of potential 
biomarkers of MDD, consisting of the BDNF val66met polymorphism, amygdala 
volume and the CAR as an index of the HPA axis combined with early life stress, 
as explained in detail in the previous chapters. 
In brief, our first study did not find any modulatory effects of the val66met 
polymorphism on the grey matter volume of right and left amygdala. In the second 
study, we showed that the CAR was most elevated in those who were both 
depressed and had a history of ELS, which supports the argument that the effects 
of early life stress and MDD on the HPA axis may be additive. This is a novel 
result in the literature. 
 4.2 The first study  
Our study aimed to find a link between the val66met BDNF polymorphism and 
the grey matter of the amygdala. This study did not focus on other brain 
structures, although, it was a part of a wider study which did investigate the 
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modulatory effect of val66met BDNF polymorphism on the grey matter volume of 
several other areas of the brain (see Appendix A)  
4.2.1 Structure of the Brain, Amygdala 
4.2.1.1 Healthy controls and MDD Patients 
Amygdala volume was compared between healthy controls and MDD patients; 
our study did not find a reduction of amygdala volume in MDD patients. This result 
is in agreement with an early meta-analysis that found no changes in amygdala 
volume associated with depression (Campbell et al., 2004). In association with 
this, our result is consistent with a 1 year follow-up study by Frodl et al. (2004) 
which was conducted on 30 MDD patients (HAM-D17=23.7±6.9; and age=18-65 
years; and mean±SD age=48.4±13.4 years; and mean±SD duration of 
illness=9.1±10.2) consisting of 11 patients with first episode of depression and 
19 patients with recurrent depressive disorder. They matched 30 healthy controls 
in terms of age (20-65 years, and mean±SD age=45.7±12.9), gender and the 
tendency to use either the right or left hand. All the subjects were tested after 1 
year. Remission was defined as HAM-D 17 score ≤ 7. No changes in amygdala 
volume were observed either in remitted or non-remitted MDD patients with first 
episode of depression or recurrent depressive disorder. As explained before our 
patients were in their acute phase of third depressive episode and they had a 
history of recurrent depression. 
Another study that did not find significant changes on amygdala volume was 
conducted on 34 drug-resistant MDD patients compared to 17 age-matched 
healthy control subjects (Mervaala et al., 2000). Although our subjects had a 
history of recurrent depression rather than a more chronic, treatment-resistant 
type of depression, this result was consistent with our result. 
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In contrast, in a more recent meta-analysis, Sacher et al. (2012) found lower grey 
matter amygdala volume in MDD patients, a result which is different to our result. 
This latter meta-analysis consisted of VBM and MRI studies that investigated 
structural changes, as well as functional (18F)-fluorodeoxyglucose Positron 
Emission Tomography (FDG-PET) studies, designed to show changes in 
glucose-metabolism at rest; whereas, we did not use VBM or FDG-PET ; In our 
study , instead magnetisation-prepared rapid gradient echo (MP-RAGE) T1-
weighted scans were acquired at 1.5 T and the MP-RAGE volume acquired using 
the Alzheimer’s disease Neuroimaging Initiative (ADNI) custom pulse sequence. 
In association with this, related to treatment of MDD, the previous meta-analysis 
by Hamilton et al. (2008) found that the amygdala volume was decreased in un-
medicated MDD patients and increased in MDD patients who received 
medication. Although, most of our MDD patients were taking antidepressant 
medication, no amygdala volume changes were observed in our study which is 
not in agreement with this meta-analysis. The inconsistency between the results 
could be due to the chronicity of MDD of the subjects, as our participants had a 
history of recurrent depression characterized by discrete acute depressive 
episodes with periods of euthymia rather than a more chronic, treatment-resistant 
type of depression; the other issue could be due to the way that the amygdala 
was characterized for the volume estimation ; because although they mentioned 
that they included studies in which the amygdala was defined independent of the 
hippocampus, the definitions of amygdala volume reported in the larger literature 
were highly variable and not easily quantifiable, thus the impact of variation in 
amygdala boundary definition could lead to this inconsistency ; and the last factor 
should be considered is that the characteristic of the subjects in terms of age, 
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gender and the proportion of medicated or un-medicated patients were not similar 
between our study and theirs (Hamilton et al., 2008). 
In line with these results, Eijndhoven et al. (2009) conducted a study on 20 MDD 
patients with a current first episode of depression (age=18-56 years; mean 
age±SD=34.1±11.6 years), 20 MDD patients without medication who had 
recovered from a first episode (age=18-53 years; mean age±SD=35.8±11.6 
years), and 20 healthy controls (age=18-53 years; mean age±SD=37.3 ±12.7 
years). They found a heightened amygdala volume in first episode MDD patients 
compared with the other groups. It was argued that the enlargement of amygdala 
volume was a state marker of depression, and it was not associated with any 
medication used by MDD patients. This result was also in agreement with a study 
by Frodl et al. (2003) conducted on 30 inpatients with a first episode of depression 
and 27 inpatients with recurrent major depression, together with healthy controls 
from the local community matched for age, gender, and the tendency to use either 
right or left hand. Enlargement of amygdala volume was observed only in patients 
in the first episode of depression compared with patients with recurrent major 
depression and healthy control subjects. Our subjects were not in their first 
episode of illness, as our participants had a history of recurrent depression 
characterized by acute depressive episodes with periods of euthymia, and this 
could be an explanation for the inconsistency between the results, from this study 
and ours.  
In contrast with finding of amygdala volume enlargement, decreased amygdala 
volume were observed in MDD patients compared with healthy controls in several 
other previous studies (Hasting et al., 2004; Tang et al., 2007; Frodl et al., 2008). 
For example, Frodl et al. (2008) investigated 38 inpatients with major depression 
(mean±SD age=46.1±11.3 years) and 30 healthy controls, matched for age 
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(mean±SD age=43.6 ±11.3 years), gender and the tendency to use either right 
or left hand. VBM volumes were estimated from magnetic resonance images; 
regular assessment of psychopathologic results was conducted during the 
inpatient phase, and then after 1, 2, and 3 years. MDD patients showed a 
decrease in grey matter density of the left amygdala. Most of their patients 
remitted after the inpatient treatment phase, but during the follow-up period, about 
17 patients (45%) relapsed. The remaining 21 patients (55%) did not relapse over 
3 years. No differences in grey matter amygdala volume were observed between 
remitted patients without relapse and remitted patients with relapse. This was a 
prospective, longitudinal 3 year study, which did not use similar MRI acquisition 
methods to ours. In agreement with this result, Tang et al. (2007) in another VBM 
MRI study, found decreased grey matter volume in the right amygdala in a group 
that consisted of 14 female MDD patients (mean age±SD=29.5 ± 6.84 years; 
mean education±S.D years=11.43±2.65; and mean depressive episode 
duration±S.D months=5.44 ± 5.22 ) who had a score of ≥ 18 on HAM-D 17 with 
a first episode of major depression in comparison to 13 healthy females controls, 
matched for age (mean age±S.D years=29.46±6.86) and education (mean 
education±S.D years=12.23±3.30). A few subjects in both groups had 
comorbidity with general anxiety disorder. It should be considered that our 
subjects were not restricted to females and they were not in their first episode of 
their illness.  
Similar to their results, decreased amygdala volume was demonstrated by 
Hasting et al. (2004) in MDD females compared with MDD males. Of note, several 
subjects had a history of childhood abuse in the female group. The result of their 
study could support the assertion that decreased amygdala volume may be 
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related to gender. However, our study did not make a comparison between males 
and females. 
In brief, the results from these previous studies described above, are inconsistent 
as to the presence of changes to grey matter amygdala volume in MDD, and in 
regard to illness factors that may be associated with the presence of such 
changes such as the lack of similarity in characteristics of the subjects, such as 
gender and the form of MDD e.g. severity, chronicity and number of recurrences. 
In our study, subjects had a history of recurrent depression characterized by 
acute depressive episodes with periods of euthymia rather than a more chronic, 
treatment-resistant type of depression.  
4.2.1.2 Comparing Val/Val Carriers and Met Carriers  
The mean amygdala volume was analyzed in val/val genotype and met carrier 
subjects. The results showed that carrying the met allele did not have a significant 
impact on the amygdala volume. 
Previous studies investigating the influence of the val66met BDNF polymorphism 
on amygdala volume have shown inconsistent results. Similar to our result, Forde 
et al. (2014) did not find an effect of met-homozygosity and heterozygosity on 
grey matter and white matter of the brain structure. In particular, they recruited 
60 healthy controls, 20 in each genotypic group (val/val, val/met and met/met). 
They used VBM and surface reconstruction methods. MRI scans were acquired 
on a 3 T scanner. They found no evidence to show a met dose-effect on amygdala 
volume˗˗from an intracellular point of view, there seems to be a met-dose effect , 
with increasing the number of met allele, on intracellular localization (Chen et al., 
2004) and adjustment of activity-dependent secretion of BDNF (Chen et al., 
2006); These effects are presumably caused by abnormal intracellular packaging 
and regulation of the secretion of BDNF in the presence of Met (Egan et al., 2003; 
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Chen et al., 2004). These abnormalities cause changes in the BDNF activity-
dependent processes of human brain development and cortical plasticity. 
Previous studies have selected met-carriers to investigate the effects of the 
val66met BDNF polymorphism rather than the certain met-dose effect, probably 
due to an absence of met-homozygotes in the population ˗˗ in any of the balanced 
genetic group of their subjects. This study has shown that the met-allele has a 
significant but non-uniform effect on the brain structure, with homozygotes 
(met/met and val/val) more similar than heterozygotes (val/met). Not similar to 
our study, their subjects consisted of healthy controls instead of both MDD and 
healthy controls. However, they argued that by grouping all met-carriers together, 
previous studies, similar to our study, may have missed an important factor in the 
interaction between the met and val alleles. Thus, their results presented a U-
shaped profile in BDNF, where heterozygotes were not similar to both sets of the 
homozygotes (Forde et al., 2014).  
4.2.1.2.1 Val/Val Carriers and Met Carriers in healthy controls 
In order to investigate the role of the met allele in healthy controls, the amygdala 
volume was compared between val/val genotype and met carrier groups. There 
were no differences between these two groups. 
Our result differ from the outcome of a study by Montag et al. (2009), who showed 
decreased right and left amygdala volumes, using VBM, in healthy controls who 
were met allele carriers. It should be noted that their subjects relied on a self-
reported assessment of depression and they did not use a standardized 
structured interview for psychiatric diagnoses to characterise the healthy controls. 
Substance abuse was not considered to be an exclusion criterion for their study, 
which is problematic given evidence that this can affect amygdala volumes 
(Padula et al., 2015).  
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However, our results are consistent with research conducted by Frodl et al. 
(2007) in MDD patients and by Gerritsen et al. (2012) showing no effect on 
amygdala volume in healthy subjects of carrying the BDNF met allele with a 
history of childhood adversity ; although we didn’t measure childhood adversity in 
our study. 
Consistent with our result, in particular, Frodl et al. (2007) investigated the effect 
of the BDNF val66met polymorphism on amygdala volume in MDD patients and 
in healthy control subjects, in 120 subjects consisting of 60 patients with major 
depression (age=18-65 years; mean ±SD age=44.2 ±11.8 years; HAM-D 17=23 
± 6.3) and 60 healthy controls (age=22-64 years; mean ± SD age=41.6 ± 12.3 
years). No differences in amygdala volume were observed in MDD patients 
compared with healthy controls. All MDD patients were inpatients. 30 patients 
had a first depressive episode, and 30 patients had recurrent episodes. Almost 
all patients, except those who were not taking antidepressants medications, were 
in an outpatient service and were treated with antidepressants before the current 
admission. MRI was conducted in the first 2 weeks after admission to the hospital. 
In agreement with our study, no significant changes of amygdala volume were 
observed. 
4.2.1.2.2 Val/Val carriers and Met carriers in MDD patients 
The argument about the function of the met allele in MDD was tested by 
comparing val/val genotype and met allele carriers in MDD patients. The finding 
of an insignificant reduction of amygdala volume supports the suggestion that the 
met allele does not play a major role in determining amygdala volume in MDD. 
To our knowledge, there is no previous study that has investigated the effect of 
carrying the met allele on grey matter amygdala volume in comparison to the 
val/val genotype in only MDD patients groups. 
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4.3 The second study  
Cortisol secretory activity increases at the early morning and reaches a peak 
point following awakening; thereafter it falls with a decreasing trend over the 
remainder of 24 hours (Edwards et al., 2001), although inconsistent results of 
cortisol secretory activity have been previously observed in subjects experiencing 
MDD (Trestman et.al., 1995; Goodyer et al., 1996). 
Our study found that, among all subjects (including healthy controls and patients), 
the peak cortisol level was observed at 30 minutes after awakening (mean ± 
SD=15.3 ± 8.2; median=15.10 nm/l); which was consistent with previous findings 
which observed the rises of cortisol by anywhere between 38% and 75%˗˗of note, 
our study observed a 46% increase˗˗compared to the cortisol at awakening, 
peaking 30-45 minutes after awakening (Clow et al., 2004; Fries et al., 2009).  
 4.3.1 CAR in Healthy Controls and MDD Patients 
The study found a higher cortisol and AUC-CAR- in MDD patients compared with 
healthy controls. Thus, when all patients were combined together, the total post-
awakening secretion of cortisol -AUCg- and the responsivity of the HPA axis -
AUCi- were both higher in MDD. It should be noted that this overall comparison 
consists of both healthy controls and MDD patients who had experienced early 
life stress, as well as those who had not. As will be explained later, the lack of 
similarity between those subjects with and without a history of childhood abuse, 
and the extent to which it is MDD rather than childhood abuse causing the 
increasing in the CAR, cannot be addressed in a straightforward comparison of 
patients and controls. However, this result is consistent with a number of previous 
studies which have shown an increased CAR in MDD patients (Vreeburg et al., 
2009; Ulrike et al., 2013; Dienes et al., 2013). In particular, an increased CAR 
was found in the following groups of MDD patients: middle aged subjects 
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(Vreeburg et al., 2009), adolescent girls (Ulrike et al., 2013) and adult females 
(Dienes et al., 2013). These prior studies findings are consistent with our results, 
although our subjects were both females and males with a wide age range.  
In contrast, however, other studies have shown a blunted CAR in young adult 
women with mild to moderate depression (Stetler et al., 2005) and in older people 
with a 6 month depression (Rhebergen et al., 2015).  
The inconsistency between the prior results, in regards to the CAR in MDD 
patients, could be caused by a number of issues. First of all, the severity of 
depression might be a potential factor; whilst most studies consisted of MDD 
patients who had undergone appropriate diagnostic assessment, others 
investigated subjects with increased depressed mood without actual diagnosis of 
depression. However, to our knowledge there has been no study investigating 
the effect of severity of depression on the CAR in MDD patients. The other issue 
which should be considered is that psychosocial factors associated with 
depression, such as work stress and financial strain, were not always considered 
in all studies; it is well documented that these factors may be associated with both 
increased vulnerability to depression and alterations in the CAR (Chida et al., 
2009; Dedovic et al., 2015). In detail, Chida et al.(2009), in a meta-analysis, 
showed that job stress and social stress were related to an increased CAR, 
whereas fatigue, burnout, or exhaustion were characterized by a decreased CAR 
Thus, ignoring the psychosocial factors could be another important issue 
contributing to the inconsistency of the results between previous studies. 
4.3.2 Effects of childhood abuse 
Our study did not find a significant difference in the cortisol at any time point or in 
AUC-CAR- when comparing abused and non-abused groups when all subjects 
were considered together. As explained before, such a comparison does not take 
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full account of the effects of depression. However, this result is inconsistent with 
a previous study which found a decreased CAR in subjects with a history of early 
life stress (Heim et al., 2001) and with a study which found a flattened CAR in 
mid-adulthood in association with cumulative maltreatment in childhood (Power 
et al., 2012).  
These inconsistent results could be due to a number of reasons. One explanation 
could be that the studies select other methods to assess childhood adversity. The 
ascertainment of childhood adversities and other psychosocial maltreatments is 
not straightforward because all methods may be affected by biases and 
inconsistencies (Power et al., 2012). In particular, biases in self-reported of 
sexual abuse have been observed in previous research, consisting of problems 
such as forgetting, denial, misunderstanding, and embarrassment; all these 
factors and issues may cause under-reporting rather than over-reporting of child 
abuse. Assessment of childhood adversities using a comprehensive test-retest 
methodology in young adults has found that self-reported sexual or physical 
abuse several years later is not as careful as the reports which were made 
several weeks later (Gilbert et al., 2009).  
In order to attempt to determine the effect of depression and childhood abuse 
separately as explained in the method and result sections, our study recruited 4 
distinct groups (non-abused healthy controls, abused healthy controls, non-
abused MDD patients, abused MDD patients) rather than simply making a 
comparison between either MDD patients or healthy controls or abused and non-
abused subjects all together. 
The comparisons of these 4 groups are discussed in the following section. 
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4.3.3 Healthy controls without a history of childhood trauma and healthy 
controls with a history of childhood trauma (CB and CA)  
There was no difference in the cortisol or AUC-CAR- between healthy controls 
without childhood abuse and healthy controls with childhood abuse. Thus, there 
was no effect of childhood maltreatment on the CAR in healthy controls in our 
study.  
Previous studies have reported conflicting results. An increased CAR was shown 
in a previous study of healthy young adults who had received low parental care 
in their childhood compared with healthy young adults who had received high 
parental care (Engert et al., 2011). Similar to this result, an increased CAR was 
observed in healthy pregnant women who were sexually abused in their 
childhood compared with healthy pregnant women and non-sexually abused 
pregnant women (Bublitz et al., 2012). Considering these studies in detail, Engert 
et al. (2011) examined 58 subjects between 18 and 30 years of age, consisting 
of 11 males and 17 females with a history of low parental care, and 8 males and 
22 females with high parental care. Parker’s questionnaire (1979) was selected 
to assess childhood maltreatment. All subjects collected saliva by Salivette at 
awakening and 30 minutes thereafter on 3 non-consecutive weekdays. In 
comparison to our study, Engert et al. (2011) examined a younger subject group 
with more males, and used a different method of saliva collection after awakening 
as explained. They did not control for cycle phase or oral contraceptive use in 
their analyses, which is in contrast to our study. This is an important consideration 
because gonadal steroid secretion in females changes during the menstrual cycle 
and with the usage of oral contraceptives. Gonadal steroids can affect the HPA 
axis function; thus previous studies have shown that the activation of the stress 
response and paraventricular nucleus of hypothalamus neurons is higher in 
158 
 
females than males (Seale et al., 2004 ; Viau et al., 2005; Larkin et al.,2010), and 
that this could be due to the changes in estradiol in the estrous cycle of females 
(Viau et al.,1991; Rhodes et al., 2004; Iwasaki-Sekino et al., 2009). This is 
supported by studies investigating patterns of corticosterone secretion, where 
females present a higher amplitude, frequency and number of corticosteroid 
pulses compared to males (Seale et al., 2004). However, the mechanism by 
which gonadal steroid hormones may act to influence the HPA function has not 
been resolved in these previous studies. Nonetheless, it appears that increased 
responses to stress are most common in the proestrus phase, when estradiol 
levels are highest; whilst progesterone may decrease the effects of estradiol on 
HPA axis function. Taken together, these effects of gonadal steroids on circadian 
rhythms and the CAR, should be considered as a potential confounder when 
designing and interpreting studies.  
On the other hand, a number of recent reviews have argued that the influence of 
gender, gonadal steroids or contraceptives use on the CAR is inconsequential 
(Wust et al., 2004; Fries et al., 2009).  
Our abused healthy controls had experienced a variety of types of abuse, 
differently from the study which focused on parental care only. Another difference 
lies in the method of assessment of childhood abuse that we selected (Bernstein 
et al., 2003). Thus, the subjects may not be similar in terms of the nature of 
childhood abuse they had experienced. 
Another study by Bublitz et al. (2012) was conducted on healthy pregnant women; 
an increased CAR was found in healthy control women with a history of childhood 
sexual abuse when compared with healthy control non-sexually abused˗˗with 
other types of abuse˗˗ and non-abused healthy pregnant women. 135 participants 
(childhood sexual abuse n=30, non-sexual childhood abuse n=58, non-abuse 
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n=47) collected salivary cortisol by the drooling method at awakening time and 
30 minutes after awakening for 3 consecutive days at 1-3 time points over the 
second and third trimester. Subjects were tested with a self-report measure of 
childhood abuse experiences comprising 15 items from the Adverse Childhood 
Experiences Scale (Dube et al., 2003). Participants reported on childhood sexual 
abuse, physical abuse, domestic violence, and physical neglect. In this study, 
saliva was collected using the same drooling method as our study, but with a 
lower number of saliva collections post-awakening. Another issue is that this 
study consisted of pregnant women, where there may be obvious effects of 
gonadal steroids as explained before. It is unclear whether results in pregnancy 
are generalizable to results outside of pregnancy, or to males.  
It has been suggested that the characteristics of the study population, the type of 
adversity experiences, and the proneness to psychopathological vulnerability 
interact to explain whether the CAR is increased or decreased (Engert et al., 
2011). In this regard, our subjects consisted of abused subjects with a moderate 
severity of childhood abuse comprising one or more types of childhood 
maltreatment (emotional, physical, sexual and neglect-emotional and physical- 
as explained in the previous chapters).  
4.3.4 Healthy controls with a history of childhood trauma and MDD patients 
with a history of childhood trauma (CA and PA) 
The cortisol at 15 and 45 minutes after awakening, and the AUCg-CAR- were 
higher in abused MDD patients than abused healthy controls. This result is not in 
agreement with a previous study which found a higher CAR at awakening time 
and 30 minutes after awakening in healthy controls with a history of childhood 
neglect compared to depressed patients without a history of childhood neglect 
(Peng et al., 2014). In detail, they had a total of 28 patients – both inpatients and 
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outpatients – with a history of childhood neglect (no comorbidity with any other 
type of childhood abuse) (mean ± SD age=28.8 ± 6.28 years; mean ± SD illness 
course=21.68 ± 22.12 months; 15 males and 13 females) and 30 patients – both 
inpatient and outpatient – without child neglect (There was no comorbidity with 
any other type of childhood abuse) (mean age=28.37 ± 8.27 years; mean illness 
course=25.48 ±19.06 months; and , 16 males and 14 females).Their comparison 
groups were 29 gender and age matched healthy controls without childhood 
neglect (mean age=27.87 ± 4.28 years; 15 males and 14 females) and 22 healthy 
controls with childhood neglect (mean age=28.37 ± 5.28 years; 12 males and 10 
females). Akin to our study the CTQ (Bernstein et al., 1998; 2003) was used to 
measure early life stress (cut-off score at ≥15 for emotional neglect, ≥10 for 
physical neglect). Salivary cortisol was collected at home with Salivettes on two 
consecutive working days, at awakening and 30 minutes after awakening, 
representing a lower number of assessments of post-awakening cortisol rather 
than in our study. In addition, the calculation of the awakening response was not 
the same as in our study. Instead of using an AUC calculation, HPA axis 
functioning was characterized as the change between cortisol levels at 30 
minutes after awakening and at awakening. The mean value of the consecutive 
two days was presented as the index of HPA axis functioning. It is of note that 
they recruited younger subjects with shorter length of illness compared to our 
subjects. This is important that the age of the subjects could have influenced the 
CAR, since older age is associated with a decreased CAR (Kudielka et al., 2003; 
Rhebergen et al., 2015). 
Of note, Peng et al (2014) examined both outpatient and inpatient subjects; this 
too might have affected the CAR, as previous studies have found an increased 
CAR in healthy subjects with depressive symptoms and in acute MDD outpatients 
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compared to a blunted CAR in inpatients (Pruessner et al., 2003; Huber et al., 
2006). The number of saliva assessments differed between our study with Peng 
et al. (2014), and it could have affected the results; Of note, appropriate results 
of the CAR were observed in the previous studies in which the CAR were 
assessed on minimum of 2 days rather than one day, representing that we could 
decrease the biases of our results, by rising the number of assessment to 2 
consecutive days (Wust et al., 2000; Hucklebridge et al., 2005). Another 
important factor is that Peng et al. (2014) focused on neglect in childhood, 
whereas our study consisted of a wider range of abuse types or of multi-abuse 
comorbidity. Thus our results might be a consequence of the cumulative effect of 
several types of abuse rather than one type of abuse.  
However, In association with this, previous studies which investigated ELS either 
in MDD patients or healthy controls argued that the alteration of the CAR, both 
decreased and increased, could be observed (Earls et al., 1997; Stein e al., 1997; 
Heim et al., 2001; Gunnar et al., 2001; Roy et al., 2002; Weissbecker et al., 2006; 
Power et al., 2012, Peng et al., 2014).  
 
4.3.5 Healthy controls without a history of childhood trauma and MDD 
patients without a history of childhood trauma (CB and PB) 
Our study found no effect of depression on salivary cortisol or AUC-CAR- in non- 
abused patients compared with non-abused controls. This result is not consistent 
with the results of numerous studies that have found a hyperactivity of the HPA 
axis in MDD patients compared with controls (Gold et al., 1985; Holsboer et al., 
1985; Sacher et al., 1973; Bhagwagar et al., 2005; Cowen et al., 2010; Vreeburg 
et al., 2009). Of note, among all the previous studies, there were some 
confounding factors which could affect the results. For example, the alteration of 
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the CAR – whether increased or decreased – could be associated with the 
characteristics of the subjects (Bauer et al., 2002, Weber-Hamann et al., 2002, 
O’Brien et al., 2004; Peeters et al., 2004; Juruena et al., 2006; Khnor et al., 2010) 
which could play an important role in incontinency of the results. 
Another confounding factor about previous studies showing HPA axis 
hyperactivity is that, they did not usually assess the history of probable childhood 
abuse, which our results suggest to have an effect on HPA axis activity in 
depression, and could possibly explain the differences in those studies compared 
to our findings. In particular, because of the high unreported experience of ELS 
among MDD patients and healthy controls, numerous previous studies have not 
been able to separate out the effect of ELS and the effect of MDD. It suggests 
that previous findings about the neurobiology of depression might be confounded 
due to the lack of clear reported of childhood abuse.  
Considering each of these studies, Bhagwagar et al. (2005) conducted a study 
on 20 patients without medication (mean age=43.6±11.0 years; 10 male and 10 
female) recruited from primary care sources with a Hamilton score of 19.8; and 
40 healthy controls (mean age=40.5±13.6 years; 19 male and 21 female). Saliva 
collections were obtained by the participants at home, using Salivettes, at 
awaking time and at 15 minutes intervals for the next hour. The time of the 
menstrual cycle in female subjects was not controlled. Two controls and three 
patients were on oral contraceptives at the time of the study. Increased salivary 
cortisol was found in MDD patients compared to healthy controls; and the authors 
suggested that this was independent of age, gender, and hours of sleep, time of 
awakening and severity of depression.  
It is noteworthy to consider that in both Bhagwagar et al’s study and ours, there 
were a number of issues which could have affected the results and led to biases. 
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First of all, it has been well documented that delays of 5-15 minutes between 
awakening and the beginning of saliva collecting should be considered in the 
assessment of the CAR (Smyth et al., 2013). In our studies, the actual timing of 
each saliva collection was assessed by using self-reported times, which might 
not be the exact time of collection in all cases, even though both studies asked 
subjects to report the exact time of collecting. Second, awakening time in controls 
and patients in both studies differed; this could confound results as MDD subjects 
usually wake up earlier than controls (Edwards et al., 2001). Bedtime and total 
sleep duration were not considered in both studies, which could affect the result; 
as a number of studies could show a clear effect of awakening time with subjects 
waking up early having a higher CAR than subjects waking up late (Edwards et 
al., 2001; Kudielka et al., 2003; Aubry et al., 2010). 
Bhagwagar et al’s results are not similar with our finding and this could be related 
to a number of issues. The most important factor could be the characteristics of 
subjects of the studies, in that they did not consider a history of childhood abuse 
in their subjects which could have affected their results; of note, this is an 
important issue because if they could consider this issue, the results might be 
consistent. Another issue was that they recruited un-medicated MDD patients 
from primary care, whereas our study was conducted in inpatients and 
outpatients who were receiving several types of antidepressant. The use of 
antidepressant medication is a potential confounding factor; as previous studies 
have shown a flattened CAR in association with tricyclic antidepressant (TCA) 
use, and higher evening cortisol levels and decreased cortisol suppression after 
dexamethasone ingestion with the use of SSRIs (Manthey et al., 2011; Khnor et 
al., 2012).In addition, in regards to the study by Kunz et al. (2004), the day of 
saliva collection i.e. working or non-working day, or weekends versus weekdays, 
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is a crucial factor that can affect results as higher CAR on weekdays than 
weekends and working days than non-working days has been found (Kunz et al., 
2004; Schlotz et al., 2004). Although, the majority of subjects in Bhagwagar et al. 
(2005) did not collect saliva on working days, making it unlikely that this was a 
factor that could affect their results, it is clear that this confounding factor should 
be considered in their future studies. 
 As mentioned before, another issue is that the lack of control for menstrual cycle 
phase and use of contraceptives could be a potential confounding factor as the 
CAR may be increased during ovulation (Bouma et al., 2009; Wolfram et al., 
2011) which means, if their subjects collected saliva during ovulation, 
Bhagwagar’s results may be influenced, as Wolfram et al. (2011) showed the 
higher CAR during ovulation compared to the menses, the follicular phase and 
the luteal phase in healthy controls. However, to our knowledge, the effect of 
ovulation on CAR specifically in MDD patients is unclear.  
In sum, our study did not show a significant difference in the CAR between non-
abused healthy controls and non-abused MDD patients in contrast to previous 
studies. 
 4.3.6 Healthy controls without a history of childhood trauma and MDD 
patients with a history of childhood trauma (CB and PA)  
A higher cortisol and AUC-CAR- at all time points except at time of awakening 
was observed, which raise the assertion that the effect of early life stress and 
depression may have an additive or cumulative effect on basal cortisol and the 




4.3.7 MDD patients without a history of childhood trauma and MDD patients 
with a history of childhood trauma (PB and PA) 
Although an influence of ELS on the CAR in healthy controls was not observed 
in our study, the comparison between non-abused MDD patients and abused 
MDD patients did show an effect of ELS on the cortisol at 15 and 45 minutes after 
awakening and an increase in the AUC-CAR. This result is consistent with a 
previous study, showing increased salivary cortisol at awakening time and 30 
minutes after awakening in MDD patients with history of childhood neglect 
compared with MDD patients without a history of childhood neglect as explained 
before (Peng et al., 2014). To our knowledge, there is no study that has looked 
at the effect of other types of ELS than neglect in MDD and its relation with CAR. 
In association with this, previous studies have shown that adult women with a 
history of childhood sexual or physical abuse exhibit increased neuroendocrine 
and autonomic reply to psychosocial laboratory stress, in particular, those with 
MDD (Heim et al., 2001). Other changes demonstrated in subjects with ELS 
experiences have included glucocorticoid resistance and increased central 
corticotropin-releasing hormone activity (Heim et al., 2012).  
In association with this, the investigation about MDD and the CAR in previous 
research, shows there is a strong association between them, presenting the 
important character of the CAR in MDD patients. It was argued that there is a 
relation between the CAR and several risk factors of depression. It was 
suggested that the CAR is a predictor of stressors to come such as increasing 
the CAR on working days. As explained before, MDD itself has been associated 
with both increased and lowered or blunted CAR; even attempts have been made 
in investigating whether CAR may serve to anticipate depression onset (Dedovic 
et al., 2015). 
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However, our study did not separate out the different types of abuse and we 
cannot conclude which particular types of abuse played the most important role 
in the changes to the cortisol or AUC-CAR- in the abused MDD groups.  
  
4.3.8 All the groups 
In sum, MDD patients who suffered from childhood abuse presented the highest 
CAR among all the groups. Our study showed that the total cortisol released in 
the period after awakening AUCg-CAR- increased when patients were abused in 
their childhood. 
4.4 Clinical results 
Although a previous study argued that the type of treatment did not seem to have 
an influence on cortisol (McKay et al., 2010), an association between 
antidepressants and cortisol was observed in a previous study by Manthey et al. 
(2011). This was conducted on 1526 subjects who were using a serotonin 
reuptake inhibitor (SSRI) (n=309), TCA (n=49) or other type of antidepressants 
(n=100), or who were non-users of medication (n=1068). All subjects had a 
current or past diagnosis of anxiety and/or depression. As compared to non-
users, TCA users had a flattened CAR; SSRI users had higher evening cortisol 
levels and they showed decreased cortisol suppression after receiving 
dexamethasone ingestion. By findings of their study they suggested that different 
subtypes of antidepressants were associated with distinct alterations of the HPA 
axis. TCA users, who presented a flattened CAR, showed the strongest 
alterations of salivary cortisol. Another study by Ruhe et al. (2015) conducted on 
MDD patients without medication and healthy controls investigated the change 
from the baseline CAR after 2 weeks of Paroxetine treatment during 12 weeks. 
Although the study did not show a significant difference in the CAR between MDD 
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patients and healthy controls at baseline, they observed a reduced CAR in MDD-
patients after 12 weeks of treatment; especially when patients achieved 
remission. 
Thus, it is important to consider that the MDD patients in our study were using 
several types of antidepressant, which might have affected the CAR. We were 
not able to compare medicated to un-mediated subjects due to the small numbers 
who were without medication, nor did we have sufficient power to compare 
differential effects of the type of medication patients were taking. However, we 
did not observe a strong and significant correlation between the usage of 
antidepressant and cortisol values or AUC-CAR. 
Of note, investigating the CAR in remitted patients could be helpful in 
understanding the effect of previous depressive episodes on the HPA axis. In line 
with this, Aubry et al. (2010) conducted a study on 38 remitted MDD patients (age 
=24-66 years; 11 men and 27 women) and 52 healthy controls (age=24-63; 18 
men and 34 women); all patients were without medication at least for 3 months 
and they had experienced at least 3 previous depressive episodes. Saliva was 
collected at home, either at the weekend or on a weekday, at 0, 15, 30, 45 and 
60 minutes after awakening. The results supported the hypothesis that remitted 
MDD patients continue to show an increased CAR in compared with controls. In 
line with this, in previous studies, it has been argued that in the long-term course 
of depression, the HPA axis abnormality increases in parallel with the number of 
previous episodes (Aubry et al., 2010). 
Our study found MDD patients who had experienced their first episode later in life 
showed a higher individual cortisol at 15 minutes after awakening; although this 
result could be explained by gender of the patients, as we recruited more females 
rather than males in our patients group and the CAR is higher in female compared 
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to male(Dedovic., 2015). In line with this, we should consider about the age of 
our subjects; as older age seems to be related to lower CAR, rather than higher 
CAR (Kudielka et al., 2003); although it does not seem our finding could be 
confounded by the age of our patients as we recruited older patients rather than 
younger ones. 
4.4.1 Type of abuse and severity of depression 
Childhood abuse is an important environmental risk factor which can increase the 
risk of developing depression (Heim et al., 2008). Hoven et al. (2015) showed 
that emotional neglect, physical and sexual abuse were associated with an 
increased risk of first onset and relapse of MDD. They showed that a higher 
severity of depressive symptoms at baseline and the presence of a prior lifetime 
diagnosis of a depressive and/or anxiety disorder, mediated these associations. 
This study argued that emotional neglect was the most important predictor of first 
onset and recurrence of any depressive or comorbid disorder among all types of 
abuse. 
The results of our study showed a positive correlation between the severity of 
depression in terms of Hamilton score (HAM-D 17, 21) and sexual and emotional 
abuse, and are thus supportive of the findings of Hoven et al (2015).  
4.5 Self-rated questionnaires  
4.5.1 Work and Social Adjustment Scale (WSAS) 
The level of functioning of MDD patients is not highlighted in standard 
symptomatic measures of depression severity, such as HAMD-17. That is the 
reason that DSM-V has introduced a new measure of functioning (e.g. the WHO 
Disability Assessment Schedule) to provide a more comprehensive assessment 
of functioning in patients with psychiatric disorders (Lin et al., 2015). Although 
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symptoms recover within several weeks after beginning of treatment, functioning 
does not improve as quickly (Lenderking et al., 1999). 
In our study, abused and non-abused MDD patient groups both presented higher 
scores on the WSAS compared with the healthy control groups, supporting the 
assertion that MDD affects the everyday tasks of the subjects. We could not 
observed any effect of ELS on the score of WSAS. 
There was a positive correlation between CAR and the WSAS, signifying that 
when level of function decreases, the cortisol is higher. It should be noted that in 
healthy controls, physical good health and better function is related to higher 
CAR. Our result is a correlation between CAR and the score of both healthy 
controls and patients; thus, we could not specified that this higher CAR correlated 
with higher level of function is the impact of MDD or general good health of our 
controls.  
4.5.2 Zung self-rating anxiety scale and anxiety index (Zung) 
Moffitt et al. (2007) in a cohort study revealed that there is a strong association 
between GAD and MDD; their study investigated the cumulative and sequential 
comorbidity of these disorders. The sequential overlap of GAD and MDD is 
considered to involve an initial onset of anxiety, followed by development of MDD. 
Longitudinal studies have argued that childhood anxiety predicts later MDD. 
Carr et al. (2013) in a systematic review argued that ELS is associated with 
anxiety disorders. In particular, physical abuse is related to PTSD and the severity 
of anxiety disorder. Sexual abuse is related to PTSD, panic disorder, 
agoraphobia, and obsessive-compulsive disorder. Emotional abuse is associated 
with social phobia combined with substance abuse. Emotional neglect is 
generally related to the severity of psychopathology.  
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In our study, MDD patients compared to healthy controls and abused subjects 
compared to non-abused subjects, had higher scores, which confirms that these 
subjects suffered from more level of anxiety.  
The positive correlation between CAR and the degree of anxiety supports the 
argument that anxiety is associated with higher CAR. This finding is consistent 
with the study conducted by Vreeburg et al. (2010) which showed current anxiety 
disorder was related to higher CAR. In details, their findings were based on 
patients with panic disorder with agoraphobia and anxious patients with comorbid 
depressive disorder. They also could show trend toward higher morning cortisol 
for remitted anxiety patients.  
4.5.3 Medical Outcomes Survey Short Form 36 (SF-36) 
Childhood abuse may have a strong effect on general health, with evidence of 
long terms effects on health outcomes in adulthood (Font et al., 2015). In 
consistent with this, in our study, non-abused subjects and healthy controls had 
higher SF-36 scores, confirming that these subjects had higher levels of general 
well-being.  
The correlation between the CAR and SF-36 was negative, showing that with 
increasing general health, the CAR was lower , which was not in agreement with 
the study conducted by Kudielka et al.(2003), in which the higher CAR was 
associated with physical health. Of note, we made the correlation among all the 
subjects which consisted of MDD and controls with and without a history of abuse; 
thus, it could be the reason of this incontinency between our results with theirs.  
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4.6 Strengths and Limitation  
4.6.1 The first study  
To our knowledge, there are no studies that have investigated the modulatory 
effects of the BDNF val66met polymorphism on grey matter amygdala volume in 
MDD; thus, the novelty of the work is an important strength of our study. 
Nevertheless, there are a number of limitations within the first study. First, our 
study was restricted to the analysis of one priori region of interest, the amygdala, 
although as noted earlier, the study was a part of a wider study in which other 
regions of the brain were investigated (see Appendix A).  
The lack of data on the history of early life stress in the subjects could be one of 
the important factors, as there is evidence that stress could lead to brain atrophy 
by modifying BDNF levels (Gerritsen et al., 2012); and reduced grey-matter 
volume in the amygdala and hippocampus was observed in healthy subjects 
carrying the met allele with a history of greater stressful events (Gatt et al., 2009) 
; thus we could investigate whether this polymorphism modifies the effect of early 
life stress on grey matter  amygdala volume. Another restriction could be that the 
most of the subjects with MDD were taking antidepressant medications, which 
could have an effect on neural volumes. Medication and treatment influences on 
amygdala volume have not been well documented in previous studies; thus, we 
cannot exclude an effect of medication on our results.  
Another factor which should be considered is that in our study we classified met-
homozygous and heterozygous in one group-named met carrier, due to small 
population of met/met homozygote, therefore, there is a possibility that we miss 
the real effects of met homozygotes on amygdala volume.  
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4.6.2 The second study 
In terms of strengths, we considered and attempted to control for numerous 
confounders to maximize the validity of the results. For example, previous studies 
showed that the day of the week is important as the CAR is higher when 
measured on a weekday than on a weekend (Edward et al., 2003; Kudielka et al., 
2003). Because of this we controlled the day of the collections of the subjects and 
we measured the CAR on weekdays. We considered smoking, alcohol and drug 
consumption in our subjects and we decreased the confounding effects of these 
factors on our results by not recruiting heavy smokers or alcohol and drug 
dependent subjects. 
Our study did not include patients with an identified organic aetiology to their 
psychiatric diagnosis. Moreover, we did not include subjects with major physical 
illnesses, or medication use, in particular corticosteroids that might affect the HPA 
axis. We excluded pregnant or lactating women. For healthy controls we did not 
include those with a history of psychiatric illness in their first degree relatives. All 
of these factors will have minimized the possibility that factors other than 
depression or childhood trauma could have affected the observed changes in the 
CAR between groups. 
It is noteworthy that there is no previous study which has demonstrated the 
additive effect of MDD and early life stress together on CAR as our study has 
done, emphasizing the novel nature of these findings. There have been a number 
of studies in which the effect of early life stress or the influence of MDD has been 
investigated, but to our knowledge, there have been no studies that have 
investigated the effect of early life stress and MDD in four groups of healthy 
controls and MDD patients, and using multiple time points to evaluate the CAR. 
Our study made a comparison between abused MDD and non-abused MDD, and 
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showed a differential pattern of HPA dysfunction in MDD patients on the presence 
or absence of ELS, a novel finding. 
Against these strengths, we need to be weighed some limitations. Although we 
did control for many potential confounding factors, one of the limitations of our 
study is the presence of some other important factors we were not able to control.  
In detail, more reliable and true investigation of the CAR have been observed in 
the previous studies in which the CAR was investigated on a minimum of 2 days. 
This may be because collecting the cortisol for more than one day can minimize 
the effect of random factors that might affect the CAR if collected on just one day 
(Wust et al., 2000; Hucklebridge et al., 2005; Deodovic et al., 2015).  
Gender could be an important factor as females have been found to have a higher 
CAR than males in previous studies (Pruessner et al., 1997; Wust et al., 2000). 
Our subjects were not fully matched for gender. There were significant 
differences between groups in terms of gender (Male and Female, CB = 19 and 
24; CA = 14 and 12; PB = 5 and 10; PA=5 and 23) as we found a higher CAR in 
PA compared to PB, and in PA compared to CA, and the PA group had the 
highest number of females, it is possible that our result could have been affected 
by the higher number of females in PA compared to PB or CA. 
Although older age has been associated with a lower CAR and we had older MDD 
patients than healthy controls, it was unlikely to have affected our results as the 
CAR was higher in MDD patients than healthy controls (Kudielka et al., 2003). 
The time of awakening of the MDD patients was not standardized and could be 
a confounding factor as earlier awakening time is associated with a higher CAR 
(Markopoulou et al., 2008; Deodovic et al., 2015).  
Another issue which should be considered is that the groups were not divided in 
regards to the sub-type of abuse: all subtypes of abuse were considered together. 
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Therefore, it is not clear whether it was one or more particular types of abuse, or 
in fact the cumulative effect of several types of abuse, which were the important 
factors mediating the effects of childhood trauma on the CAR.  
The use of antidepressants by the MDD patients is another limitation of our study, 
as antidepressant use might affect the HPA axis and the CAR as explained before 
(Manthey et al., 2011; Ruhe et al., 2015). It would have been ideal if patients were 
all using the same type of antidepressant or were un-medicated rather than taking 
several types of antidepressant.  
The assessment of early life stress was restricted to a self-report questionnaire 
measure of childhood experiences, whereas formal interview may give more 
comprehensive evaluation of the objective level of early life stress (Suzuki et al., 
2014). However, this assessment using the CTQ is a well-validated and widely 
used approach used in the literature. Finally, there are several potential 
unmeasured confounders that might be associated with cortisol collection, such 
as sleep quality, on which we were not able to gather appropriate information 
from our subjects. 
4.7 Future studies 
4.7.1 The first study 
One of the important factor which should be considered is the possible epistasis 
of genes. Future studies need to focus on the interaction of BDNF and the other 
genes such as 5 Serotonin-Transporter-linked Polymorphic Region (5HTTLPR) 
(Wang et al., 2012; Grabe et al., 2012), because based on biological interactions 
between the serotonergic system and BDNF, BDNF is a reasonable candidate 
for a gene-gene-environment interaction moderating the interaction between the 
s/l- promoter polymorphism of the serotonin transporter (5-HTTLPR) and 
childhood abuse.  
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Another gene which might be a new candidate in MDD is Catechol-O-
methyltransferase (COMT) which is a methylation enzyme engaged in the 
degradation of dopamine and noradrenaline by catalyzing the transfer of a methyl 
group from S-adenosylmethionine. It is noteworthy to investigate about the 
interaction of BDNF and COMT as there is evidence about val158met COMT 
polymorphism in association with MDD (Cao et al., 2014); an effect of 
val108/158met COMT on brain morphology (e.g. smaller caudate volume) in 
patients with first episode and treatment naïve MDD compared to healthy 
subjects (Watanabe et al., 2015); and epistatic interaction of BDNF and COMT 
on the frontostriatal system which is an important area to play a role in cognition 
and emotion (Wang et al., 2015), were observed before. 
 
In our study there were no measures of possible environmental factors that could 
influence the expression of the genetic vulnerability into reduced amygdala 
volume. These could include recent as well as childhood stresses. Thus, in future 
studies, both environmental and biological factors should be included as there 
seems to be a link between these factors such as stress and BDNF (Gatt et al., 
2009). Furthermore, the effects of treatment, as well as the type of treatment used 
(such as antidepressant class or CBT) should be considered; as these treatments 
could affect the results (Choi et al., 2006), and in line with this, the effects of 
treatment on brain structure, and whether there are differential effects of such 
treatments on brain structure depending on genotype, needs to be considered 
and accounted for in future studies. Furthermore, BDNF may be implicated not 
only in depression but in other psychiatric disorders (Green et al., 2006), and it 
may affect the other parts of brain such as the anterior cingulate cortex (Gerritsen 
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et al., 2012) which is thought also to play a crucial role in MDD and in the 
response to treatment. 
4.7.2 The second study 
The work to date shows that CAR is immensely heritable which suggests that to 
a certain degree, it is a trait-like feature. As it is also highly affected by 
environmental and situational factors, it can serve as an index of one’s overall 
vulnerability to depression as it is associated with stressful experiences.  
Findings from the longitudinal studies suggest that increased CAR being linked 
with MDD onset and recurrence. Focusing on the link between stress and 
depression, it is not only the number of major stressful events experienced but 
also the type of stress and one’s perceived levels of stress and coping abilities 
that are of importance. In association with this, CAR could be particularly relevant 
when it comes to recurrence of depression, given that the onset of the first 
depressive episode is often linked to experience of a major stressful event, 
whereas the following episodes could be triggered by more minor events, due to 
stress sensitization. 
Previous studies suggest that in the healthy controls, increased CAR is 
associated with being able to meet specific demands of the upcoming day (e.g. 
workday vs weekend), and decrease of stress on that certain day, and therefore 
has been linked to coping (Deodovic et al., 2014). It is noteworthy to wonder that 
this association may become dysregulated once coping employed is ineffective 
in removing feeling of stress during time. In that case, heightened CAR (and 
possibly inflexible or stiff CAR) may switch from signaling coping to signaling 
prediction of stress of the day after. It has been argued that it is likely that at a 
specific threshold, persistent increased CAR may be downregulated, and 
become blunted. This could be the reason for the observation of heighted CAR 
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and others blunted CAR in MDD patients. These factors can be investigated in 
future studies. 
In line with this, future research should focus on differential effects of individual 
types of early life stress as the effect of specific types of abuse have not been 
well documented either in the current study or in previous studies (Heim et al., 
2000; 2010). It has been argued that poor adult health is associated with 
childhood physical, emotional, and sexual abuse (Font et al., 2015). Therefore, 
investigating the influence of specific type of early life stress on health outcomes 
in adulthood would be an important and interesting area to develop this work 
further. 
In order to clarify that whether the CAR abnormalities anticipate the onset of 
depression, are present in the first episode, whether they are associated with the 
number of recurrences or the total duration of illness episodes, future research 
would also need to measure the endocrine factors during earlier stages of the 
illness, ideally in the first episode and in subjects that are not taking medications. 
Increased salivary cortisol might be a predictive biomarker of MDD in both young 
people and adults (Goodyer et al., 2000; Harris et al., 2000); from this point of 
view, salivary cortisol secretion has the characteristics of an endophenotype of 
MDD and it might be a reasonable marker for genetic analysis. This is likely to be 
a fruitful area in future research (Cowen et al., 2010). However, the contribution 
of genetic polymorphisms in certain genes such as those encoding the 
corticosteroid receptors has not been well documented. It has been argued that 
carriers of the short allele of the serotonin transporter exhibit an increased 
salivary awakening cortisol but the results have not been consistent (Mannie et 
al., 2008).  
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In sum, the association between CAR and vulnerability to depression is important 
but complex; and we found an additive association between MDD and early life 
stress on the CAR. In line with this, our findings suggest that MDD patients with 
a history of early life stress could be considered as a specific group which is more 
sensitive to show the abnormality of HPA axis and it might argue that early 
intervention, supportive care, and specific or combined treatment could be useful 
to prevent the next depressive episode in these subjects. Further research with 
comprehensive methods could bring more insight into other association between 
CAR, MDD and ELS.  
  
4.8 Conclusion  
4.8.1 The first study 
Inconsistent results had been found about the role of BDNF in the pathogenesis 
of MDD and its effects on grey matter of amygdala volume in previous research. 
Evidence from neuroimaging studies about the important effects of the BDNF 
val66met polymorphism on amygdala volume in healthy controls (Montag et al., 
2009), and the association of the val66met polymorphism with reduced 
hippocampus volume – as a part of limbic system – in MDD patients compared 
to controls (Frodo et al., 2007), raised the assumption that the BDNF val66met 
polymorphism may have a considerable influence on the amygdala volume in 
MDD patients. Supporting this argument, decreased amygdala volume in 
unmediated patients (Hamilton et al., 2008) and alteration of amygdala volume in 
first episode MDD patients (Frodo et al., 2002) had also been found in previous 
studies. 
However, our study did not find a clear effect of met allele on the amygdala 
volume either in healthy controls or MDD patients.  
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4.8.2 The second study 
The study attempted to find a link between abnormalities in the CAR and early 
life stress in MDD patients in order to identify a biomarker of MDD, which could 
be important either in prevention or treatment of MDD.  
In healthy controls, the study found no effect of a history of childhood abuse on 
the CAR.  
In MDD, disregarding the presence or absence of childhood abuse, the CAR was 
higher in MDD patients compared to healthy controls. Both the AUCg and the 
AUCi were higher, suggesting higher total secretion of cortisol and a hyperactivity 
of the HPA axis in MDD patients.  
However, this result obscured a significant difference in MDD patients in 
association with their history of childhood abuse. The CAR was higher in those 
MDD patients with a history of abuse compared to those without, supporting the 
argument that early life stress may play a major role in the aetiology of HPA axis 
hyperactivity in MDD. Consistent with this result, the CAR in non-abused MDD 
patients was not increased compared with non-abused healthy controls.  
A major suggestion of the study is that many of the previous studies that have 
found HPA axis hyperactivity in MDD have not assessed for the presence of 
childhood abuse. It may be that MDD in patients with a history of childhood 
trauma has a certain aetiology that involves HPA axis hyperactivity, whereas 
MDD in those without such a history is not associated with the same, or indeed 
any, HPA axis changes.  
These results could support the argument that the effect of childhood abuse and 
MDD on the CAR are additive. On the other hand, the CAR in abused MDD 
patients were higher than all three other groups, which could support the idea 
that the combined effect of MDD and early life stress on the CAR can cause HPA 
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axis hyperactivity. It is noteworthy that this is a novel finding in the literature. Our 
study did not observe any change in the CAR either in abused healthy controls 
compared with non-abused healthy controls or non-abused MDD patients 
compared with non-abused healthy controls, thus showing that there is no 
influence of early life stress on the CAR without the additional effect of MDD. 
Similarly, no clear effect of MDD on the CAR was seen without the presence of a 
history of early life stress. In contrast, abused MDD patients compared with 
abused healthy controls showed higher CAR and total secretion of cortisol; 
abused MDD patients compared with non-abused healthy controls demonstrated 
higher CAR and total secretion of cortisol and abnormal HPA response; and the 
comparison of abused MDD patients and non-abused MDD patients showed an 
important effect of early life stress in MDD.  
Our study found that the CAR increases when the severity of emotional, physical 
and sexual abuse increases. We also showed that there is an association 
between anxiety and the CAR, and that anxiety levels are higher in abused MDD 
patients. The result on the SF-36 questionnaire provide further confirmation of 
the marked effects of MDD on all aspects of patients’ lives and functioning.  
In terms of clinical outcomes, we showed that a later onset of the first episode of 
MDD is associated with an increase in cortisol levels at 15 minutes after 
awakening in MDD patients, although this association could also be confounded 
by other clinical factors such as the number of previous episodes and duration of 
current illness. 
 
4.8.3 Overall Conclusion 
The two studies outlined in this thesis focused on several of the major areas 
where progress is being made in the attempt to solve the riddle of depression, 
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i.e. genetic, neuroimaging and endocrinology research. Although we found no 
modulatory effect of val66met BDNF polymorphism on amygdala volume in MDD 
patients, we showed that the effect of early life stress and MDD are additive in 
that the CAR is most increased in those who are both depressed and have a 
history of early life stress. This finding supports the argument that an association 
between MDD and the CAR is only observed in those with a history of abuse. 
This is a novel finding, and of importance in trying to unravel the aetiology of HPA 
axis dysfunction in MDD.  
 
However, MDD and child abuse remain global concerns; many children and 
adults are continuing to suffer from the damaging consequence of MDD and early 
life stress. It is hoped that one of the outcomes of the work in this thesis is to help 
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Appendix A.  The First Study  
 
Modulatory effects of brain-derived neurotrophic factor Val66Met 
polymorphism on prefrontal regions in major depressive disorder 
Legge RM*, Sendi S*, Cole JH, Cohen-Woods S, Costafreda SG, Simmons A, Farmer AE, 
Aitchison KJ, McGuffin P, Fu CH. 
Br J Psychiatry. 2015 May;206(5):379-84. doi: 10.1192/bjp.bp.113.143529. Epub 2015 Mar 5. 
Abstract 
BACKGROUND: 
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism contributes to 
the development of depression (major depressive disorder, MDD), but it is 
unclear whether neural effects observed in healthy individuals are sustained in 
MDD. 
AIMS: 
To investigate BDNF Val66Met effects on key regions in MDD neurocircuitry: 
amygdala, anterior cingulate, middle frontal and orbitofrontal regions. 
METHOD: 
Magnetic resonance imaging scans were acquired in 79 persons with MDD 
(mean age 49 years) and 74 healthy volunteers (mean age 50 years). Effects on 
surface area and cortical thickness were examined with multiple comparison 
correction. 
RESULTS: 
Subjects who were Met allele carriers showed reduced caudal middle frontal 
thickness in both study groups. Significant interaction effects were found in the 
anterior cingulate and rostral middle frontal regions, in which participants in the 





Modulatory effects of the BDNF Val66Met polymorphism on distinct subregions 
in the prefrontal cortex in MDD support the neurotrophin model of depression. 




Appendix B. The Second Study  
 
HORMONE MEASUREMENT  
Saliva measurements of hormonal concentration 
Saliva cortisol concentrations were determined using the chemiluminescence 
assay of ‘Immulite’- DPC’s automated Immunoassay analyzer. 
(www.diagnostic.siemens.com).  
a. The cortisol concentrations of unknown saliva specimens were read off a 
calibration graph constructed from 10 cortisol standards in saline- concn 
0- 160 nmoles/L. 
b. The volume of the specimen taken for analysis was increased by 40Ul. 
 
Multicalc v 2.65 (part no 1224-310; www, perkinelmer.co.uk) was used to plot the 
calibration graph and for immunoassay data processing. 
The method correlated well with an in-house and previous published study 
(Juruena et al., 2006) TR-FIA (r=0.94, y=0.004+1.08 x, N=41), had analytical 
sensitivity of 0.2 nm/l, mean % recovery of cortisol of 106.1 (range 5 to 65 nm/l).  
 
And inter/intra-assay precision (% CV) of less than 10% (range 5 to 25 nm/l).  
The linearity upon dilution test (parallelism) resulted in a straight line (r=0.99, 
y=0.144+1.014 x). The calibration graph was highly reproducible (n=11 assays) 
with slope (mean±sem) of 0.197+0.004. 
The percentage cross reactivity of the antiserum with cortisol was 0.35%.  
The short and long term performance of the assay was monitored with  
a. Biorad commercial control sera (www.bio-rad.com) 
b. Human saliva pools and  
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c. Participation in external QC scheme for saliva steroids organized by IBL 
(www.ibl-hamburg.com) 
Saliva specimens collected at each time point were defrosted, mixed and after 
centrifugation at 3500 rpm at room temperature, were treated as explained below. 
In brief, using the Genesis 100 Robotic Sample processor (Tecan UK, Theale, 
Reading, UK), 50 μL of the test saliva or standard was boosted to the wells of 
microtitration strips. This was followed by 50 μL of a solution of the enzyme 
labelled hormone and 50 μL of the hormone antibody. Both of these reagents 
were boosted using an electronic Eppendorf Repette. 
After an incubation of 4hrs at room temperature, the incubation solution was 
abandoned and the wells were washed 4 times with 250 μL of wash out buffer 
and 50 μL of chemiluminescence reagent. The luminescence of the bound 
fraction was measured in a Berthold Luminometer (MPLI, Berthold Detection 
Systems, and Pforzheim, Germany) which was linked to MicroWin 2000 Version 














We used the Detailed Instructions for Saliva Collection of previous studies, 
although we explained to each subject in detail what they need to do. 
Detailed Instructions for Saliva Collection 
We ask you to collect your saliva on 4 consecutive days or if not then as close to 
each other as possible. You can decide which days. 
Choose the days when you are in good health and have no heavy social 
commitments i.e. late evenings, parties, social gatherings, entertainment and so 
on. 
We will provide you with 4 small plastic bags. These will be labelled as DAY 1, 
DAY 2, DAY 3, and DAY 4. They will contain the tubes you need to collect your 
specimens in. All tubes are labelled on the outside and numbered at the top. 
Each day we ask you to collect your saliva immediately upon waking up 
(whichever time that is) and then at +15 mins, +30 mins, +45 mins, +60 mins, +90 
mins and before your lunch. We also ask you to collect an evening specimen at 
10 pm, a total of 8 specimens. 
We will give you a form to fill in. Please complete this every time you collect your 
specimen inserting the date, time, you woke up and collected the specimens or 
telling us something about the events that took place the hour before you 
collected the specimens. 
DAY 1,2,3,4 
Morning specimens 
Wake up between 6 and 9:30 am and take the tubes from the bag labelled DAY 
1, 2, 3 or 4 according to the days you are collecting. 
Do not brush your teeth and do not have breakfast or any other drinks. You can 
clear your throat before starting to collect specimens. 
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Sit by your bed or choose another quiet part of your bedroom and make a note 
on the collection form of the exact time you woke up e.g. 7.15 am. Start collecting 
your specimens in the tubes provided closing them firmly after each collection 
and noting the time on the collection form. Remember you need to fill each tube 
with clear saliva at least up to the 1 ml mark and above. 
Take tube No 1 (labelled immediately on wake up) and collect your saliva. 
15 minutes after waking up take tube no 2 and collect your saliva. Note the time 
on the collection form. 
30 minutes after waking up take tube no 3 and repeat the saliva collection. 
45 minutes after waking up take tube no 4 repeat the saliva collection. 
60 minutes after waking up take tube no 5 repeat the saliva collection. 
90 minutes after waking up take tube no 6 repeat the saliva collection. 
Return your tubes into the plastic bag labelled DAY 1, 2, 3 or 4 and store in the 
freezer/leave your room. 
Throw away your plastic straws once you have finished using them. 
You can have breakfast now and continue with your other normal daily activities. 
Before your lunch take tube no 7 and repeat the saliva collection. 
Evening specimen 
At 10 pm choose a quiet part to stay and preferably sitting down and take the 
tube labelled 10 pm and collect your saliva. Make a note on the collection form of 
the exact time e.g. 10.15 pm that you collected the specimen. 
Return the tube to the bag labelled DAY 1 and leave in the freezer/your room. 
Remember it is important that in the HOUR before giving the specimen you 




Eating or drinking anything- if you do have something accidentally you must make 
a note of it. 
Demanding social activities i.e. late night parties/entertainments or any hassles 
e.g. arguments with friends/relatives, difficult conversations. If you cannot then 
make a note on the collection sheet. 
You should make a note if you are in any kind of pain (headache, migraine, 
toothache, backache) or feeling sick for some reason. 
IMPORTANT POINTS TO HELP YOU COLLECT ENOUGH SALIVA WITH THE 
“STRAW AND TUBE METHOD” 
Collect enough saliva in your mouth. 
Take the appropriate tube and plastic straw out of the labelled bag, remove the 
cap and place one end of the straw in your mouth and the other end low down, 
near the bottom of the collection tube. 
Slowly pass the saliva/spit through the straw to the tube- do not blow otherwise 
this will cause frothing. Tap gently the bottom of the tube on a table top a few 
times – this helps a clear layer of saliva collect at the bottom of the tube and 
reduces “frothing”. 
Move the end of the straw above the surface of the collected saliva in the tube 
and repeat the process until you have collected enough – well above the 1 ml 
mark on the tube. 
 
Close the tube tightly, put it in the appropriate bag and leave it in the freezer/your 
room. 
Remember 
Morning specimens- these should be collected before you brush your teeth and 
before you have any breakfast or other drinks. 
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Evening specimens- Have your evening meal early. Do not have anything to drink 
or eat or chew gum or smoke about 1 hour before giving the specimen. 
To make a note on the collection forms the time you collect each specimen and 
also if you experience any hassles (e.g. difficult conversations, arguments with 
friends/relatives) pain of any kind e.g. headache, migraine, toothache. 
Post all your specimens to the National Affective Disorders Unit. We shall provide 






Subject Code= Patient/Control 
Name Age 
Date 
PLEASE DO NOT BRUSH YOUR TEETH EAT OR DRINK ANYTHING FOR AT 
LEAST ONE HOUR BEFORE THE COLLECTION. IF YOU DO HAVE TO DRINK 

















 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 










 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 












 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 










 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 









 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 









 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 









 Where were you? How were you 
feeling?  
 
What were you doing before the 
collection of the samples? 
 







10 pm  Where were you? How were you 
feeling?  
 





Did you accidentally eat or drink? 
 
What were you doing before the 
collection of the samples? 
 
Did you eat or drink? 
 
 
 
 
 
  
 
